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Abstract 
The idea of regulating complex biological processes by the use of light has been appealing for the 
scientific community for a long time. At the same time, soon after the impressive arriving of kinase 
inhibitors in clinic, the occurrence of adverse effects and rapid resistances lowered the expectations e.g. 
for anticancer approaches and called for more innovational therapy strategies. As combination, using 
light to control biological activity of highly potent drugs like kinase inhibitors or microtubule-targeting 
agents both temporal and spatial became a promising strategy.  
This study reports on the development of both a photoactivatable small-molecule microtubule-targeting 
agent (smMTA) as well as a photoactivatable cyclin-dependent kinase inhibitor. Therefore, in a caging 
approach the 4,5-dimethoxy-2-nitrobenzyl photoremovable protecting group (DMNB PPG) was attached 
to crucial pharmacophoric functionalities of both active drugs in order to biologically inactivate them. 
Upon irradiation with near UV light, the PPG was rapidly cleaved and the active drugs released. The 
subsequent biological evaluation of the photoactivatable prodrugs addressed two major objectives: 
biological inactivity of the caged prodrugs as well as the restoration of biological activity upon irradiation 
with UV light in vitro. Attachment of the PPG to the active drugs led in both projects to a significant loss 
of biological function. As an important proof of concept, biological activity was completely restored upon 
irradiation with near UV light within a time of irradiation which did not affect cell viability. Thus, both the 
photoactivatable smMTA as well as the photoactivatable CDK inhibitor represent highly valuable tool 
compounds for studying biological processes. Despite this important proof of concept, the limited 
penetration depth of UV light into biological tissues remains. In order to address this issue and enhance 
translational value for medical applicability, two promising strategies to overcome this limitation were 
investigated. First of all, a BODIPY caged CDK inhibitor, which could be photoactivated upon irradiation 
with deeper penetrating green light, was developed and its utility for biological applications could be 
demonstrated. Secondly, the possibility to use Cherenkov radiation induced by beta emitting 
radionuclides to photocleave the DMNB caged prodrugs was evaluated. As an important result, evidence 
for photoactivation of the DMNB caged CDK inhibitor upon incubation with an acid solution of the beta 
emitter 68Gallium was demonstrated.  
In conclusion, the first photoactivatable smMTA and a photoactivatable CDK inhibitor with high 
biological utility have been developed. Furthermore, two strategies to overcome the limited penetration 
depth of UV light were evaluated. Utilization of Cherenkov radiation induced by radionuclides represents 
an exciting strategy and could lead to a novel therapeutic approach combining caged prodrugs with 
existing radiotherapeutic applications.  
  
Kurzzusammenfassung 
Die Idee, komplexe biologische Prozesse mit Licht zu steuern, beschäftigt Wissenschaftler seit einiger 
Zeit. Gleichzeitig, kurz nach dem beeindruckenden Einzug der Kinase Inhibitoren in die Klinik, senkten das 
Auftreten von schweren Nebenwirkungen und erworbenen Resistenzen die klinischen Erwartungen an 
Kinaseinhibitoren und der Ruf nach innovativen Therapiekonzepten wurde laut. Licht als Trigger für die 
Steuerung der Wirkung hochpotenter Arzneistoffen stellt möglicherweise eine vielversprechende 
Strategie dar. Diese Arbeit berichtet über die Entwicklung eines photoaktivierbaren “caged“ 
niedermolekularen Tubulininhibitors als auch eines photoaktivierbaren CDK Inhibitors. Dabei wurden die 
aktiven Wirkstoffe jeweils durch Einführung der 4,5-Dimethoxy-2-nitrobenzyl Schutzgruppe (DMNB) an 
die Pharmakophore geschützt. Durch Bestrahlung mit nahen UV Licht konnten die Schutzgruppen 
abgespalten und die aktiven Wirkstoffe wieder freigesetzt werden. Die nachfolgende biologische Testung 
zielte darauf ab, zwei wichtige Ziele des Proof-of-concept zu adressieren: die biologische Inaktivität der 
geschützten Prodrugs genauso wie die anschließende Wiederherstellung der biologischen Wirkung durch 
Bestrahlung mit nahem UV Licht. In beiden Fällen führte das Einführen der photoabspaltbaren 
Schutzgruppe zu einem signifikanten Verlust an biologischer Aktivität. Die biologische Aktivität konnte 
anschließend durch Bestrahlung mit UV Licht einer Dosis, die die Viabilität der Zellen nicht 
beeinträchtigt, vollständig wiederhergestellt werden. Zusammenfassend stellen beide 
photoaktivierbaren Prodrugs wertvolle Werkzeuge für die biochemische Kinase- und Tubulinforschung 
dar. Trotz dieser großen Nützlichkeit limitiert die geringe Eindringtiefe von UV Licht in biologisches 
Gewebe Studien mit beiden photoaktivierbaren Substanzen auf oberflächliches Gewebe. Um diese 
Limitierung zu überwinden, wurden zwei vielversprechende Strategien untersucht. Zum einen konnte die 
photoaktivierbare Schutzgruppe BODIPY an das Pharmakophor des CDK inhibitors gekoppelt, dann mit 
grünem tiefer eindringenden Licht abgespalten und die Nutzbarkeit für biologische Anwendungen 
demonstriert werden. Zum anderen wurde untersucht, ob die durch radioaktive Betastrahler im Medium 
induzierte Cherenkov Strahlung zur Aktivierung von DMNB geschützten „caged“ Prodrugs genutzt 
werden kann. Dabei wurde die Aktivierung des DMNB geschützten CDK Inhibitors durch Inkubation mit 
68Gallium in Lösung gezeigt. Zusammenfassend wurde der erste photoaktivierbare niedermolekularen 
Tubulininhibitor als auch der erste photoaktivierbare CDK Inhibitor entwickelt und charakterisiert. 
Weiterhin konnten zwei Strategien zur Überwindung der limitierenden Eindringtiefe des UV Licht 
entwickelt werden. Dabei erscheint vor allem die Ausnutzung von radioaktiv induzierter Cherenkov 
Strahlung von hohem Wert und würde ein neuen innovativen Therapieansatz darstellen, der 
photoaktivierbare Prodrugs mit bereits genutzten radiotherapeutischen Ansätzen kombiniert. 
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1 Introduction 
The idea of regulating complex biological processes by the use of light has been appealing for the 
scientific community for a long time. The orthogonality towards biological tissues, the precisely 
controllable intensity and spatial resolution of light highlights an ideal external trigger for remote 
control. Although the idea is not new, a major interest in improved photopharmacological technologies 
and applications have emerged in recent years. At the same time, soon after the impressive arriving of 
kinase inhibitors in clinic, the occurrence of adverse effects and rapid resistances lowered the 
expectations and called for more innovational therapy strategies.1,2 Using light to control biological 
activity of highly potent drugs like kinase inhibitors in both temporal and spatial manner became a 
promising strategy.  
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1.1 Activation by light 
Light exhibits some unique characteristics, attractive for photochemistry. Adjustable intensity and 
wavelength, non-invasiveness and orthogonality towards most biological systems enables a precise 
photopharmacological control over time and place with modern light sources such as lasers and LEDs.3–5 
There are four major approaches to implement light as a trigger for a remote control of biological 
activity. First of all, the “caging concept” utilizes photoremovable protecting groups (PPGs) for an 
irreversible photoactivation. Secondly, photoswitches enable a reversible activation and deactivation 
upon irradiation.6,7 A third technique utilizes encoded light-responsive elements called optogenetics 
aiming for dynamic control over biological events in living cells such as neurons.8–10 Finally, 
photodynamic therapy (PDT) bases on photosensitizers, which are molecules that generate cell toxic 
reactive oxygen species (ROS) upon irradiation with light.11–13 As a milestone in the field of 
photopharmacology, the photosensitizer Padeliporfin (Tookad®) was approved for the treatment of low-
risk prostate cancer by the EMA in 2017.14 Thereby, Padeliporfin is given as an injection and 
subsequently locally activated by laser light using optical fibers placed in the prostate.15,16 However, the 
present work aims to bring the caging concept for photocontrol over biological activity of potent drugs 
into focus.  
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1.2 Caging concept 
The idea of the caging concept is straightforward: A photoremovable protecting group is covalently 
attached to a biologically active compound. The so called “caged” compound  is not capable of binding to 
its target or receptor anymore, hence biologically inactive. By irradiation with light, the “cage” is 
removed and the original biological activity is restored (Figure 1). This results in a rapid concentration 
jump upon irradiation, thus became a powerful tool for studying biological processes and regulation of 
biological activity.4 The introduction of large PPGs severely changes the molecules structure typically 
resulting in complete loss of biological activity. Furthermore, there is no steady state in the reaction of 
photoactivation. This combines to an excellent active/inactive ratio, which happens to be particularly 
useful for biological and medicinal applications.17 Several examples of caged compounds have proven the 
utility in biological research. Kaplan et al. introduced the first caged compound by caging ATP to study 
the Na+/K+ pump in 1978.18 Since then extensive research was carried out to improve the characteristics 
of PPGs and many examples followed like caged neurotransmitters19, nucleotides20, mRNA21, peptides22 
or kinase inhibitors23,24. 
 
 
 
Figure 1: Schematic representation of the caging concept.
25
 The photoremovable protecting group is covalently attached to the 
active inhibitor. The caged inhibitor is not capable of binding to its target. After irradiation with light, the photoremovable 
protecting group is cleaved and the inhibitor is able to bind to its target. The biological activity is restored. 
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Due to their biological inactivity, the caged compounds ideally prevent systemic side effects. Upon 
irradiation of the treatment site only, the active compound is spatiotemporally released in high 
concentrations. This might not only reduce systemic side effects, but also allow higher local drug doses 
compared to systemic administration. Additionally, since the release of the active drug is temporally 
controllable it might offer the opportunity of a potent intermittent therapy which could be favorable in 
prevention of resistances.26,27   
Besides the irreversibility of the activation, the caging concept exhibits another drawback. The activation 
upon irradiation is always accompanied by the formation of a byproduct – the cleaved protecting group. 
This byproduct might not only be toxic, but interfere with the photoreaction by absorbing light of the 
respective wavelength. However, the issue of toxicity is controvertible. For the purpose of medicinal 
applications e.g. caged kinase inhibitors for cancer treatment, toxicity of the photoactivation byproduct 
might be beneficial in terms of a synergistic effect together with the active drug, since a photoactivation 
upon irradiation ideally occurs exclusively at the treatment site. Caged compounds for medicinal use are 
termed as photoactivatable prodrugs.  
1.3 Photoremovable protecting groups 
The selection of an adequate PPG is vital to benefit from the particular advantages of the caging concept. 
The requirements for a suitable PPG in medicinal chemistry approaches are manifold. The synthetic 
introduction has to be simple and should not impair pharmacokinetic parameters such as solubility. The 
caged compound should be stable in solution as well as under physiological conditions and low toxicity of 
the cleaved protecting group is favored. Additionally, high light absorption at the irradiation wavelength 
is essential for an efficient photoactivation.8,28  
This photoactivation does not only depend on excitation, but rather on the percentage of the excited 
molecules that actually undergo photocleavage.8 The quantum yield Φrel describes the ratio between the 
effectively cleaved compound and the photons absorbed, as an important measure for the efficacy of a 
PPG.28  A remarkable research effort has been devoted to the development and applications of UV-light-
absorbing PPGs, such as o-nitrobenzyl29, benzoinyl (desyl)30 and coumarinyl moieties (Figure 2).31 o-
Nitrobenzyl derivatives were introduced among the first PPGs and are still most widely used due to their 
robust and well understood photochemistry.32 The most prominent member of this group of PPGs is the 
4,5-dimethoxy-2-nitrobenzyl protecting group (DMNB, 4) with an excitation wavelength of 365 nm for 
photocleavage.28 For most parts of the present work the DMNB protecting group was utilized.  
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Figure 2: Overview of different PPG classes.
17,28,33–36
 “X” represents the compound released upon irradiation. 
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The mechanism of photoactivation of o-nitrobenzyl caged compounds has been studied intensively.28 It 
includes the formation of an aci-nitro derivative (12), followed by an irreversible cyclization (13) and 
rate-determining ring-opening (14). In the final step the leaving group is released as an anion leaving the 
cleaved protecting group as o-nitroso aldehyde (15, Figure 3).28  Early reports show, that the efficacy of 
this photoactivation is depended on the solvent, pH and substitution of the o-nitrobenzylic ring. Recent 
studies gave guidance that the leaving group X is of similar importance.37 In the context of 
photoactivatable prodrugs, the selection of the leaving group, in this study an inhibitor, might be 
essential for success. 
 
 
Figure 3: Mechanism of photoreaction of o-nitrobenzyl caged compounds.
28
 
 
1.4 Strategies to overcome the limiting penetration depth of light into 
biological tissues 
As a matter of course, a photoactivation can only occur if enough light of the respective wavelength 
reaches the photosensitive target molecule, in this case the photoremovable protecting group of the 
caged inhibitor. Hence, to utilize the caging concept for translational medicinal applications in particular, 
the most crucial selection criterion is the wavelength required for photoactivation. Most treatment sites 
of highly potent drugs (e.g. tumors) lie in deeper, vascularised tissues. The penetration depth of light into 
these tissues is strongly dependent on the wavelength (Figure 4). Below 600 nm the penetration depth is 
only a few millimeters deep, below 500 nm even less than a millimeter. The key players for light 
absorption in biological tissues are melanin, hemoglobin and water. Between 650 and 900 nm the light 
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absorption of hemoglobin and water is low, which results in decent tissue penetration. Biological tissues 
are considered optically transparent within this range which is referred to as the bio-optical window.38,39 
Limited penetration into tissue, restricts studies utilizing UV light to superficial tissues in vivo as well as in 
vitro.40 Furthermore, UV-light with wavelength shorter than 300 nm can cause unwanted tissue 
damage.28,41   
 
 
Figure 4: The penetration depth of light into biological tissues.
39,42,43
 
 
Since it is not possible to change the penetration depth of light, scientist developed different strategies 
to overcome this restriction. Significant progress has been made in the field of light sources and fiber 
optics together with microendoscopic technology. Laser light of any wavelength can be focused into thin 
optical fibers with high intensity for light delivery into difficult to access treatment sites such as 
pancreatic, head or neck tumors.44 However, the necessity of surgical intervention to facilitate optical 
fibers goes hand in hand with tissue damage.45 Another exciting strategy to overcome the limiting tissue 
penetration of light is the two-photon excitation. Simultaneous absorption of two photons of 
approximately twice the wavelength (half the energy) by the same molecule results in excitation. Two-
photon excitation is a true nonlinear optical effect, which only happens at high light intensities with poor 
efficacy.8 The advantage of doubling the irradiation wavelength is offset by following key limitation: PPGs 
suitable for a two-photon uncaging are generally very large and inefficient, which renders them 
inappropriate for medicinal applications so far.46   
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By reason of an inefficient two photon excitation, PPGs absorbing light within the bio-optical window are 
highly desired for biological and medicinal applications.17 
1.4.1 Visible light absorbing PPGs 
Visible light absorbing PPGs have been reported only recently.17 In 2007 the first introduced PPG 
activated by visible light was based on a ruthenium complex absorbing blue light around 447 nm.35 In 
2012  the groups of Klan and Wirz managed a green shift by reporting of PPGs incorporating xanthene 
and pyronin chromophores with absorption maxima around 550 nm.33,34 At the same time the 
workgroup of Ellis-Davies evolved a PPG (DEAC, 6) with a strong absorption at 450 nm from the 
coumarin-4-ylmethyl moiety (5).36 But in the recent years another potential candidate came into 
spotlight: the hemi-porphyrin like BODIPY core (9).  
 
 
Figure 5: Chemical structure of the meso-BODIPY core. 
 
BODIPY derivatives are widely used as probes47, laser dyes48,49, photosensitizers50 and fluorescent tags51. 
This popularity results from their superior properties, such as stability in various media, sharp absorption 
peaks, low toxicity and high quantum yields.52 In 2015 Winter et al. introduced the idea of utilizing 
BODIPYs as photoremovable protecting group.40 Thereupon great interest has been aroused and 
different groups proved the applicability. The BODIPY core is easily accessible by organic synthesis. By 
substitution of the ring system, residue R particularly (Figure 5), the absorption maximum and the 
quantum yield can be altered dramatically.17 Even near-infrared BODIPY dyes are available through ring 
substitution.53 To further improve the efficacy of the photocleavage and the synthesis, the Feringa group 
showed that it is feasible to implement a carbamate linker in the meso position between the BODIPY 
core and the leaving group.52 However, all these studies could not yet demonstrate the in vivo 
applicability. The full potential of BODIPY based PPGs might not be exploited so far. 
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1.4.2 Cherenkov radiation 
Besides visible light absorbing PPGs, the idea of using Cherenkov radiation to approach photoactivatable 
prodrugs is more than exciting. If the required light for photoactivation is not able to penetrate to the 
place of destination, it might be an option to generate the irradiation in place. 
In modern tumor therapy both radiopharmaceuticals and external beam radiotherapy play a vital role. 
Radiopharmaceuticals are radiolabeled molecules designed to deliver therapeutic doses of ionizing 
radiation to specific therapy sites in the body. In combination with sophisticated tumor targeting vectors 
(e.g. immuno-derived molecules or receptor-avid tracers) radiation is specifically delivered to tumor sites 
in vivo. Radionuclides that decay by β-particle emission are most extensively used.54 β-decay comes 
along with emission of high energy electrons or positrons from the nucleus. These high energy particles 
interact with tissue and matter to consequently kill tumor cells. Energy of the emitted electrons or 
positrons by β-decay is not quantized, but a continuum of energies up to a maximum value.54 Beyond a 
certain level of energy charged particles like electrons or positrons induce an secondary effect known as 
Cherenkov radiation. The phenomenon is commonly known as the blue luminescence in the cooling pool 
of a nuclear reactor (Figure 6).  
 
 
 
Figure 6: Cherenkov radiation in a cooling pool of a nuclear reactor core.
55
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Cherenkov radiation is induced when a charged particle moves faster than the speed of light in a 
dielectric medium (e.g. water).56 The charged particle locally polarizes the medium and thereby excites 
the medium molecules. During return to the ground state, the energy is emitted as radiation.57 The 
threshold condition for induction of Cherenkov radiation is not only dependent on the energy of the 
charged particles but also on the refractive index of the medium.57 Cherenkov radiation is emitted as a 
continuous spectrum ranging from ultraviolet to visible light with its maximum intensity in the UV range, 
thus outside the bio-optical window.58 Since its first observation by Pavel Cherenkov in 1937, Cherenkov 
radiation was mainly of academic interest to physicists for particle identification59 or detection of high-
energy gamma-rays.60,61 However, a few years ago Cherenkov radiation became more and more 
important for optical in vivo imaging and as a readout method in biochemical assays.62–66 Taking into 
account that most of the Cherenkov radiation is emitted as ultraviolet light, the idea of utilizing it for the 
activation of o-nitrobenzyl caged prodrugs is obvious. 
 
Figure 7: Schematic representation of utilizing Cherenkov radiation for activation of caged compounds. Clinically used 
radiopharmaceuticals such as 
18
Fluorodeoxyglucose (
18
FDG), a positron emitter, accumulates in the tumor (red circle) due to the 
high metabolic rates of tumor cells. The emitted positron is not only detected during a PET scan (A) but also induces blue 
Cherenkov radiation in the tumor cells. Subsequent, the Cherenkov radiation cleaves the PPG and activates the caged inhibitor 
(B). The inhibitor is able to bind to its target. 
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In 2012 Ran et al. gave evidence that Cherenkov radiation induced uncaging is feasible. Herein in a proof-
of-concept study a caged derivative of luciferin was uncaged by 18Flurodeoxyglucose in a mouse breast 
cancer model.67  However, up to date there are no photoactivatable prodrugs using Cherenkov radiation 
for photoactivation. The concept would offer some unparalleled advantages. Multiple 
radiopharmaceuticals are already approved for clinical use. Together with tumor targeting vectors a 
specific activation only in tumor sites could be achieved detached from the limited penetration depth of 
UV light. Unfortunately, the intensity of Cherenkov radiation is relatively weak.58 The question if the 
intensity is sufficient to induce photoactivation of caged prodrugs remains to be answered. Since the 
intensity is dependent on the energy of the charged particle the intensity might be increased 
dramatically by the use of linear particle accelerators.56,57 Linear particle accelerators are already used 
for external beam radiotherapy in clinic.54 Earlier studies showed that accelerated high energy electrons 
can induce Cherenkov emission.56 Importantly, particle beams from linear particle accelerators are able 
to reach deep tissues with high local resolution.68  
Utilizing Cherenkov radiation either induced by therapeutic radiopharmaceuticals or external beam 
radiotherapy offers a great possibility to combine radiotherapy with targeted pharmacotherapy (e.g. 
kinase inhibitors or microtubule-targeting agents). A novel synergistic therapy strategy is conceivable.  
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1.5 Protein kinases and kinase inhibitors 
Protein kinases are enzymes that catalyze specific protein phosphorylation. Thereby, a phosphate group 
from a phosphate donor, usually adenosine triphosphate (ATP), is transferred onto a substrate protein 
subsequently modulating its activity.69 Modulating activity of proteins by phosphorylation is one of the 
major tools of signal transduction within a cell. Protein kinases play key regulatory roles in nearly every 
aspect of cell biology. Apoptosis, cell cycle progression, cytoskeletal rearrangement, differentiation, 
development and transcription are just some examples of transduction cascades regulated by kinases. 
Due to their physiological relevance, aberrant kinase function caused by mutation, chromosomal 
rearrangements or gene amplification is closely linked to a variety of pathophysiological events and 
diseases.70–72 Especially cancer is highly related to kinase dysfunction. As a consequence protein kinases 
became one of the most important targets for drug development in the last two decades.73   
The architecture of protein kinases consists of two subdomains: a N-terminal lobe with mainly β-sheets 
and a C-terminal lobe with α-helices. The two lobes are connected by a cleft called hinge region (Figure 
8). The hinge region represents the binding site of the essential phosphate donor ATP, which is targeted 
by the majority of small-molecule kinase inhibitors (smKI).69,71  
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Figure 8: General architecture of kinases.
74
 Exemplified on the structure of CDK2 (pdb 4FKO). The ATP binding pocket is 
occupied by AZD5438 (16). 
 
Since the approval of the first small-molecule kinase inhibitor Imatinib (Gleevec®) in 2001, great effort in 
development of new smKIs for so called “targeted therapy” has been expended. Conventional 
chemotherapeutics affect all rapidly proliferating cells likewise. In contrast, kinase inhibitors target 
specific cellular transduction pathways. As of 2017 39 small-molecule kinase inhibitors have been 
approved for clinical use by the FDA mainly for oncological indications.75 Despite this success some major 
restrictions have emerged. Due to the highly conserved ATP binding pocket selectivity towards a 
particular kinase remains difficult to achieve. Although therapy with kinase inhibitors is generally less 
toxic than conventional chemotherapy, kinase inhibitor can cause severe side effects. Non-selectivity 
with subsequent off-target effects might be one reason.71 Another major drawback of kinase inhibitors 
are rapidly emerging resistances, limiting therapy prospects.76  
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The human genome encodes for 518 protein kinases, but only a small subset has been studied.77 Thus, 
there is a need to develop tools and selective probes to uncover functions of the unknown kinases. 
Promising results are emerging for the inhibition of cyclin-dependent kinases (CDKs).78 CDKs are enzymes 
whose activity depends on a regulatory subunit – a cyclin. Human cells exhibit not less than 20 different 
CDKs together with 29 cyclins.79 Regarding their function within a cell, CDKs can be subdivided into two 
groups. The first group is involved in gene transcription. But more importantly the second group of CDKs 
are enzymes that drive the cell through every transition of cell cycle in mitosis and are therefore 
responsible for functional cell division.80 Since cell cycle regulation is a highly sensitive process, 
aberrations of CDK activity is a common characteristic of cancer cells.81,82 CDKs have been in focus for 
drug developers since the 1990s.83 It took until 2015 before the first CDK inhibitor, Palbociclib, got 
approval for clinical use by the FDA. Up to date there are already three clinically approved CDK inhibitors 
available in the United States (Figure 9).84–86  
 
 
Figure 9: FDA-approved CDK inhibitors until 2018.
84–86
 Both Palbociclib and Ribociclib got clinical approval by the European 
Medicines Agency (EMA) as well. Clinical approval of Abemaciclib by the EMA is still pending.
87,88
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However, a tremendous number of CDK inhibiting candidates entered clinical trials but failed mostly due 
to high toxicity. It appeared that there is a lack of therapeutic window.80 This might be due to the fact 
that correct function of certain CDKs are critical for survival of healthy cells. So far most of the CDK 
inhibitors showed intrinsic inability to discriminate between cancerous and healthy tissues.80  
To achieve this discrimination between therapy site and healthy tissue, innovational therapy strategies 
like activation by light, at therapy sites only, might be helpful. To examine this hypothesis we chose 
AZD5438 (16) as a model compound for potent CDK inhibition, but low tolerability in clinical studies.89,90   
 
Figure 10: Chemical structure of AZD5438. AZD5438 as oral inhibitor of CDK 1,2 and 9 showed potent antitumor effects in 
human tumor xenografts. Due to a lack of tolerability the clinical development program was stopped.
89
  
 
 
 
1.6 Microtubule-targeting agents (MTAs) 
Microtubules are hollow tubes composed of polymerized α- and β-tubulin. Microtubules represent one 
major component of the cytoskeleton of eukaryotic cells. They are critical in various cell processes, such 
as cell movement, intracellular transport and cell division.91 The polymerization and depolymerization of 
α- and β-tubulin is a highly dynamic process.92 By rapid addition or removal of tubulin subunits at the 
end of microtubules, human cells are able to precisely regulate growth and shrinking of microtubules.93 
During mitosis microtubules are required to separate the chromosomes and partition them to each 
daughter cell.94 To ensure flawless cell division, tightly regulated microtubule dynamics are crucial.  
Compounds that interfere with microtubule dynamics disrupt the progression of the cell cycle during 
mitosis and subsequently provoke apoptosis. Therefore, microtubule-targeting agents are highly 
effective in killing rapidly dividing cells. Importantly, functioning microtubules are of vital significance 
also for non-mitotic cells.95  This has made microtubules an attractive target for development of 
anticancer drugs.96   
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Microtubule-targeting agents (MTAs) disrupt microtubule dynamics and can broadly be classified into 
microtubule-stabilizing (such as Taxanes e.g. Paclitaxel) and microtubule-destabilizing (such as Vinca 
alkaloids e.g. Vincristine and Colchicine) agents.91 As the vast majority are natural products isolated from 
bacteria, plants and marine sponges, MTAs are very often structurally diverse and complex molecules 
(Figure 11).97  
 
 
 
Figure 11: Chemical structures of chosen MTAs. 
Left: Paclitaxel (Taxol®) stabilizes microtubules, protects it from disassembly and subsequent blocks the progression of mitosis. 
Taxanes are isolated from the Pacific yew Taxus brevifolia.
98
 
Right: Vincristine (Oncovin®) as a microtubule-destabilizing agent inhibits the formation of the spindle apparatus during mitosis. 
Vinca alkaloids are isolated from the Madagascar periwinkle Catharanthus roseus.
99
 
 
 
The binding modes of MTAs are diverse and complex. There are three major binding domains on 
microtubules identified:  the taxane-binding domain on the inside surface of the microtubule tube, the 
colchicine-binding domain, where colchicine-tubulin complexes copolymerize into the microtubule 
lattice and finally the Vinca-binding domain at the very end of the microtubules. Furthermore Vinca-
domain binders rapidly bind to soluble tubulin dimers, the building blocks for microtubule tubes, as well. 
Occupying any of these binding sites results in a disruption of microtubule dynamics.96,97 Although the 
exact binding modes of most classical MTAs such as Paclitaxel is fully understood100, the binding 
mechanisms of some MTAs particularly novel small-molecule MTAs (smMTAs) remain unclear.      
With the long history of clinical efficacy, MTAs remain to date the most classical yet reliable 
chemotherapeutics which are often integrated in combination chemotherapy regimens.97,101 
Microtubule-targeting Vinca alkaloids and Taxanes are frontline treatments for several tumors such as 
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breast, ovarian and non-small cell lung cancer as well as non-Hodgkin’s lymphoma.102–106 Despite this 
broad applicability, clinically approved MTAs are ineffective for treatment of brain tumors as their large 
molecular weight (> 800 g/mol) renders them unable to cross the blood-brain barrier.107 Hence, there 
has been increasing research interest towards the development of effective MTA delivery methods and 
small-molecule microtubule-targeting agents able to cross the blood-brain barrier.108–110 In 2015 the 
group of L. Munoz discovered compound 17 as a small-molecule inhibitor of tubulin polymerization and 
demonstrated its anticancer efficacy in patient-derived glioblastoma cells.101,104,111  
 
 
Figure 12: Small-molecule tubulin inhibitor as an attractive lead for development of potential chemotherapeutics for brain 
tumors. 
 
 
 
 
 
Cancer therapy with established MTAs has two major drawbacks. Unfortunately, resistance acquired  
during treatment is a common event and has plagued the overall success.112 Since classical 
chemotherapeutics like MTAs attack all rapidly proliferating cells, regardless of whether being tumor or 
healthy cells,  severe side effects such as neuropathy further restrict therapy.113,114 Combination of a 
small-molecule microtubule targeting agent together with the advantages of the caging concept could 
not only make MTAs available for brain tumor therapy while also limit systemic side effects and 
resistances. At the same time, since knowledge about binding modes and the structure-activity 
relationships of small-molecule MTAs is little, photoactivatable small-molecule MTAs could serve as 
valuable tools to study their binding mechanisms and kinetics.    
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2 Aims and Objectives 
The general aim of this work was the development of a photoactivatable CDK inhibitor as well as a 
photoactivatable small-molecule microtubule-targeting agent (MTA). By implementation of the caging 
concept, its unique features might be used to address two major issues both of smKIs and MTAs: 
systemic side effects and acquired resistances.115–120 Based on an excellent active/inactive ratio, a rapid 
concentration jump of the active drug upon irradiation of only the cancer-afflicted tissues is possible.121 
As a consequence, cancer cells have to face abruptly high drug concentrations, compared to a slow 
increase of the drug concentration with oral administration. The intrinsic inability of smKIs and MTAs to 
discriminate between tumor and healthy cells, can be overcome by an external discrimination using light 
as a remote trigger to regulate the biological activity of the drugs. Systemic side effects might be 
minimized, which would enable higher local drug doses if required. Additionally to this novel therapeutic 
approach, photoactivatable inhibitors could serve as valuable tools to study biological processes e.g. 
kinetics and binding mechanisms.122–127 
 
Figure 13: General workflow for the development of photoactivatable prodrugs. 
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2.1 Photoactivatable cyclin-dependent kinase inhibitor 
The objective of this project included the design, synthesis, photochemical characterization and 
biological evaluation of a photoactivatable prodrug of a CDK inhibitor. The workflow (Figure 13) for the 
development of photoactivatable prodrugs was followed.  
Starting point was the selection of the particular inhibitor on which the caging concept should be 
applied. AZD5438 (16) was the CDK inhibitor of choice and all further experiments within this project 
were dedicated to it (see chapter 1.5). Additionally, selection of the photoremovable protecting group 
was of similar importance (see chapter 1.3). To exploit the features of the caging concept, inhibitor 
stability upon irradiation with light of the respective wavelength needed for photoactivation is 
indispensable to preclude inhibitor degradation right after photoactivation. Subsequently, molecular 
modeling studies were to be performed to reveal the binding mode together with key interactions 
between the active inhibitor and the kinase. Regarding a high active/inactive ratio it was considered to 
be essential to block these key interactions by attachment of the PPG to the pharmacophore. In order to 
save some valuable inhibitor material prior to the actual usage of AZD5438 (16), dummy experiments 
were to be carried out. Therefore, the pharmacophore of the inhibitor had to be synthesized (Figure 14) 
and subsequently caged with the PPG by the intension of optimizing reaction conditions.  
 
 
 
Figure 14: Chemical structure of AZD5438 (16). The pharmacophore is highlighted in grey. 
 
By the time an efficient way to cage the pharmacophore with the chosen PPG was found, synthesis of 
the actual caged inhibitor had to be performed. Having the caged inhibitor in hand, the photochemical 
characterization should be one of the central parts of this work. It should include the identification of the 
ideal irradiation wavelength for photoactivation with subsequent studies of the efficacy of the 
photoactivation. In order to function as a valuable probe for biological applications, a quick and efficient 
20         Aims and Objectives 
 
photoactivation in vitro is desperately needed, since cell viability should not be impaired by the 
irradiation. Therefore, photoactivation experiments had to be designed as close to the in vitro conditions 
as possible.  
The following biological evaluation had to address two major objectives. First of all,  it had to be shown 
whether the biological activity could had been diminished by attachment of the PPG. In order to tackle 
the problems of side effects and resistances or to serve as a tool compound, biological inactivity of the 
caged prodrug is crucial for success. Secondly, the local and temporal restoration of biological activity 
upon irradiation had to be demonstrated in vitro. Biological inactivity of the prodrug as well as its 
restoration upon irradiation are of major significance for the proof of concept. Both kinase assays and 
cell viability assays were to be utilized to examine the biological activity of the prodrug as well as the 
subsequent photoactivation. Furthermore,  the impact of the applied light on cell viability had to be 
evaluated. Since the photoactivation is accompanied by the formation of a byproduct a possible cell 
toxicity of the cleaved protecting group had to be investigated.  
To determine whether a photoactivatable compound is valuable for biological applications or as a tool 
compound, the  reaction rate of the photoactivation is a critical attribute. Obviously the PPG plays the 
key role, but recent reports show that the leaving group, in this study the inhibitor, effects the rate of 
photoactivation as well.37 To elucidate this issue, several analogues of the pharmacophoric scaffold with 
different substituents in position R (Figure 15) had to be synthesized and caged with the PPG following 
the objective of studying the influence of the electronic and mesomeric effects of the substituent R on 
the rate of photoactivation. 
 
 
 
Figure 15: Chemical structure of the pharmacophoric scaffold of AZD5438 (16).  
Residue R (highlighted in grey) was to be modified to study the influence of the electronic and mesomeric effects of R on the 
reaction rate of the photoactivation.  
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Although extensive effort has been devoted to the development of visible light absorbing PPGs and a 
couple of promising candidates were introduced, the vast majority of the photoactivatable prodrugs for 
biological applications known today utilize near UV light absorbing PPGs.125 In the course of this project 
two promising strategies to overcome the limited penetration depth of UV light were to be further 
investigated. On the one hand, the applicability of a visible light absorbing PPG, namely BODIPY (9), 
towards the chosen CDK inhibitor was to be examined. Therefore, a strategy to synthesize the PPG as a 
precursor which can serve as a universal coupling reactant together with the actual synthetic attachment 
of the PPG to the inhibitor had to be found. Again, dummy experiments utilizing the pharmacophore of 
the inhibitor seemed to be useful prior synthesis of the BODIPY caged prodrug of inhibitor 16. 
Subsequent photochemical characterization should examine whether a fast and clean photoactivation 
with visible light is feasible. To be useful for biological applications a quantitative photoactivation by 
irradiation has to occur within a short period in which the cell viability is not impaired. Hence, impact of 
irradiation of the respective wavelength on the cell viability had to be investigated, further referred to as 
light titration experiments. Photoactivation experiments together with light titration experiments should 
answer the question of the BODIPY group’s utility for biological applications. 
On the other hand, the possibility of utilizing beta radiation respectively thereupon induced Cherenkov 
radiation for a photoactivation was to be investigated. Two strategies had to be followed. Firstly, the 
ability of β-emitting radionuclides to activate a photoactivatable prodrug in solution should to be 
determined. In a second setup, particle beams of a linear particle accelerator were to be used to induce 
Cherenkov radiation in solution in the interest of investigating a potential subsequent photoactivation. 
For both reasons a cooperation with the clinic for nuclear medicine and radio pharmacy at the university 
hospital (UKSH) in Kiel, Germany, has been established.  
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2.2 Photoactivatable small-molecule microtubule-targeting agent 
The objectives of this project compromised the design, synthesis, photochemical and biological 
evaluation of a photoactivatable small-molecule MTA. The general workflow (Figure 13) had to be 
followed with few exceptions. The binding modes of MTAs are complex since there is no tight and 
distinct binding pocket compared to the ATP binding pocket of kinases.96,97 Also, the microtubule 
polymerization and depolymerization is a highly dynamic process thus molecular modeling studies 
struggle to predict a reliable binding mode for small-molecule MTAs. Since the pharmacophore of the 
chosen small-molecule MTA is unknown, structure activity data had to be used to reveal a favorable 
position to attach the PPG. Nonetheless, whether the biological activity could had been significantly 
diminished by introduction of the PPG had to be examined. Therefore, cell viability assays, tubulin 
polymerization assays, colchicine binding assays, immunofluorescence imaging and apoptosis assays had 
to be performed to not only demonstrate a potential inactivation due to the caging, but also the 
restoration of biological activity upon irradiation in vitro. A cooperation with the workgroup of Lenka 
Munoz from the school of medical science, University of Sydney has been established to perform all 
experiments of the biological evaluation at the University of Sydney. 
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3 Results and Discussion 
3.1 Photoactivatable small-molecule microtubule-targeting agent  
3.1.1 Selection of inhibitor and PPG 
In 2015 the workgroup of L. Munoz discovered compound 17 as a potent inhibitor of microtubule 
polymerization (Figure 12). Consequently, effective antimitotic and apoptotic activity was demonstrated 
in vitro on established glioblastoma cell lines as well as on patient-derived primary glioblastoma 
cells.104,111 Cytotoxic activity together with its low molecular weight (349 g/mol) renders 17 an attractive 
lead for the development of potential agents against brain tumors. Hence, we chose compound 17 for 
the development of a photoactivatable small-molecule MTA (smMTA) – a novel concept in the field of 
smMTAs.  
Due to its well understood photochemistry, a rapid photocleavage upon irradiation with UV light and the 
simple chemical accessibility, the 4,5-dimethoxy-2-nitrobenzyl protecting group (DMNB, Figure 16) was 
the PPG of choice for this proof of concept study.28  
 
 
Figure 16: Chemical structure of the DMNB protecting group. X represents the leaving group. 
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3.1.2 Stability upon irradiation 
Inhibitor stability upon irradiation of light with the wavelength required for photoactivation is an 
essential prerequisite of the caging concept. Otherwise, the active inhibitor might degrade during or 
right after the photoactivation. Therefore, UV stability of 17 was examined by irradiation of a 1 mM 
compound solution in DMSO with UV light of 365 nm. The content determination was carried out by 
HPLC analysis. Under this conditions the compound appeared to be stable for up to 20 min of irradiation.  
 
 
Figure 17: UV stability of smMTA 17. The compound solution (1mM) in DMSO was irradiated at 365 nm (5.4 W) and 
subsequently analyzed by HPLC. Each value is a mean ± SD of two independent experiments. 
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3.1.3 Synthesis 
Since chosen smMTA 17 is commercially not available, it had to be synthesized.  Hence, the  four step 
synthesis route discovered by the Munoz group was followed (Figure 18).104 Starting from 
bromobenzene, the first step represents a Friedel-Crafts acylation with succinic anhydride to yield a 4-
oxo-4-phenylbutanoic acid derivative. The resulting ketone function of the oxobutanoic acid derivative 
was subsequently reduced in terms of a Clemmensen reduction by the use of amalgamated zinc. Next, 
the carboxylic acid was converted to an amide by peptide coupling with 4-aminophenol utilizing PyBOP 
as the coupling reagent. In the last step a Suzuki coupling with an aryl boronic acid using microwave-
assisted organic synthesis was carried out to substitute the bromine by a fluoropyridine to gain the 
desired inhibitor 17 in decent yields. 
 
 
Figure 18: Synthesis of smMTA 17 according to literature
104
.  
 
 
Having the inhibitor in hand, the decision where to attach the PPG had to be made. Since molecular 
modeling studies appeared to be unfavorable to identify the pharmacophore, information from former 
structure-activity relationship studies had to be used. Data from cell viability assays using the U87 and 
U251 glioblastoma cell lines indicate the phenolic moiety as important for biological activity. By removal 
of the phenolic moiety the EC50 values increase by factor 16 respectively 12 (Table 1).
104,111 Furthermore 
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the phenolic moiety appeared to be easily chemical accessible for caging due to its terminal position in 
the molecule as well as the decent phenolic reactivity. By this reasons the phenolic moiety was 
considered to be most appropriate for caging.  
 
Table 1: Cellular efficacy on the glioblastoma cells U87 and U251 of smMTA 17 and its dehydroxylated derivate 18. 
Cellular efficacy (EC50) was determined after 72 h of drug treatment. Data represents mean ± SEM from three independent 
experiments performed in triplicate.
104
 
Compound Chemical Structure U87 (EC50, µM) U251 (EC50, µM) 
17 
 
0.4 ± 0.1 0.4 ± 0.1 
18 
 
6.6 ± 0.9 4.6 ± 0.4 
 
 
The caging of inhibitor 17 was accomplished by the use of DMNB-Br (19). In terms of a nucleophilic 
substitution the benzylic bromine of 19 was replaced by the inhibitor using potassium carbonate as a 
base with a yield of 60% (Figure 19). The main reason for a decreased yield was an elaborate purification. 
In order to eliminate residual educt 17 thoroughly from the product, two sequential flash 
chromatography columns were necessary. Since the caged prodrug 20 is photoactivatable by UV light, 
avoidance of extensive light exposure during all steps of synthesis and purification was of great 
importance. Minor impurities with the active inhibitor might result in remnant biological activity. This 
issue is particularly relevant for the handling of the caged prodrug during in vitro testing as a full 
avoidance of light exposure is hardly manageable. In order to detect whether an unwanted 
photoactivation during in vitro testing is relevant, derivative 21 was synthesized. Due to the lack of the o-
nitro group compound 21 is not photoactivatable (Supplementary Figure 1) but should exhibit similar 
biological activity since interactions of the phenolic moiety with the target is disrupted in similar 
manners as by the caged prodrug 20.  
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Figure 19: Synthesis of the caged prodrug 20 from smMTA 17 (top). Derivative 21 was synthesized under the same reaction 
conditions from smMTA 17 using (bromomethyl)benzene (bottom).  
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3.1.4 Photochemical characterization 
In order to evaluate the photochemical characteristics of the caged prodrug 20, UV/Vis absorption 
spectra of the unprotected inhibitor as well as the caged prodrug were recorded. The optimal irradiation 
wavelength is characterized by a high light absorption of the caged prodrug  while the uncaged inhibitor 
should not absorb light of the respective wavelength at all by the reason of inhibitor stability as well as 
non-interference with the photoreaction. The unprotected smMTA 17 shows no light absorption above 
320 nm whereas the caged prodrug exhibits a broad absorption band around 360 nm (Figure 20). This 
result is in good agreement with the generally described wavelength for photocleavage of the DMNB 
protecting group.28 By the intention of utilizing the caged prodrug for biological applications, tissue 
damage of shortwave UV irradiation below 300 nm has to be minded. Hence, a wavelength of 365 nm 
was considered to be optimal. Due to the high intensity and easy handling of LEDs, custom made LED 
lamps with a emission wavelength of 365 nm were utilized for all further photochemical characterization 
as well as for the biological evaluation. 
 
 
Figure 20: UV/Vis absorption spectra of smMTA 17 and its DMNB caged prodrug 20. UV/Vis absorption spectra of caged 
prodrug (solid line) in comparison with the unprotected inhibitor (dashed line) in DMSO at a concentration of 25 µM. 
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Having identified the optimal wavelength for irradiation, the next step represents the photoactivation 
experiment in order to investigate whether it is possible to cleave the PPG upon irradiation thus 
reactivating the prodrug 20. Specifically, the kinetics of the photoactivation reaction were quantified. A 
compound solution of 1 mM in DMSO was irradiated by a LED reactor with an emission maximum at 365 
nm (5.4 W) for 10 min (Figure 21). Samples were taken at indicated time points and quantified by HPLC  
analysis. Within less than 1 min half of the photoactivatable prodrug could have been cleaved under 
these conditions. After 2 min of irradiation, 100% of the photoactivatable prodrug has been converted, 
resulting in a full release of the active smMTA. In conclusion the phenolic moiety of smMTA 17 proved to 
be suitable for caging with a subsequent rapid and quantitative photoactivation.  
 
Figure 21: Photoactivation of the photoactivatable prodrug 20 at a concentration of 1 mM in DMSO. The compound solution 
was irradiated at 365 nm with 5.4 W for 10 min. After indicated time points samples were taken and analyzed by HPLC (n = 2). 
The amount of the caged prodrug 20 (squares) is plotted against the released inhibitor 17 (triangles). Each value is a mean ± SD 
of two independent experiments. 
 
3.1.5 Biological evaluation 
Having demonstrated a rapid and quantitative photoactivation under experimental conditions, the 
question of utility in biological systems remains to be answered. In order to evaluate whether 
photoactivation occurs under biological conditions too, biological activity was measured with and 
without irradiation utilizing several biological assays. All of these should address two major issues: 
biological inactivity of the caged prodrug 20 as well as the restoration of biological activity upon UV 
irradiation.  
 
30         Results and Discussion 
 
Tubulin polymerization assay 
First of all, the ability of 20 to inhibit the assembly of β-tubulin to microtubules was evaluated by 
performance of a tubulin polymerization assay (Figure 22). Within this assay Paclitaxel as the most 
prominent member of microtubule-stabilizing agents, Vinblastine a microtubule-destabilizing agent as 
well as DMSO were used as controls to ensure correct assay function. In agreement with their generally 
valid mechanism of action, Paclitaxel increased tubulin polymerization compared to the DMSO control 
whereas Vinblastine inhibited tubulin polymerization. Incubation with the caged prodrug 20 showed a 
negligible effect on tubulin polymerization. Upon irradiation, the cleaved prodrug decreases tubulin 
polymerization to a similar effect as smMTA 17. Since inhibition of tubulin polymerization of smMTA 17 
and its caged prodrug 20 irradiated with UV light was indistinguishable, the photoactivation within this 
assay worked perfectly. Furthermore, biological efficacy to inhibit tubulin polymerization could be 
significantly diminished by the caging with the PPG.    
 
 
 
Figure 22: Tubulin polymerization assay. Purified porcine brain tubulin was incubated with paclitaxel, vinblastine, DMSO, 
smMTA 17  and caged prodrug 20 ± UV irradiation (365 nm, 1.8 W, 5 min). The assembly of microtubules was monitored by an 
increase in fluorescence. The data represents the mean from three independent experiments. Each data point was performed in 
triplicate. 
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Cell viability assays 
In order to further validate the observed effects, cell viability assays with U251 and patient-derived RN1 
glioblastoma cells were performed. Impairment of the irradiation on cell viability is a knock-out criterion 
in order to utilize caged prodrugs for biological applications. Hence, U251 and RN1 cells were treated 
with UV light (365 nm, 1.8 W) solely in order to determine tolerable levels of UV light exposure. U251 
cells tolerated up to 60 s of irradiation without any implication (Supplementary Figure 2). In contrast, 
patient-derived RN1 cells tolerated only 30 s of irradiation which might be due to the characteristics of 
primary cancer cells. Primary cancer cells, such as patient-derived RN1 glioblastoma cells, are cultured as 
stem cells under specifically defined, in vivo simulating conditions in order to maintain both phenotype 
and genotype of the primary resected tumor.101,128 Viability of primary tumor cells is strongly related to 
these defined conditions making them presumably less resistant to external impacts such as irradiation 
by light.128–132   
Subsequently, cell viability was assessed by treatment of both cell lines with smMTA 17 and its caged 
prodrug 20 for 48 h respectively 72 h for RN1 cells (Figure 23). Without UV irradiation smMTA 17 showed 
an EC50 of 1.3 µM on U251 cells respectively 0.2 µM on RN1 cells, which corresponds with previously 
published data.104,111 Addition of the bulky PPG decreased cytotoxicity dramatically. Caged prodrug 20 
exhibited no significant cytotoxicity up to high micromolar concentrations, resulting in an increase of the 
EC50 by factor 55 respectively factor 185 (EC50 = 72 µM, EC50 = 37 µM for U251 and RN1 cells, 
respectively). The marginal residual cytotoxic activity of the caged prodrug could be due to several 
reasons. Minor impurities of the active smMTA originating from synthesis could have stayed undetected 
by the test of purity prior biological testing due to detection limits of the HPLC analysis. Off-target effects 
of the caged prodrug could furthermore contribute to cellular toxicity. More importantly, the binding 
mode of smMTA 17 is unknown. Although structure-activity relationship studies identified the terminal 
phenolic moiety as relevant for biological activity, the question whether a DMNB caged prodrug is still 
able to bind to its binding site remains uncertain, especially since microtubule binding sites lie on the 
surface of the protein. Hence, it is conceivable that the DMNB caged prodrug 20 still possesses a certain 
binding affinity to microtubules resulting in marginal residual biological activity.  
Since remaining biological activity of the caged prodrug 20 was assessed, photoactivation in vitro had to 
be investigated next. Additionally to compound treatment, U251 and RN1 cells were irradiated for 60 s 
respectively 30 s with UV light (365 nm, 1.8 W). As an important result, cytotoxic efficacy of the caged 
prodrug 20 can be restored upon UV irradiation, while cytotoxic efficacy of smMTA 17 remains 
unchanged (Figure 23). Using RN1 cells, the slightly reduced cytotoxic activity of 20 irradiated with UV 
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light might be explained by the shortened time of irradiation. However, the dose-response curves of 
smMTA 17 and its caged prodrug 20 both irradiated with UV light coincide clearly to further provide 
evidence for an efficient photoactivation in vitro.  
 
  
 
Figure 23: Photoactivation of the caged prodrug in cell viability assays. The restoration of biological activity of caged prodrug 
20 upon irradiation with UV light was demonstrated in vitro using glioblastoma cell lines. A) U251 and B) patient-derived RN1 
glioblastoma cells were treated with smMTA 17 and its caged prodrug 20 without UV irradiation (left). In a second setup, U251 
and RN1 cells were irradiated with UV light (365 nm, 1.8 W) after treatment with smMTA 17 and caged prodrug 20. U251 cells 
were irradiated for 1 min and RN1 cells for 30 s. Cell viability was determined after 48 h of drug treatment respectively 72 h for 
RN1 cells. Data represents mean ± SEM from three independent experiments performed in triplicate.     
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Despite permanent dimming of compound solutions, unwanted photoactivation by ambient light is a 
common problem while working with photoactivatable compounds during all steps of an experiment e.g. 
handling, dilution or cell treatment. In order to quantify this effect, benzyl protected analogue 21 was 
synthesized (Figure 19). Due to similar spatial extension of the benzyl and DMNB moiety, biological 
activity of 20 and 21 is presumed to be equal. However, the absence of the o-nitro group in 21 prevents 
photocleavage of the benzyl moiety (Supplementary Figure 1). Using U251 cells, 21 affected cell viability 
only at concentrations higher than 40 µM, which is in good agreement with cytotoxic efficacy of caged 
prodrug 20 (Figure 24 A). Unwanted photoactivation of the caged prodrug 20 during performance of the 
cell viability assays did not seem to occur.  
Having demonstrated the prove of concept in vitro, the question of toxicity of the cleaved protecting 
group had to be addressed. Due to the intrinsic cytotoxicity of smMTA 17, its caged prodrug 20 is 
unsuitable to address this issue. In 2015 Horbert et al. showed that both tert-butyloxycarbonyl (boc) 
protected alanine as well as its DMNB caged derivative 22 had no effect on the cell viability of SKMel13 
cells.25 Hence, DMNB caged boc-protected alanine 22 was utilized to investigate the impact of the 
cleaved protecting group on cell viability, since a photoactivation upon UV irradiation should release the 
biologically inactive boc-protected alanine, and more importantly the cleaved protecting group. Thus, 
U251 cells were treated with compound 22 and subsequently irradiated with UV light for 60 s (365 nm, 
1.8 W). The cleaved protecting group had no impact on the cell viability up to the highest concentration 
of 100 µM (Figure 24 A). This data indicates that cytotoxic efficacy after UV irradiation results from 
uncaging of 20, but not from the cleaved protecting group. 
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Figure 24: Effects of negative controls 21 and 22 on U251 cell viability. A) U251 cells were treated with compound 21 as well as 
compound 22 plus UV irradiation (365 nm, 1.8 W, 1 min). Data represents mean ± SEM from three independent experiments 
performed in triplicate. B) Chemical structures of compound 21, a benzyl protected analogue of smMTA 17 and compound 22, 
DMNB protected boc-L-alanine. 
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Immunofluorescence imaging 
An essential requirement to utilize photoactivatable prodrugs for biological applications is leaving 
healthy tissues unaffected. Since a correct microtubule network is crucial for healthy cell function, 
investigation whether the caged prodrug 20 interferes with the microtubule network of U251 cells was 
conducted by immunofluorescence imaging. Thereby, U251 cells were treated with smMTA 17 and its 
caged prodrug 20. By the addition of DAPI, the DNA of the cell nuclei became visible. The microtubule 
network of the cells was subsequently visualized by β-tubulin staining. Healthy U251 cells are 
characterized by a spindle shaped body and neuron-like morphology.133,134 Treatment with smMTA 17 
led to a pronounced disassembly of microtubule network as well as a distinct alteration of cell 
morphology in the form of a spherical shape and shrinkage (Figure 25). In contrast, caged prodrug 20 had 
no effect on both the microtubule network and cell morphology. Importantly, upon irradiation with UV 
light of 20, the microtubule network lost their organization and cells rounded up, indicating a release of a 
microtubule-targeting agent upon irradiation. 
 
 
Figure 25: Immunofluorescence imaging of treated U251 cells. U251 cells were treated with smMTA 17, the caged prodrug 20 
and the caged prodrug 20 in combination with UV irradiation (365 nm, 5 min, 1.8 W). Cells were exposed to 5 µM of  smMTA 17 
and caged prodrug 20 respectively for 24 hours. Cells were fixed with and stained with Alexa488-labeled anti-β-tubulin antibody 
(green) or DAPI (blue). Representative images of three independent experiments are shown. 
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Apoptosis assay 
In addition to the disrupting of the tubulin filaments, microtubule-targeting agents are characterized by 
the induction of apoptosis through the intrinsic (mitochondrial) apoptotic pathway.101,135 In order to 
determine whether this mechanism contributes to the cytotoxic activity of photoactivated 20, Annexin V 
staining experiments have been performed. Early stage apoptosis is characterized by a translocation of 
phosphatidylserine (PS) to the outer surface of the cell membrane where they are exposed to Annexin V. 
Annexin V represents a Ca2+-dependent phospholipid-binding protein with a high affinity to PS, hence 
being a sensitive probe for apoptosis.136 RN1 cells have been treated with UV light solely, smMTA 17 and 
the caged prodrug 20 with and without UV irradiation. Apoptosis has subsequently been determined by 
quantification of Annexin V positive cells using flow cytometry. In agreement with data from cell viability 
assays, 30 s of UV irradiation (365 nm, 1.8 W) did not increase the basal level of apoptosis (Figure 26). In 
contrast, treatment with 17 results in a significant increase of apoptotic cells, whereas the caged prodrug 
20 had no effect. However, upon UV irradiation of 20 the amount of apoptotic cells is comparable to 
treatment with 17, suggesting that decreased cell viability is due to cells undergoing apoptosis. 
 
 
Figure 26: Quantification of apoptosis by Annexin V staining. RN1 cells were treated with smMTA 17, the caged prodrug 20, the 
caged prodrug 20 in combination with UV irradiation (365 nm, 30 s, 1.8 W) at a concentration of 5 µM for 48 hours. Control cells 
received an equivalent amount of DMSO or UV irradiation (365 nm, 30 s, 1.8 W). Cells were stained with Annexin V and analyzed 
by using the MUSE Cell Analyzer. Data represents mean ± SEM from three independent experiments (****P < 0.0001, one-way 
ANOVA followed by Tukey’s multiple comparison test). 
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In summary, extensive biological evaluation of the DMNB caged prodrug 20 provided a notable proof of 
concept. All biological assays were successfully adapted for the specific issue. Only marginal biological 
activity of the caged prodrug could be detected examining tubulin polymerization, cell viability, 
microtubule interference and apoptosis. Additionally, the restoration of biological activity upon 
irradiation with UV light worked perfectly in vitro even with a significantly reduced irradiation time of 30 
s working with the primary cancer cells RN1. Importantly, the required irradiation dose for a rapid and 
quantitative recovery of biological activity does not affect cell viability of the glioblastoma cells U251 and 
RN1, rendering the DMNB caged prodrug 20 valuable for biological applications. 
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3.2 Photoactivatable cyclin-dependent kinase inhibitor 
3.2.1 Selection of inhibitor and PPG 
The idea of regulating biological activity of cytotoxic compounds by using light under spatial and 
temporal control mainly aims to diminish systemic side effects as well as resistances, while executing 
biological activity in the targeted tissues. Hence, a spatial controlled prodrug concept is considered as 
highly beneficial to biological potent but low tolerable compounds. In order to satisfy these 
requirements, CDK inhibitor 16 was chosen for this project. Cyclin-dependent kinases (CDKs) are involved 
in the cell cycle transition in many ways. Since cell division is a highly sensitive process, CDK inhibition 
presumably goes hand in hand with cell toxicity (see chapter 1.5). As the photoremovable protecting 
group (PPG) for the caging of the inhibitor, the DMNB group was chosen to start this project with, due to 
its well understood and efficient photochemistry.   
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3.2.2 Stability upon irradiation 
Stability of the inhibitor upon irradiation at the wavelength required for photoactivation represents a 
crucial criterion which had to be proved before the beginning of the project. Since the DMNB group shall 
be utilized for this project, UV stability of the inhibitor at a relevant wavelength has to be determined. By 
the intension of developing a caged prodrug of inhibitor 16 for biological applications, the experiments 
were designed as close to the in vitro conditions as possible. As a consequence the compound solution 
was not only prepared in DMSO (1 mM), but also in PBS buffer with 10% DMSO (25 µM). The addition of 
DMSO is necessary in order to prevent precipitation of the inhibitor. Subsequently, 100 µL of each 
solution were irradiated in a well of a commonly used 96-well plate for different durations up to a 
maximum of 10 min at 365 nm (360 mW). A custom made LED lamp particularly designed for irradiating  
96-well plates was used for all photoexperiments within this project. The content determination was 
carried out by HPLC analysis. Both in high concentrations in DMSO as well as in low concentrations in PBS 
buffer, inhibitor 16 withstands UV irradiation for up to 10 min utterly (Figure 27).    
 
 
 
Figure 27: UV stability of inhibitor 16. A) A 1 mM compound solution in DMSO was irradiated at 365 nm (360 mW) in a 96-well 
plate for up to 10 min. B) A 25 µM compound solution in PBS buffer with 10 % DMSO was irradiated at 365 nm (75 mW) in a 96-
well plate for up to 10 min. Subsequently, samples of both A) and B) were analyzed by HPLC. Each value is a mean ± SD of two 
independent experiments.  
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3.2.3 Molecular modeling 
On the bases of molecular modeling studies the decision where to attach the PPG to the inhibitor had to 
be made. Inhibitor 16 exhibits different moieties available for the attachment of a PPG. However, with 
the objective of biologically inactivating the inhibitor by attachment of the PPG, the pharmacophore 
together with its key interactions with the target kinase had to be identified. Blocking these key 
interactions by the PPG was assumed to result in a loss of biological activity.  
The binding mode of inhibitor 16 in the ATP binding pocket of CDK2 is shown in Figure 28 A and B (pdb 
4FKO). Figure 29 shows the simplified corresponding two-dimensional (2D) ligand-interaction diagram. 
The N-phenylpyrimidine-2-amine moiety forms two H-bonds towards leucine 83 of the hinge region of 
the kinase rendering it as the critical core for binding to the target kinase. Furthermore the 
methylsulfonyl moiety is exposed to the solvent, whereas the 1-isopropyl-2-methyl-1H-imidazole moiety 
lies deeper in the ATP binding pocket of the kinase. The N-phenylpyrimidine-2-amine moiety was 
identified as the pharmacophore of inhibitor 16. Both the NH as well as the pyrimidine nitrogen seem to 
be suitable for caging. Since attachment of the PPG to the pyrimidine nitrogen would entail a quaternary 
nitrogen with a permanent positive charge, the NH moiety was supposed to be most suitable for caging.   
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Figure 28: 3D binding mode of inhibitor 16 in the ATP binding pocket of CDK2 predicted by molecular modeling studies 
(pdb 4FKO). H-bonds formed between the ligand and the protein backbone are indicated by black dotted lines. B) Enlarged view 
of the binding mode. C) Superimposed DMNB caged derivative  23 in the ATP binding pocket. Red dashed lines represent sterical 
clashes between the PPG and the CDK2. 
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Figure 29: 2D ligand-interaction diagram of inhibitor 16 in CDK2 (pdb 4FKO).  H-bond interactions of the ligand towards the 
protein backbone are shown in purple. Solvent exposure is highlighted in grey. 
 
The assumption is supported by the simulated superposition of the NH caged prodrug 23 (Figure 30) in 
the ATP binding pocket of the target kinase CDK2 (Figure 28 C). Attachment of the DMNB group to the 
NH of the pharmacophore results in significant sterical clashes with the protein, while a plausible binding 
mode could not be calculated. Furthermore, the PPG presumably prevents formation of both H-bonds 
between the ligand and the kinase thus suggesting a loss of biological activity. Motivated by this 
hypothesis, the objective of synthesizing the NH caged prodrug 23 was subsequently pursued.  
 
 
 
Figure 30: Chemical structure of the caged prodrug of inhibitor 16. The DMNB PPG is highlighted in grey. The pharmacophoric 
scaffold is highlighted in green. 
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3.2.4 Synthesis 
Synthesis of the caged inhibitor 23 was approached by a one-step reaction between the inhibitor and a 
reactive precursor of the DMNB protecting group, since inhibitor 16 is commercially available (Figure 31). 
Considering the NH as the most nucleophilic  moiety of inhibitor 16, an one-step reaction appeared to be 
promising. 
 
Figure 31: Strategy for caging of inhibitor 16 with the DMNB PPG. Caging was approached by a nucleophilic substitution 
reaction. Inhibitor 16 acts as the nucleophile. X represents a suitable leaving group of the DMNB precursor. 
 
 
In the interest of saving valuable material of the inhibitor 16, dummy experiments have initially been 
performed with the intention of optimizing the reaction conditions first. Hence, the key pharmacophoric 
scaffold 24 of the inhibitor, identified by molecular modeling studies, was prepared. In the sense of a 
nucleophilic aromatic substitution (SNAr) 4-(methylsulfonyl)aniline and 2-chloropyrimidine were refluxed 
in isopropyl alcohol with a few drops of hydrochloric acid to yield scaffold 24 (Figure 32).137  
 
 
 
Figure 32: Synthesis of the pharmacophoric scaffold of inhibitor 16. Synthesis was adapted from 
137
. The already electron 
deficient 2-chloropyrimidine is activated for a SNAr by protonation. Consequently, the aniline attacks the pyrimidine C2 and 
substitutes the chlorine.   
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In a next step efficient reaction conditions for the attachment of the DMNB PPG to scaffold 24 were 
investigated. Since bromine at the benzylic position represents a good leaving group, 4,5-dimethoxy-2-
nitrobenzyl bromide 19 was used as the reactant. Earlier works revealed reaction conditions utilizing 
potassium carbonate in dimethylformamide (DMF) at room temperature as superior for the caging of 
amines with 19.23,101 Unfortunately, in the present case conversion could not be observed under these 
reaction conditions (Figure 33). Assuming that the nucleophilicity  of the NH moiety was not sufficient, a 
stronger base should be beneficial. After screening different bases, sodium hydride (NaH) turned out to 
be advantageous. Additionally to the higher basicity of hydride, the sodium counterion appeared to be 
favorable. The sodium cation might have the appropriate size to stabilize the resulting scaffold anion by 
complexing both the amine and one pyrimidine nitrogen. In order to enhance yields and prevent 
decomposing of 19 by sodium hydride, the reaction had to be performed at -30 °C to gain the caged 
scaffold 25 in decent yields. Importantly, the reaction was carried out darkened to avoid unwanted 
photoactivation of the product by ambient light conditions.  
 
 
 
Figure 33: Caging of the scaffold 24. Top) Standard protocol to cage amines with the DMNB PPG from earlier works did not yield 
the desired product. Bottom) Adapted protocol utilizing sodium hydride as a stronger base while reducing the temperature 
significantly. 
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Having identified an efficient way to cage the NH moiety with the DMNB PPG as well as having proved a 
fast and clean photoactivation of the caged scaffold 25 (see chapter 3.2.5), the optimized reaction 
conditions were applied on the actual inhibitor 16. Fortunately, caging of inhibitor 16 proceeded 
accordingly, yielding the desired caged inhibitor 23 (Figure 34). However, subsequent purification turned 
out to be tedious. Remaining educt, especially inhibitor 16, had to be removed thoroughly from the 
product in order to prevent interference of residual biologically active inhibitor with biological testing. 
Two sequential flash chromatographies were necessary to gain the product at the required purity. Also 
the high light-sensitivity of photoactivatable compounds results in an elaborate purification since light 
exposure has to be diminished as much as possible. Particularly, handling solutions of photoactivatable 
compounds renders them endangered. This elaborate purification decreased the overall yield to 50%. 
Again a benzyl protected analogue 26 without the o-nitro group and thus lacking photocleavable 
properties was prepared (Figure 34) in order to detect unplanned photoactivation by ambient light 
during biological testing (see 3.1.5 cell viability assays).  
 
 
Figure 34: Caging of inhibitor 16 with the DMNB protecting group. Top) Preparation of the caged inhibitor 23 according to 
optimized reaction conditions. Bottom) Preparation of benzyl caged analogue 26 as a non-photoactivatable reference 
compound for biological testing. 
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3.2.5 Photochemical characterization 
The subsequent photochemical characterization was composed of two steps. Firstly, the optimal 
irradiation wavelength for a rapid and clean photoactivation had to be identified. The efficacy of that 
photoactivation had to be determined in a second step. As discussed in chapter 3.1.4 high light 
absorption of the caged prodrug is mandatory for a rapid photoactivation, whereas the inhibitor itself 
should not show any absorption at the respective wavelength to ensure inhibitor stability on behalf of a 
rapid and clean photoactivation. Obviously, light absorption at the wavelength needed for 
photoactivation by the inhibitor could furthermore quench the photoactivation.  
Identification of the optimal irradiation wavelength was accomplished by analysis of UV/Vis absorption 
spectra. The pharmacophoric scaffold 24 absorbed light up to 320 nm in DMSO (Figure 35). By 
attachment of the DMNB protecting group, a broad absorption band with a maximum around 365 nm 
emerged, which corresponds with the established wavelength for photocleavage of the DMNB PPG. 
However, inhibitor 16 absorbs light up to 360 nm in DMSO, making the compound potentially unstable 
towards irradiation with 365 nm (Figure 35). Since potential inhibitor instability towards irradiation with 
365 nm represents an exclusion criterion for the use of the DMNB protecting group, UV stability of 
inhibitor 16 was proven for up to 10 min of irradiation at the very beginning of the project (chapter 
3.2.2). UV/Vis spectra recorded in PBS buffer with 10% DMSO showed similar results. Again, attachment 
of the DMNB protecting group caused a broad absorption band in the near UV range. Consequently, a 
wavelength of 365 nm  was considered optimal for an efficient photoactivation. 
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Figure 35: UV/Vis absorption spectra. UV spectra of both the pharmacophoric scaffold 24 and the actual inhibitor 16 (dotted 
lines) as well as their DMNB caged prodrugs (black lines) were recorded in A) DMSO and B) PBS buffer with 10% DMSO.  
 
The quantification of efficacy of the photoactivation was one of the central parts of this work. The 
hypothesis of a rapid and clean photoactivation of the caged prodrug 23 still remained in question. The 
mechanism and efficacy of the photocleavage of o-nitrobenzyl PPGs is mainly examined for the caging of 
oxygens, presumably due to the fact that nitrogens represent poor leaving groups in terms of a 
photoactivation.28,37,138,139 However, in order to utilize the caged prodrug for biological applications as 
well as a tool compound a rapid photoactivation is crucial, since assays or cell viability should not be 
disturbed by the irradiation. 
The conditions for the investigation of the photoactivation were designed as close to eventual biological 
evaluations as possible. Therefore, all photoactivation experiments were performed in an opaque 96-
well plate commonly used in biochemical assays using a custom made LED lamp for focused irradiation. 
Additionally to DMSO, commonly used to perform photoexperiments, the photoactivation was also 
examined by using PBS buffer with 10% DMSO in order to mimic biological conditions such as aqueous 
medium, pH and electrolyte concentration. Furthermore, photoactivation involves a bond cleavage 
between the PPG and the leaving group, in this study the inhibitor. On the supposition that this bond 
cleavage requires energy, provided by light, the concentration of the photoactivatable compound will be 
a relevant parameter for rate determination of the photoactivation. In line with this notion, less energy 
might be required for a quantitative photoactivation at lower concentrations typically present in 
biochemical assays. Regarding this assumption, investigation of the photoactivation in PBS buffer with 
10% DMSO was performed at significant lower concentrations compared to the experiments in DMSO to 
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mimic the biochemical assay situation. Unfortunately, due to the limit of quantification set by HPLC 
analysis, low micromolar or even nanomolar concentrations as used in biological assays remained 
unfeasible in our lab.   
In a first step the photoactivation of the caged scaffold 25 was investigated. Both in DMSO (1 mM) and in 
PBS buffer with 10% DMSO (25 µM), the caged scaffold was entirely activated within 120 s of irradiation 
at 365 nm by using 37.5 mW (Figure 36, top).  Since 37.5 mW is a considerably low power regarding UV 
light, the rate of photoactivation was considered to be more than sufficient. Motivated by these results, 
the caged prodrug 23 was prepared. The photochemical characterization delivered comparable results. 
Again, a full photoactivation occurred within a period of 120 s of irradiation (365 nm, 37.5 mW, Figure 
36, bottom). Furthermore, no byproduct except the cleaved protecting group could be detected at 
significant concentrations, rendering the caged compound 23 a promising tool for further biological 
applications. 
 
Figure 36: Photoactivation of the caged scaffold 25 (top) and the caged prodrug 23 (bottom). 100 µL of each compound 
solution in A) DMSO (1 mM) and B) PBS buffer with 10% DMSO (25 µM) were irradiated in wells of a 96-well plate for the 
indicated time at 365 nm (37.5 mW) and analyzed by HPLC (n = 2). The amount of the caged compound (diamonds) is plotted 
against the released scaffold 24 (top, squares) respectively inhibitor 16 (bottom, squares). Each data point is a mean ± SD of two 
independent experiments. 
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3.2.6 Biological evaluation 
The photochemical characterization demonstrated a rapid and clean activation of the DMNB caged 
prodrug 23 upon irradiation with UV light under experimental conditions. Although photoactivation 
experiments were designed as close to biological conditions as possible, the photoactivation in vitro had 
to be assessed in order to determine utility for biological applications. Furthermore biological inactivity 
of the caged prodrug represents another central prerequisite. Molecular modeling studies exposed the 
NH caged prodrug 23 as incapable of binding to its target kinase (chapter 3.2.3). However, biological 
evaluation aimed to prove biological inactivity of the DMNB caged prodrug 23. Both kinase and cell 
viability assays were performed with the intention of investigating remaining biological activity of 23 as 
well as its photoactivation in vitro.  
Since photochemical characterization exhibited 23 as highly light sensitive, stability in solution was 
examined prior to biological evaluation. Regarding conditions during a cell viability assay, the DMNB 
caged prodrug 23 as well as its benzyl caged analogue 26 were incubated in PBS buffer with 20% DMSO 
for up to 48 h at 37°C in the incubator of the cell culture, reducing light exposure to a minimum. A 
second sample was stored in the lab being exposed to ambient light and room temperature. As an 
important result, storing a solution of the DMNB caged prodrug 23 at ambient light results in an 
significant activation whereas no activation was observed under dark conditions, indicating that all 
experiments of the biological evaluation had to be performed under light exclusion in order to avoid 
artefacts (Figure 37). Larger error bars obtained storing the sample at ambient light are due to natural 
differences of the light conditions. As expected, the benzyl caged analogue 26 was stable under both 
conditions. 
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Figure 37: Stability of the DMNB caged prodrug 23 and its benzyl caged analogue 26 in solution. A) A compound solution of the 
DMNB caged prodrug 23 (100 µM) in PBS buffer with 20% DMSO was incubated either in a cell culture incubator in the dark at 
37°C (left) or in the lab exposed to ambient light at room temperature (right). After indicated time points peak area 
determination was performed using HPLC analysis. Contents of the caged species is plotted against the uncaged species. B) The 
experiment was repeated analogously with the benzyl caged analogue 26 (50 µM). Each value is a mean ± SD of two 
independent experiments.  
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Kinase assay 
In a next step, the inhibitory efficacy of the DMNB caged prodrug 23 with and without UV irradiation was 
determined using the target kinase, cyclin-dependent kinase 2 (CDK2), in an ADP-GloTM Kinase Assay. Due 
to 23’s light sensitivity, the kinase assay was performed using only red light for room illumination, since it 
does not show any light absorption above 450 nm (Figure 35). CDK inhibitor 16 exhibited an IC50 of 
2.86 nM, which was in good agreement with published data.89 Attachment of the DMNB protecting 
group to the inhibitor resulted in an extensive loss of inhibitory efficacy, rendering the DMNB caged 
prodrug 23 inactive up to micromolar concentrations (IC50 ≈ 4798 nM). Importantly, upon irradiation with 
UV light (365 nm, 600 mW, 120 s) the inhibitory efficacy was completely recovered (IC50 = 5.64 nM). 
 
 
Figure 38: Kinase assays of inhibitor 16 and its caged prodrug 23 using the target kinase CDK2/cyclin E1 with and without UV 
irradiation. CDK2 in complex with cyclin E1 was incubated with inhibitor 16 as well as its caged prodrug 23 to determine kinase 
activity (left). In a second setup, 10 minutes after compound addition both 16 and 23 were irradiated with UV light for 2 minutes 
(365 nm, 37.5 mW). Data represents mean ± SD from two independent experiments performed in triplicate.     
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Cell proliferation assays 
Having impressively demonstrated both inactivity of the DMNB caged prodrug 23 as well as its 
quantitative photoactivation in kinase assays, cell proliferation assays were performed using the 
pancreas carcinoma cell line Panc89 to further validate the observed effects. A pancreatic cancer cell line 
was chosen since CDK inhibition represents a promising strategy to effectively kill pancreatic tumor 
cells.140–142 In a first step, the resistance of Panc89 cells towards UV irradiation was to be investigated in a 
UV titration experiment. Panc89 cells were therefore treated with UV light solely for a maximum of 
5 minutes (365 nm, 37.5 mW). Cell viability was respectively determined for the indicated irradiation 
times. Importantly, up to 5 minutes of irradiation the cell proliferation was not impaired (Figure 39). In 
relation, not more than 2 minutes of irradiation (365 nm, 37.5 mW) are sufficient to completely activate 
the DMNB caged prodrug 23. Thus, a quantitative photoactivation should be feasible without affecting 
cell proliferation.  
 
 
Figure 39: UV titration using Panc89 cells. Panc89 cells were irradiated with UV light (365 nm, 37.5 mW) for up to 5 min. Cell 
viability was determined after 48 h of drug treatment using Resazurin. Each value is a mean ± SD of two independent 
experiments.  
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Consequently, cell proliferation assays using Panc89 cells with the uncaged inhibitor 16 and its caged 
prodrug 23 with and without UV irradiation were performed. Regarding results from stability 
experiments, cell proliferation assays were carried out under red light illumination. CDK inhibitor 16 
exhibited an EC50 of 0.70 µM without irradiation (Figure 40). As seen in kinase assays, attachment of the 
DMNB protecting group significantly diminished biological activity, hence increasing the EC50 to high 
micromolar concentrations (≈ 17.3 µM). Noteworthy, the caged prodrug exhibited a poor water solubility 
resulting in compound precipitation at the highest concentration. Hence, cell proliferation at a 
compound concentration of 100 µM was not measured, complicating a relevant EC50 calculation. 
However, the results show clearly that 23 does not affect cell proliferation up to high micromolar 
concentrations. Since the DMNB caged prodrug 23 was inactive utilizing CDK2 kinase assays, off-target 
effects might contribute to residual cytotoxic efficacy. As an important prove of concept, the biological 
efficacy of the DMNB caged prodrug can be completely recovered upon irradiation with UV light, 
producing an EC50 of 0.80 µM, which is perfectly comparable to the EC50 of inhibitor 16 (EC50 = 0.85 µM).  
 
 
Figure 40: Cell proliferation assays of the inhibitor 16 and its DMNB caged prodrug with and without UV irradiation using 
Panc89 cells. Panc89 cells were treated with inhibitor 16 and its DMNB caged prodrug 23 without UV irradiation (left). In a 
second setup, Panc89 were irradiated for 2 minutes with UV light (365 nm, 37.5 mW) after treatment with 16 and 23. Cell 
proliferation was determined after 48 h of drug treatment. Data represents mean ± SEM from three independent experiments 
performed in quadruplicates.     
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Although red light was exclusively used for room illumination, inadvertent photoactivation during both 
preparation of the compounds solutions as well as performance of the assays might additionally 
contribute to remaining biological activity of the caged prodrug. In order to address this issue, the benzyl 
caged analogue 26 was synthesized and consequently tested as a non-photoactivatable control (Figure 
41). Due to the removal of the o-nitrogroup a cleavage upon irradiation cannot proceed (Supplementary 
Figure 3). Yet, both analogues 23 and 26 presumably exhibit comparable biological activity due to similar 
spatial extension of the benzyl and DMNB moiety. Cell proliferation assays showed that both EC50 curves 
overlap, suggesting that these compounds might affect other targets than CDKs at higher concentrations.  
 
 
 
Figure 41: Cell proliferation assays of the benzyl caged analogue 26. Panc89 cells were treated with the DMNB caged prodrug 
23 and its benzyl caged analogue 26 without UV irradiation. Cell proliferation was determined after 48 h of drug treatment. Data 
represents mean ± SEM from three independent experiments performed in quadruplicates.     
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In a last experiment, potential cellular toxicity of the photocleaved DMNB protecting group was assessed 
by the use of two tool compounds: Boc-protected L-alanine 22a and its DMNB caged analogue 22. The 
Boc-protected L-alanine 22a did not affect cell proliferation of Panc89 cells up to the highest 
concentration of 100 µM and was thus accepted as biologically inert. Upon UV irradiation of the DMNB 
caged analogue 22  the biologically inert Boc-protected L-alanine 22a as well as the cleaved protecting 
group showing a nitrosobenzyaldehyd moiety was formed.23,25 The UV irradiated DMNB caged analogue 
22 exhibits moderate cytotoxic effects only at concentrations above 50 µM (Figure 42). Nevertheless, 
potent kinase inhibitors exhibit cytotoxic effects at significantly lower concentrations rendering the 
observed cytotoxic effect of the cleaved DMNB protecting group as negligible suggesting a wide 
therapeutic window of a potential DMNB caged prodrug. 
 
 
Figure 42: Effect of the cleaved DMNB protecting group on cell proliferation. A) Chemical structure of the utilized tool 
compounds: Boc-L-alanine 22a and its DMNB caged derivative 22. B) Panc89 cells were treated with 22a and 22 without UV 
irradiation (left). In a second setup, Panc89 were irradiated for 2 minutes with UV light (365 nm, 37.5 mW) after treatment with 
22a and 22. Cell proliferation was determined after 48 h of drug treatment. Data represents mean ± SEM from two independent 
experiments performed in triplicates.     
56         Results and Discussion 
 
3.2.7 Scaffold project 
Regarding applicability of photoactivatable compounds in biological setups, timing and rate of 
photoactivation are the most critical parameters. Regardless of whether photoactivatable compounds 
shall be used to study biological processes or for medicinal approaches, a fast and clean photoactivation 
is indispensable. Obviously the utilized PPG represents the decisive factor, but recent studies showed 
that the leaving group affects the rate of photoactivation as well.25,37,143 The photoactivation mechanism 
of the most commonly used DMNB protecting group has been studied intensively yet the leaving groups 
feature responsible for affecting the photoactivation remains unclear.144 Regarding this issue, a solely 
computational study was performed by Il’ichev et. al in 2003.145 Their calculated results suggest that 
electron-donating substituents in the benzylic position hence electron-donating leaving groups improve 
the photocleavage. Furthermore, in 2011 Solomek et. al argued that radical stabilizing features of the 
leaving group enhance the photoreaction.37 Radical stabilizing characters of different leaving groups have 
thereby been calculated by computational studies, actually making experimental data on the influence of 
the leaving group rarely available. Unfortunately, this experimental data would be markedly valuable in 
terms of developing photoactivatable prodrugs, since the uncaged biological active compounds 
themselves represent the leaving groups. These biological active compounds possess a specific 
pharmacophore which typically cannot be structurally modified without affecting important properties 
such as biological activity or pharmacokinetic  parameters. Hence, some pharmacophores might be more 
suitable for the caging concept than others. 
In order to address this issue, we aimed for a systematic investigation of substituents towards the N-
phenylpyrimidine-2-amine scaffold regarding the photoactivation. The N-phenylpyrimidine-2-amine 
scaffold appeared to be highly suitable for this study since it is present in many kinase inhibitors and 
additionally gives more than 24000 hits upon inhibitor substructure search including biological studies 
using SciFinder® (Figure 43).  Furthermore, the N-phenylpyrimidine-2-amine scaffold was identified as 
one of the most promising scaffolds for the development of CDK inhibitors.146–148 Not surprisingly, all 
three clinically approved CDK inhibitors possess a closely related N-pyridinepyrimidine-2-amine scaffold 
as part of their hinge binding motif (Figure 43). The understanding of the influence of the substitution of 
the N-phenylpyrimidine-2-amine scaffold on the photoactivation would be of great value for the 
development of future photoactivatable CDK or further photoactivatable inhibitors.  
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Figure 43: Examples of FDA-approved kinase inhibitors exhibiting the N-phenylpyrimidine-2-amine scaffold as their hinge 
binding motif (top) and FDA-approved CDK inhibitors exhibiting the N-pyridinepyrimidine-2-amine scaffold as part of their 
hinge binding motif (bottom). The hinge binder forming the H-bonds towards the target kinase is highlighted in grey. The C2-NH 
as well as the pyrimidine N1 is particularly important for binding to the target kinase. The respective target kinase is shown 
beneath the drug name.
78,149–151
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Importantly, the PPG is attached to the exocyclic NH, so both aromatic systems will influence the 
uncaging. In this study, exclusively the substitution in the para-position of the phenyl system is 
systematically investigated while maintaining the pyrimidine. In particular, electronic and mesomeric 
effects of different  ±M/I-substituents on the photoactivation rate were to be investigated. Therefore, 
eight analogues of the caged scaffold 25 have been synthesized (Table 2). The amino group in the 2-
position of the pyrimidine has been chosen for effective caging, since it was identified as critical for 
binding to the target kinase in all examples (Figure 43). In order to quantify the electronic and 
mesomeric effects of these substituents, their Hammett constants were used, respectively. In 1936 
Hammett studied the correlation between the electronic character of substituents and the rate and 
equilibrium of organic chemical reactions, quantified as the Hammett constants σ (σpara or σmeta).
152 Taft 
et. al extended the concept by applying the same principles on steric as well as inductive and resonance 
effects.153 Till this day, revised Hammett constants are generally utilized to quantify electronic and 
mesomeric effects of different substituents. More positive σ-values are associated with a more electron-
withdrawing character of a substituent, whereas more negative σ-values represent more electron-
donating characters (Table 2).154     
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Table 2: Overview of the examined caged N-phenylpyrimidine-2-amine scaffolds with their respective Hammett constants.
155
 
Substituents R in the para-position of the phenyl systems were altered in terms of designing a set of substituents aiming 
towards a valid hypothesis regarding a correlation between electronic parameters and the rate of photoactivation.    
 
 
# substituent (R = ) Hammett constant (σp)
155 
35 -N(CH3)2 - 0.83 
36 -OCH3 - 0.27 
37 -CH3 - 0.17 
38 -H 0 
39 -Br 0.23 
40 -COOEt 0.45 
41 -CF3 0.54 
42 -CN 0.66 
25 -SO2CH3 0.72 
 
Synthesis 
The synthesis of the differently substituted scaffolds was approached in two ways (Figure 44). 
Analogously to the preparation of the original pharmacophoric scaffold 24, scaffolds 27-30 were 
synthesized by a nucleophilic aromatic substitution: the respective p-aniline derivatives were refluxed 
together with 2-chloropyrimidine in tert-butyl alcohol to gain the desired scaffolds in good yields.137 In 
order to enhance the reactions rates, a few drops of concentrated HCl were added. In contrast,  
synthesis of the scaffolds 31-34 was achieved by a palladium catalyzed Buchwald-Hartwig amination 
utilizing either S-BINAP or Xantphos as ligand for the palladium catalyst. Dioxane has been used as the 
solvent, whereas potassium tert-butoxide was the base of choice. All Buchwald-Hartwig aminations were 
carried out in a microwave reactor to reduce reaction times.156–159 Having all N-phenylpyrimidine-2-
amine scaffolds in hand, the NH-protection with the DMNB group was carried out following the earlier 
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evaluated protocol. Accordingly to this method, the scaffolds were stirred with sodium hydride in DMF at 
0°C. After cooling to -30°C, DMNB-Br was added carefully and the reaction was left stirring for an hour. 
After quenching by the addition of water, the crude product was purified by flash chromatography. 
Importantly, light exposure was avoided as much as possible during both synthesis and purification of 
the caged scaffolds due to their potential light sensitivity.    
 
 
Figure 44: Synthesis of the caged N-phenylpyrimidine-2-amine scaffolds. Left: synthesis of the differently substituted scaffolds 
according to procedures
156–159
. Right: caging of the respective scaffolds with the DMNB protecting group.  
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Photochemical characterization 
Having the designed set of compounds in hand, the photochemical characterization aimed to determine 
and compare the photoactivation reaction rates of all scaffolds 25,35-42. With the intention of 
developing photoactivatable prodrugs for biological applications, determination of the reaction rate 
appeared superior to quantum yield determinations, since it allows the performance of 
photoexperiments utilizing the custom-made UV LED lamp for the irradiation of commonly used 96-well 
assay plates. In contrast a quantum yield determination would demand a specific experimental setup not 
meeting biological assay conditions. However, in order to evaluate utility for biological applications the 
reaction rate of the photoactivation of photoactivatable prodrugs is highly valuable. 
In a first step, light absorbance at the respective wavelength required for photoactivation was assessed. 
Higher light absorption at the respective wavelength required for photoactivation might enhance the 
rate of the photoactivation thus falsify results. However, all caged scaffolds showed comparable light 
absorption at 365 nm, with the exception of a slightly higher light absorption of the carboxyethyl 
substituted scaffold 40 (Table 3, Supplementary Figure 4). 
Next, the photoactivation of each scaffold was examined using a UV LED with an emission maximum at 
365 nm. The photoactivation experiments were carried out in a 96-well plate in order to maintain the 
relatedness to future biological applications. Furthermore, the experiments were not only performed in 
DMSO at a high 500 µM concentration, but also in PBS buffer with 20% DMSO at a considerably lower 
concentration of 25 µM. The concentration was not be further decreased in order to meet 
quantifications limits of the HPLC analysis. All scaffolds were irradiated for up to 2 min at a power of 
7.5 mW in order to examine the photoactivation reaction. This resulted in a zero-order like curve shape 
within the first 45 s of irradiation, when plotting the amount of the caged species against the irradiation 
time. The decrease of the caged species as a result of a photoactivation was considered a reliable 
determinant for the rate of photoactivation due to a considerably low error-proneness, a procedure 
according to a similar study by Solomek et. al.37 However, the photoactivation rate slows down after 45 s 
resulting in a flattening of the curve (Figure 45).  
This is due to the fact that the number of photocleavage events per time is directly proportional to the 
number of photons absorbed. If the absorption of the irradiated solution is large (A > 2), the number of 
photons absorbed per time is constant and independent from the concentration resulting in a zero order 
like curve shape. However, during photoactivation the concentration of the photoactivatable compound 
and consequently the absorption at the irradiation wavelength  decreases. Thus, if the absorption is little 
(A << 1) the number of photons absorbed per time is dependent on the concentration of the 
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photoactivatable compound resulting in a first order like curve shape. Noteworthy, describing of 
photochemical reactions by standard kinetic concepts remains arguable.160–165 
In order to determine reaction rates, the range between 0 and 45 seconds was considered and 
processed by a zero-order fitting. The reaction rates were subsequently calculated from the slopes of the 
zero-order fits.  
 
 
Figure 45: Photoactivation of scaffolds 25,35-42. 100 µl of each compound solution A) DMSO (500 µM) and B) PBS buffer with 
20% DMSO (25 µM) were irradiated in a typical biochemical assay setup at 365 nm (7.5 mW) for up to 120 s. Peak areas were 
determined by HPLC analysis. Each value is a mean ± SD of two independent experiments.  
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As an important result, scaffolds 35-37, substituted with the electron-donating substituents 
dimethylamine (+M), methoxy (+M) and methyl (+I), showed a significantly slower photoactivation in 
DMSO compared to the unsubstituted scaffold 38 (Figure 45, Table 3). In particular, the dimethylamine 
substituted scaffold 35 barely showed any photoactivation at all. However, scaffolds with electron-
withdrawing (-I/-M) substituents such as bromo, trifluoromethyl, nitrile or sulfonylmethyl (scaffolds 39, 
41, 42 and 25) did not result in a significant faster photoactivation compared to the unsubstituted 
scaffold 38. Hence, these substituents could not be further differentiated under the applied assay 
conditions. Only a trend in terms of a minor enhancement could be observed for the carboxyethyl ester 
substituent 40 (Table 3).  
Also the sulfonylmethyl substituent of scaffold 25, derived from the CDK inhibitor 16, does only slightly 
enhance the rate of photoactivation compared to 38. Performing the experiments in PBS with 20% 
DMSO (25 µM), comparable results have been obtained, with the exception that the dimethylamine 
substituted scaffold 35 could not be measured due to precipitation despite the addition of 20% DMSO. 
Data from experiments in DMSO were therefore used for further analysis. 
 
 
Table 3: Overview of results from photochemical characterization experiments in DMSO. 
 
# substituent 
Hammett 
σp 
155 
absorbance 
(at 365 nm) 
% photoactivated 
(after 45 s of irradiation) 
Reaction rates 
/µM*s-1 
35 -N(CH3)2 - 0.83 0.123 ± 0.001 2.5 ± 0.6  0.316 ± 0.007 
36 -OCH3 - 0.27 0.118 ± 0.004 18.4 ± 1.6 2.02 ± 0.15 
37 -CH3 - 0.17 0.122 ± 0.002 19.7 ± 0.3  2.31 ± 0.13 
38 -H 0 0.123 ± 0.010 29.9 ± 0.6 3.31 ± 0.03 
39 -Br 0.23 0.121 ± 0.003 29.5 ± 2.2 3.27 ± 0.06 
40 -COOEt 0.45 0.143 ± 0.000 37.6 ± 3.3 4.12 ± 0.33 
41 -CF3 0.54 0.125 ± 0.007 31.3 ± 0.4 3.64 ± 0.17 
42 -CN 0.66 0.123 ± 0.005 32.6 ± 0.6 3.51 ± 0.09 
25 -SO2CH3 0.72 0.115 ± 0.000 32.0 ± 0.9 3.60 ± 0.26 
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Concerning an interpretation of the obtained results, the reaction rate of the unsubstituted N-
phenylpyrimidine-2-amine scaffold 38 was taken as the reference value. Compared to that value, the 
reaction rates clearly decrease by attachment of a substituent with a more negative Hammett constant, 
implying that electron-donating substituents significantly decrease the rate of photoactivation. In 
contrast, by introduction of an electron-withdrawing substituent the reaction rate increases only 
minimally (Table 3).  Plotting the Hammett constants σp vs. the determined reaction rates, a distinct 
correlation resulted, although a leveling of more positive σp occurs (Figure 46).  
 
 
 
 
Figure 46: Correlation between the Hammett constant σp of the respective substituent and the experimental determined 
reaction rates. Squares represent means ± SD of two independent experiments.  
 
 
 
 
 
 
 
 
Results and Discussion         65 
 
In order to discuss these findings, the mechanism of photocleavage of the DMNB caged scaffolds is of 
major interest (Figure 47). Three critical steps have been identified by studying the chemical mechanism 
of cleavage. In a first step (a), a photoinduced H-atom transfer from the benzylic carbon to the oxygen 
atom of the nitro group occurs, leading to aci-nitro intermediate 44. This photoinduced H-atom transfer 
involves an excitation of the molecule. From the excited state of compound 44 two ground state 
reactions are possible, which compete with each other: reverse H-atom transfer to reform 43 
(reaction b) or ground stage cyclization to form isoxazol derivative 45 (reaction c). Importantly, the 
cyclization (reaction c) is irreversible, ultimately leading to photocleavage. Having taken the path of 
photoactivation, the irreversible cyclization is followed by a ring opening (reaction d) coming to the final 
release of the scaffold (reaction e) and o-nitrosobenzaldehyde as the by-product. Since both reaction 
paths, photocleavage or relaxation, are possible from intermediate 44, steps a-c were considered to be 
determining for the reaction rates of the photoreaction. During all steps a-c the benzyloc carbon directly 
bound to the leaving group is in the center of action. A strong electronic effect is exerted on the benzylic 
carbon by the adjacent nitrogen of the leaving group due to its free ion pair. This free ion pair is further 
affected by both the pyrimidine ring as well as the phenyl ring with the substituents in the para-position. 
An electron-donating substituent is considered to increase the electron density at the nitrogen 
considerably. This consequently results in an enlarged electron density of the benzylic carbon, increasing 
its nucleophilicity. Due to this fact, the nucleophilic attack of the oxygen (reaction c) to form isoxazol 
derivative 45 will be diminished, potentially resulting in a shift towards the reverse H-atom transfer 
(reaction b). This circumstance might explain the significantly decreased reaction rates of the caged 
scaffolds 35-37 substituted with electron-donating substituents. Bringing the electron density of the 
benzylic carbon in the center of attention, electron-withdrawing substituents in the para-position should 
consequently enhance the photocleavage. Interestingly, the reaction rates of the caged scaffolds 39-
42,25 possessing electron-withdrawing substituents are not significantly increased compared to the 
unsubstituted caged scaffold 38 although a relevant trend is discernible. The electron-withdrawing 
character of the electron deficient pyrimidine ring system might be the reason. Without an electron-
donating substituent, the free ion pair of the nitrogen is already delocalized resulting in a decreased 
electron density at both the nitrogen atom and the benzylic carbon. By the addition of a further electron-
withdrawing substituent, the electron withdrawing effect might be leveled by the pyrimidine ring 
resulting in similar reaction rates. In contrast to Solomek et. al radical stabilizing features of the residue R 
have not been quantified since relevant computational studies were not accessible in our lab.37  
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Relating to the original hypothesis, biological active compounds possessing the N-phenylpyrimidine-2-
amine scaffold substituted with electron-donating substituents in the para-position of the phenyl system 
are unfavorable in terms of caging utilizing the DMNB protecting group. Contemplating the given 
examples of clinically approved kinase inhibitors exhibiting the considered scaffold, merely Pazopanib 
appears to be a potentially appropriate candidate (Figure 43). All others possess one or several electron-
donating substituents at the phenyl ring rendering them potentially unsuitable for a NH caging due to a 
supposedly decreased rate of photoactivation utilizing the DMNB protecting group. Importantly, in order 
to ultimately assess suitability for the caging concept the whole molecule has to be considered. 
 
 
 
 
 
Figure 47: Specific reaction mechanism of photocleavage of the DMNB caged scaffolds. The leaving group and the uncaged 
scaffold, respectively are highlighted in grey. The relevant proton of the benzylic carbon for the H-atom transfer is  particularly 
depicted in 43. For clarification mechanism arrows are shown in black.    
   
Results and Discussion         67 
 
3.3 Visible light absorbing PPG 
Despite the successful in vitro proof of concept, limited penetration depth of UV light into biological 
tissues remains, restricting the utility of the photoactivatable prodrug 23 to superficial tissues or thin cell 
layers (Figure 4). As a consequence, a PPG absorbing light within the bio-optical window might be highly 
beneficial towards biological applications in deeper tissues. In order to meet this requirement, the 
photosensitive meso-BODIPY protecting group has been chosen. The chemical structure of the meso-
BODIPY core 8 is shown in Figure 48. The four methyl groups at the positions 1,3,5 and 7 are important 
for stability of the ring system, although further substitution of the methyl groups in order to modify 
photochemical characteristics such as the absorption and emission spectra is possible while retaining 
stability.166 Furthermore, the 2,6-positions are particularly accessible for an electrophilic substitution.167 
By the introduction of different residues R at the 2,6-positions as well as substituting the methyl groups 
the absorption and emission spectra of the meso-BODIPY derivatives can be significantly altered, making 
blue light absorbing to even near-IR absorbing BODIPY derivatives possible.17,40,52,53,166,168,169 As an 
example, the 1,3,5,7-methyl-substituted BODIPY core structure exhibits a light absorption maximum 
around 520 nm.  Besides modifying the photochemical characteristics, substitution of the BODIPY core 
might additionally enable an improvement of pharmacokinetic parameters e.g. solubility, particularly 
relevant for potential biological applications. Importantly, the benzyl-analogous methylene group at the 
C8 position is essential for functioning as a PPG.17,40,170 “LG” represents the leaving group thus the 
inhibitor to which the PPG should be applied. Hence, this methylene group, linking the leaving group 
with the BODIPY core has to be maintained during synthesis of a BODIPY-caged inhibitor. Although 
workgroups of Weinstain and Szymanski introduced a carbamate linker between the BODIPY PPG and 
the leaving group in order to enhance the photoactivation as well as chemical accessibility, the essential 
methylene group had to be maintained.52,170  
 
 
Figure 48: Chemical structure of the meso-BODIPY core. Numbering of the carbons is shown in black. The essential methylene 
group at the C8 position for functioning as a PPG is highlighted in grey. 
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3.3.1 Stability upon irradiation 
In correspondence with the general workflow for the development of photoactivatable prodrugs 
inhibitor stability upon irradiation with light of the wavelength required for the prospective 
photoactivation has to be verified at the very beginning of the project (Figure 13). Therefore, a 
compound solution of CDK inhibitor 16 to which the BODIPY protecting group should be applied was 
irradiated with green light (530 nm, 4.6 W) for up to 25 min. Since utility of the BODIPY protecting group 
for biological applications was to be examined, irradiation was performed in a commonly used white 
opaque 96-well plate using PBS buffer with 20% DMSO as a solvent. Under this conditions the CDK 
inhibitor 16 appeared to be stable. 
 
 
Figure 49: Stability of CDK inhibitor 16 upon light irradiation with a wavelength of 530 nm. A 25 µM compound solution in PBS 
buffer with 20 % DMSO was irradiated at 530 nm (4.6 W) in a 96-well plate for up to 25 min. Subsequently samples were 
analyzed by HPLC. Each value is a mean ± SD of two independent experiments.  
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3.3.2 Synthesis 
In accordance with the synthesis of the DMNB caged prodrug 23, direct attachment of the BODIPY 
protecting group to the CDK inhibitor was aimed for. Identifying an efficient strategy to introduce the 
BODIPY protecting group to an compound in a one-step SN reaction might prove to be useful for caging 
of further biologically active compounds. Therefore, a BODIPY precursor exhibiting a suitable leaving 
group in terms of a nucleophilic substitution at the LG position is highly desired (Figure 48). In a first 
approach the 8-chloromethyl derivative 47 was synthesized as a potential precursor adapted from 
literature 171,172 (Figure 50). Importantly, the 2,6-positions remained unsubstituted. Thus, the meso-
BODIPY core was built from 2,4-dimethylpyrrol and chloroacetyl chloride. The resulting uncomplexed 
intermediate was not isolated, but treated with triethylamine and boron trifluoride diethyletherate to 
gain the desired BODIPY precursor 47 in terms of a two-step synthesis representing a commonly used 
way for the preparation of meso-BODIPY derivatives.51  The reaction was accompanied by the formation 
of several byproducts. The dehalogenated derivative 48 represented the major byproduct. Surprisingly, 
the chromatographic behavior of both the 8-chloromethyl BODIPY precursor 47 and its dehalogenated 
byproduct 48 were similar, making the purification by flash chromatography highly elaborate. Due to the 
dirty reaction as well as the elaborate purification the yield of 47 was only 16%. In a next step the 
attachment of the 8-chloromethyl BODIPY precursor 47 to the pharmacophoric scaffold 24 was 
investigated applying the formerly optimized reaction conditions from the photoactivatable CDK 
inhibitor project. The desired BODIPY-caged scaffold 49 could be achieved, but with a low 3% yield 
considerably due to the poor leaving group properties of chlorine in a nucleophilic substitution reaction. 
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Figure 50: Synthesis of the 8-chloromethyl precursor 47 with subsequent attachment to the pharmacophoric scaffold 24. 
Synthesis of BODIPY precursor 47 was adapted from literature 
171,172
. 
 
 
Having the BODIPY-caged scaffold 49 in hand and photochemically characterized (see chapter 3.3.3), a 
modified BODIPY protecting group was to be employed. In order to achieve a bathochromic shift of the 
light absorption spectra, the 2,6-positions of the BODIPY core were to be altered. Thus, ethyl moieties 
were introduced by starting from 3-ethyl-2,4-dimethylpyrrol for synthesis of the BODIPY core. In order to 
improve the attachment of the BODIPY precursor to the scaffold 24, the 8-bromomethyl derivative 50 
was approached starting from 3-ethyl-2,4-dimethylpyrrol and bromoacetyl chloride, but due to its 
instability it could not be isolated in a sufficient purity (Figure 51). Hence, a different strategy was 
pursued. Regarding its synthetic availability, the 8-chloromethyl derivative 51 was prepared and 
afterwards converted to its 8-iodomethyl derivative 52 in terms of a Finkelstein reaction with the 
intension of exploiting the iodine’s superior properties as a leaving group.173,174 The substitution of the 
chlorine by an iodine worked in sufficient yields, although formation of the dehalogenated byproduct 
could not be prevented. Again, due to comparable chromatographic behavior an entire removal of the 
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byproduct appeared to be unfeasible without diminishing the yield. Since 8-iodomethyl derivative 52 was 
further utilized as a reactant and the impurity was characterized, purity of 90% was accepted. 
Subsequent attachment of the BODIPY protecting group to the pharmacophoric scaffold 24 utilizing the 
8-iodimethyl precursor 52 yielded the BODIPY-caged scaffold 53. Compared to the reaction with the 8-
chloromethyl BODIPY precursor 47, the yield was moderately increased to 12%.  
 
 
  
 
 
Figure 51: Route of synthesis to cage the pharmacophoric scaffold 24 with the optimized BODIPY protecting group. Synthesis 
of the BODIPY precursor 51 was adapted from literature 
173,174
. Conversion to the 8-iodomethyl BODIPY precursor 52 was 
performed according to literature 
174
.  
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Having found an sufficient way to cage the pharmacophoric scaffold 24 with the BODIPY protecting 
group, caging of CDK inhibitor 16 with the BODIPY protecting group was performed. Again, optimized 
reaction conditions identified using the scaffold were applied yielding the BODIPY-caged CDK inhibitor 
54. Considering a potential light sensitivity synthesis as well as purification was performed under light 
exclusion as much as possible.      
 
 
Figure 52: Synthesis of the BODIPY-caged inhibitor 54. 
 
The synthetic approach exploiting the accessibility of the 8-chloromethyl-BODIPY derivatives with a 
subsequent conversion to their 8-iodomethyl derivatives enables a direct attachment of the BODIPY 
protecting group to nucleophilic nitrogens e.g. NH moieties of biological active compounds, although the 
formation of dehalogenated byproducts during all steps of synthesis could not be prevented.   
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3.3.3 Photochemical characterization 
In the first step of the photochemical characterization the UV/Vis absorption spectra of both BODIPY-
caged scaffolds 49 and 53 have been evaluated in order to determine an ideal irradiation wavelength by  
identifying respective absorption maxima. This represents a crucial step for characterizing the utilized 
BODIPY protecting groups, since a high light absorption at the irradiation wavelength is mandatory for an 
efficient photoactivation.  
The 2,6-unsubstituted BODIPY-caged scaffold 49 exhibited a broad unsymmetrical absorption band with 
a maximum around 520 nm (Figure 53). From 460 nm the light absorption increases slowly up to the 
maximum whereas the light absorption drops sharply above 520 nm. By the intension of achieving a 
bathochromic shift of the light absorption maximum, the second BODIPY-caged scaffold 53 was prepared 
where two ethyl groups were introduced at the 2,6-positions of the BODIPY core. The results showed 
that the absorption maximum shifted to 550 nm. In addition to this bathochromic shift the light 
absorption increased as well compared to the 2,6-unsubstituted BODIPY-caged scaffold 49.  
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Figure 53: UV/Vis absorbtion spectra of the BODIPY-caged scaffolds 49 and 53. UV/Vis absorption spectra of both BODIPY-
caged scaffolds 49 (grey) and 52 (black) were recorded in DMSO and normalized to the UV/Vis absorption spectrum of 
pharmacophoric scaffold 24 (dashed). 
 
To examine and compare the rate of the photoactivation of both BODIPY-caged scaffolds 49 and 53 an 
irradiation wavelength of 530 nm was chosen since both compounds exhibit a decent light absorption at 
530 nm. However, the BODIPY-caged scaffold 53 showed a significantly higher light absorption at 530 nm 
compared to 49. Importantly, the uncaged scaffold 24 exhibited no light absorption above 330 nm 
implying that an interference of 24 while photoactivation with light of 530 nm is not possible. Thus, a 
custom made LED lamp with an emission wavelength of 530 nm with a maximum power of 4.6 W was 
utilized for the irradiation experiments. Thereby, compound solutions in DMSO of both BODIPY-caged 
scaffolds were irradiated in a 96-well plate for up to 20 minutes (Figure 54). Samples were subsequently 
analyzed by HPLC and LC-MS in order to determine contents of both the caged and uncaged species. 
Irradiating the 2,6-unsubstituted BODIPY-caged scaffold 49 for 20 minutes resulted in a 40% 
photoactivation (Figure 54). Introduction of the ethyl moieties at the 2 and 6 position led to an 
significant increase of the photoactivation rate. After 20 minutes of irradiation the 2,6-diethyl-
Results and Discussion         75 
 
substituted BODIPY-caged scaffold 53  was fully cleaved. This increase in the rate of photoactivation 
might be due to the higher light absorption at 530 nm of 53 compared to 49.  
Both BODIPY-caged scaffolds were prepared and photochemically characterized with the intension of not 
only finding an efficient way to chemically introduce the BODIPY protecting group to an inhibitor but also 
identifying a BODIPY protecting group with a fast photoactivation. By that reason the 2,6-diethyl-
substituted BODIPY protecting group was further chosen for caging of the CDK inhibitor 16. 
 
 
 
Figure 54: Photoactivation of the BODIPY-caged scaffolds 49 (A) and 53 (B). 100 µL of each compound solution in DMSO 
(25 µM) were irradiated in a well of a 96-well plate for the indicated time at 530 nm (4.6 W) and analyzed by HPLC (n = 2) and 
LC-MS. The amount of the caged compound (diamonds) is plotted against the released scaffold 24 (squares). Each value is a 
mean ± SD of two independent experiments.  
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As shown in chapter 3.3.2, introduction of the 2,6-diethyl-substituted BODIPY protecting group to CDK 
inhibitor 16 worked applying the prior optimized SN reaction conditions to yield the 2,6-diethyl-
substituted BODIPY-caged inhibitor 54 (Figure 52). Having 54 in hand, its UV/Vis absorption spectrum 
was recorded. In agreement with data from the respective BODIPY-caged scaffold 53, a strong 
absorption band with a maximum at 550 nm was observed (Figure 55). Since a LED lamp with an 
emission maximum of 530 nm was available, the rate of photoactivation was examined at an irradiation 
wavelength of 530 nm although the light absorption at 550 nm would be significantly higher. With the 
aim of determining utility for future biological application the irradiation experiments were again 
performed in a 96-well plate at a concentration of 25 µM. Unfortunately, due to a poor water solubility 
of 54 the rate of photoactivation could not be determined using PBS buffer as a solvent despite adding 
up to 30% of DMSO. The applied concentration of 25 µM for the photoactivation experiments could not 
be decreased due to the limit of quantification of the HPLC analysis. However, all photoactivation 
experiments were performed as close to in vitro conditions as possible. As an important result, 80% of 
the BODIPY-caged inhibitor 54 were activated after 10 minutes of irradiation (Figure 56). Furthermore, a 
full photoactivation was achieved after 15 minutes of irradiation at 530 nm.  
 
Results and Discussion         77 
 
 
Figure 55: UV/Vis absorption spectrum of the BODIPY-caged CDK inhibitor 54. The UV/Vis absorption spectrum of the BODIPY-
caged CDK inhibitor 54 (black) was  recorded in DMSO and normalized to the UV/Vis absorption spectrum of the uncaged CDK 
inhibitor 16 (dashed). 
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Figure 56: Photoactivation of the BODIPY-caged CDK inhibitor 54. 100 µL of the compound solution in DMSO (25 µM) were 
irradiated in a well of a 96-well plate for the indicated time at 530 nm (4.6 W) and analyzed by HPLC (n = 2) and LC-MS. The 
amount of the caged compound (diamonds) is plotted against the released CDK inhibitor 16 (squares). Each value is a mean ± SD 
of two independent experiments.  
 
 
 
3.3.4 Biological evaluation 
Having determined the photoactivation rate of the BODIPY-caged prodrug 54, the question whether this 
rate is sufficient to be useful for biological applications had to be answered next. An irradiation inducing 
the photoactivation of a photoactivatable prodrug should not affect cell viability. In order to investigate 
the cell’s maximum tolerable light dose of the respective wavelength, so-called light titration 
experiments were performed utilizing the Panc89 cell line which was used for the photoactivatable CDK 
inhibitor project . Therefore, Panc89 cells were irradiated at 530 nm (4.6 W) for different durations up to 
a maximum of 30 minutes with the same LED lamp used for the photochemical characterization. The 
number of living cells is subsequently detected using a resazurin assay. The cell growth is determined in 
relation to the number of living cells at the day of treatment in order to distinguish between a cytostatic 
(> 0% cell growth) and cytotoxic effect (< 0% cell growth). Interestingly the cell growth increased 
significantly by irradiation up to 5 minutes to 150% cell growth compared to the DMSO control (Figure 
57). Not until 15 minutes of irradiation the cell growth starts to be impaired significantly. Importantly, 
even after 30 minutes of irradiation no cytotoxic effect was observed, although the cell growth was 
diminished to 0%.   
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Figure 57: Light titration experiment with Panc89 cells. Panc89 cells were treated with light of a wavelength of 530 nm (4.6 W) 
using the same LED lamp used for the photochemical characterization of 54. After two days the cell growth was determined 
using a resazurin assay in relation to the number of living cells at the day of treatment. Data represents mean ± SEM from three 
independent experiments performed in a quadruplicate. 
 
Concerning the results from synthesis, photochemical characterization and biological evaluation in this 
project, utility of the 2,6-diethyl-substituted BODIPY protecting group for biological applications is 
considered to be given. Although 15 minutes of irradiation are required for an entire photoactivation of 
the BODIPY-caged prodrug 54 under experimental conditions, a compromise of 10 minutes of irradiation 
in vitro was chosen in order to minimize cell damage by light, but restore the biological activity at the 
same time. The planned biological evaluation of 54 with and without irradiation will shed light to this 
hypothesis. In the view of the UV spectrum of the BODIPY-caged prodrug 54, a considerably faster 
photoactivation might be enabled by adapting the irradiation wavelength to its absorption maximum of 
550 nm. Regarding studies from the groups of Weinstain and Symanzski a carbamate linker implemented 
between the BODIPY protecting group and the inhibitor might be beneficial to the rate of 
photoactivation as well, although 15 minutes of irradiation are acceptable in the terms of a biological 
application.52,170 Yet the issue of poor water solubility of 54 remains. Due to the introduction of the ethyl 
groups to the BODIPY core at the 2,6-positions, the water solubility further decreased. However, the 
issue of  poor water solubility can be solved by introduction of hydrophilic moieties e.g. sulfonate groups 
to the BODIPY protecting group, enhancing the water solubility dramatically, whereas absorption and 
emission maxima do not change significantly.51,167,175 In conclusion the visible light absorbing BODIPY 
protecting group exhibits unique qualities regarding the utility as a PPG for biological applications, 
especially since readily substitution of the ring systems enables custom-tailored BODIPY protecting 
groups for specific applications.   
80         Results and Discussion 
 
3.4 Activation by Cherenkov radiation 
In order to overcome the issue of a limited light penetration of UV light into biological tissues, another 
strategy next to the implementation of a visible light absorbing PPG was approached. If the required 
irradiation is not able to reach deeper tissue sites it might be an option to induce the irradiation in place. 
Since the most commonly utilized DMNB protecting group is cleaved upon irradiation with near UV light, 
induction of UV light has to be achieved. Interestingly, Cherenkov radiation, induced by fast moving 
particles such as electrons or positrons e.g. emitted during beta decay of certain radionuclides, exhibits 
an emission maximum in the near UV range. Thus, the hypothesis whether e.g. a beta emitter is able to 
activate a DMNB caged prodrug by induction of Cherenkov radiation emerged. Besides beta emitting 
radionuclides, external beam radiation commonly used for radiation tumor therapy in clinic is able to 
induce Cherenkov radiation as well.56 Thereby, charged particles such as electrons are vastly accelerated 
by a linear particle accelerator. If the charged particles’ speed exceeds a certain threshold within a 
medium such as waters, Cherenkov radiation is induced. Although the induction of Cherenkov radiation 
is subject to charged particles the effect might as well be observed by the use of high energy photon 
radiation due to Compton scattering. Thereby, a photon is scattered by a charged particle such as an 
electron resulting in a decrease in energy of the photon accompanied by an energy transfer to the 
recoiling electron.176 The energy rich recoiling electron might subsequently induce Cherenkov radiation. 
Linear particle accelerators might be capable of activating a DMNB caged prodrug due to induction of 
Cherenkov radiation in solution by high energy charged particles such as electrons or potentially high 
energy photons. Thus, a collaboration with the clinic for nuclear medicine as well as the clinic for 
radiation therapy at the university hospital (UKSH) in Kiel has been established with the intention of 
addressing both hypotheses.  
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3.4.1 Activation utilizing beta emitting radionuclides 
First, the capability of Fluorine-18 (18F)  to activate the DMNB caged prodrug 23 was investigated. 18F was 
chosen due to its everyday use for positron-emission tomography (PET) in the clinic as well as its short 
half-life of 110 min. Its decay mode is characterized by mainly positron emission with a maximum decay 
energy of 0.63 MeV, which is just above the threshold for induction of Cherenkov radiation in water 
(0.26 MeV).177,178 Thus, the readily cleavable DMNB caged prodrug 23 was incubated with 18F from two 
different radioactive sources and contents of both the caged and uncaged species were quantified by 
HPLC analysis after different times of incubation. Noteworthy, the HPLC was placed behind appropriate 
shielding and blocked for 1-2 days due to its radioactive contamination. Furthermore, incubation was 
performed in an amber glass HPLC vial in the autosampler of the HPLC in order to avoid opening the 
radioactive incubation vessel during the experiment. The first experiments were performed using pure 
18F. To exclude a possible migration of 18F into the glass of the incubation vial, following experiments 
were performed with 18Fluorodeoxyglucose (18FDG), which is commonly used for tumor imaging by PET.  
Since 23 exhibited a poor aqueous solubility, addition of an organic solvent such as DMSO or methanol 
as a solubilizer was inevitable, although the induction of Cherenkov radiation is almost exclusively 
investigated in pure water. Notably, the threshold condition for the induction for Cherenkov radiation as 
well as its intensity is strongly dependent on the refractive index of the medium rendering the solvent a 
relevant parameter.57 With the intension of identifying an activation upon incubation with a radioactive 
source, we designed five screening experiments. Thereby, the source of radioactivity, the amount of 
radioactivity, the solvent, the total volume as well as the inhibitor concentration were altered. All of 
these variables were considered as relevant for induction of Cherenkov radiation.  
Importantly, no activation was observed incubating 23 with the beta emitter 18F for up to 24 h at any 
applied condition (Table 4). In order to exclude false negative results, samples were irradiated with UV 
light after incubation to demonstrate that a photoactivation of 23 is possible under the applied 
conditions. However, the intensity of the Cherenkov radiation is strongly dependent on the decay energy 
of the utilized radionuclide.177 18F’s decay energy of 0.63 MeV is just above the threshold condition for 
induction of Cherenkov radiation in water and thus might be insufficient to induce an activation of 23.  
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Table 4: Results from activation experiments using 
18
F as the radioactive source. 
 
# 
radioactive 
source 
radioactivity solvent 
total 
volume 
compound 
concentration 
result 
  /Mbq  /ml /µM  
       
1 18F 20 10% DMSO in water 1 50 no activation 
2 18F 200 10% DMSO in water 1 50 no activation 
3 18F 150 water 1 50 no activation 
positive control samples 1-3 irradiated with UV light after incubation activation 
       
4 18FDG 107 50% MeOH in water 0.4 125 no activation 
5 18FDG 120 50% MeOH in water 0.4 125 no activation 
positive control samples 4-5 irradiated with UV light after incubation activation 
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To examine the hypothesis of an insufficient decay energy, 18F was replaced by Gallium-68 (68Ga) as the 
beta emitter. Again, decay of 68Ga is characterized by 88% positron emission but with a significantly 
higher maximum decay energy of 1.9 MeV.178 Because of its short half-life of 68 min, 68Ga had to be 
prepared in house using a gallium-68 generator. Thereby 68Ga is enriched by decay of its mother nuclide 
Germanium-68 and eluted from the generator by the use of hydrochloric acid (HCl). Since the acid 68Ga 
solution is highly radioactive, experiments had to be designed as simple as possible in order to minimize 
potential radiation exposure. Therefore, in a first approach, a solution of the DMNB caged prodrug was 
directly incubated with the acid 68Ga solution. To exclude that the low pH present in the samples results 
in an activation of the prodrug, a negative control with non-radioactive 69Ga in 1 M HCl was prepared 
and concurrently quantified. Interestingly, incubation with 68Ga in 1 M HCl results in a 26% activation of 
23 within the first 2 hours whereas the negative control showed full stability at the acid conditions 
(Figure 58). After 2 hours of incubation the effect terminates leaving a stable solution. 
Table 5: Results from activation experiments using 
68
Ga as the radioactive source. 
 
# 
radioactive 
source 
radioactivity solvent 
total 
volume 
compound 
concentration 
result 
  /Mbq  /ml /µM  
       
6 
68Ga 900 20% DMSO in 1 M HCl 1.25 50 26% activation 
69Ga - 20% DMSO in 1 M HCl 1.25 50 no activation 
       
7 68Ga 900 20% DMSO in buffer 1.25 50 to be performed 
 
The obtained results remain to be reproduced using a solvent with a neutral pH. Therefore, an efficient 
way to neutralize the radioactive 68Ga solution in HCl has to be identified. Significant dilution of the 
radioactive 68Ga solution should be avoided in order to minimize the loss of radioactivity. Furthermore 
the increase in ionic strength should be kept as small as possible. Since neutralization has to be 
performed behind radioactive shielding using robotic arms, the use of Eppendorf pipettes is precluded. 
However, the proof of activation upon incubation with 68Ga in a neutral solvent is planned to be 
performed. 
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Figure 58: Activation of DMNB caged prodrug 23 upon incubation with the beta emitter 
68
Ga in 1 M HCl. Top: 1.25 ml 
compound solution of 23 (50 µM, 20% DMSO in 1 M HCl) with 900 Mbq 
68
Ga were prepared in an amber glass HPLC vial and 
incubated for 4 hours in the autosampler of a HPLC. After the indicated time points peak areas of both the caged (23)and 
uncaged (16) species were determined using HPLC analysis. Bottom: a compound solution of 23 (50 µM, 20% DMSO in 1 M HCl) 
with non-radioactive 
69
Ga was prepared in an amber glass HPLC vial and analogously incubated in the same HPLC autosampler 
as a negative control. Peak areas were determined after the indicated time points by HPLC analysis. Each value is a mean ± SD of 
three independent experiments.  
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3.4.2 Activation utilizing external radiation beams   
Having seen evidence for uncaging of 23 by incubation with a beta emitter, the utility of external 
radiation beams from a linear particle accelerator usually used for radiation therapy in clinic were 
investigated in a second approach. In a first experiment, a  1 ml compound solution of the DMNB caged 
prodrug 23 in methanol was exposed to a beam of 6 MeV photons in a translucent HPLC vial. A maximum 
energy dose of 10 gray was applied. Peak area determination of both the caged and uncaged species by 
HPLC analysis determined that under these conditions no activation occurred compared to the negative 
control. Although due to Compton scattering, high energy photons cause energy rich electrons in 
solution, a subsequent sufficient induction of Cherenkov radiation in methanol might not have occurred 
(Table 6). Therefore, the second experiment was performed utilizing high energy electron radiation. A 
1.5 ml compound solution of 23 in water with 25% DMSO was brought into an 6 MeV electron beam of 
the linear particle accelerator and a maximum radiation dose of 3 Gy was applied. The addition of DMSO 
was inevitable to avoid compound precipitation, although the role of organic solvents in the induction of 
Cherenkov radiation is unclear. Contents were subsequently determined using HPLC analysis before and 
after the irradiation. In addition a negative control was conducted. Again, no activation was observed 
under these condition. Since the intensity of Cherenkov radiation is strongly dependent on the energy of 
the charged particles, a third experiment was performed using electrons with a significantly higher 
energy of 18 MeV. Importantly, the total volume was increased to 4 ml as well in order to enhance the 
distance the electrons have to cover within the sample solution. However, an activation of 23 did not 
occur. As usual, photoactivation of all three samples upon UV irradiation was proven afterwards as a 
positive control. 
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Results from the experiments utilizing the radiation beam of a linear particle accelerator imply that the 
Cherenkov radiation induced under the chosen conditions is not sufficient to cleave the PPG from the 
caged prodrug 23. This fact could be due to several reasons. The intensity of Cherenkov radiation 
induced by particle beams might be generally too low to induce bond cleavage. Particularly, since 
radiation exposure is no longer than a couple of seconds in order to reach the maximum radiation dose. 
Furthermore, as emphasized above, the impact of organic solvents such as DMSO on the induction of 
Cherenkov radiation is unclear. However, the total volume of the irradiated medium is considered to be 
a critical parameter. In order to address the issue of a critical distance charged particles have to cover, 
the use of a water tank around the sample vial might be highly beneficial to the induction of Cherenkov 
radiation.179 Translucent HPLC vials containing the compound solutions, fixed in the middle of the tank 
would thereby be completely surrounded by water. This experimental setup would not only allow a 
significant enhancement of the interaction between the high energy particles and the solvent but also 
allow the use of solely water as the medium in which the Cherenkov radiation should be induced. 
Table 6: Results from activation experiments using external particle beams from a linear particle accelerator. 
 
# radiation energy 
maximum 
dose 
solvent volume 
compound 
concentration 
result 
  /MeV /Gy  /ml /µM  
        
1 Photons 6 10 MeOH 1 50 no activation 
2 Electrons 6 3 
25% DMSO in 
water 
1.5 50 no activation 
3 Electrons 18 3 
25% DMSO in 
water 
4 50 no activation 
 positive control samples 1-3 irradiated with UV light activation 
    
4 Electrons 18 3 sample recessed in water tank 50 to be 
performed 
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4 Conclusion 
The unique qualities of the caging concept have been utilized for a variety of applications for decades. 
Surprisingly, only a few photoactivatable prodrugs in biological settings have been described yet despite 
the fact that the caging technique allows targeting of two major issues: severe side effects and acquired 
resistances. Both issues are commonly linked with novel potent drugs. Since implementation of the 
caging concept is limited to only a selected group of drug classes so far, the main focus of the present 
thesis was its extension to further drug classes. Since potent drugs with strong side effects may benefit 
particularly from the caging technique, a small-molecule microtubule-targeting agent (smMTA) as well as 
a CDK inhibitor have been chosen. Hence, the present thesis comprised the development of both a 
photoactivatable smMTA and CDK inhibitor by the following of a specifically evolved workflow.  
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4.1 Photoactivatable small-molecule microtubule-targeting agent 
This project included the successful design, synthesis, photochemical characterization and biological 
evaluation of a photoactivatable smMTA.  Identified as a potent inhibitor of microtubule polymerization, 
smMTA 17 represented an attractive lead for the development of an anti-brain tumor drug.104 Due to its 
well understood photochemistry as well as its rapid and clean photocleavage upon irradiation with UV 
light, the 4,5-dimethoxy-2-nitrobenzyl protecting group (DMNB) was the PPG of choice.28 Stability 
towards UV irradiation of 17 was proven at the very start of this project in order to meet this 
indispensable requirement. Since molecular modeling studies were unsuitable to reveal 17’s 
pharmacophore, the decision where to attach the PPG was based on data from earlier structure-activity 
relationship studies.104 Thereupon, the terminal phenolic group was selected for caging due its relevance 
for biological activity as well as its chemical accessibility. The smMTA 17 was subsequently synthesized 
following a characterized 4-step synthesis route and consequently caged to obtain its DMNB caged 
prodrug 20 in decent yields.104 From this point, due to its light sensitivity, light exposure had to held to a 
minimum, rendering the purification particularly elaborate. Subsequent photochemical characterization 
demonstrated a quantitative, fast and clean activation upon UV irradiation.  
An extensive biological evaluation followed to assess the utility of the DMNB caged prodrug for biological 
applications. Several biological assays have been successfully adapted for the purpose of mainly 
addressing two objectives: biological inactivity of the caged prodrug as well as its recovery of biological 
activity upon light irradiation. First of all, attachment of the DMNB protecting group to the terminal 
phenolic group clearly diminished biological activity. Examining tubulin polymerization, cell viability, 
microtubule-interference and induction of apoptosis, only marginal residual activity of the caged prodrug 
could be determined. Importantly, biological activity in cell viability assays was reduced by factor 55 
using U251 cells respectively factor 185 working with primary tumor cells, RN1. Secondly, the 
photoactivation in vitro using UV light worked perfectly. Even a to 30 s reduced irradiation time, working 
with the primary cancer cells RN1 led to an almost complete restoration of biological activity. Hence, 
providing a  notable proof of concept in vitro. 
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In conclusion, the DMNB caged prodrug 20 represents the first photoactivatable smMTA with a high 
utility for biological applications to the best of my knowledge. Specifically, 20 could serve as an attractive 
tool compound for studying of microtubule dynamics or binding kinetics of smMTAs. Importantly, the 
required irradiation dose of UV light does not affect cell viability of the primary brain tumor cells RN1, 
enabling an exciting option for novel therapeutic approaches regarding brain tumors. A valuable starting 
point for the development of an advanced photoactivatable smMTA for the treatment of brain tumors 
was therefore characterized. A targeted irradiation would allow high local drug concentrations in cancer-
afflicted tissues while reducing systemic side effects.  
Although, for future applications several barriers have to be broken down. Penetration of the blood-
brain-barrier is indispensable for anti-brain tumor drugs rendering small-molecule MTAs particularly 
attractive. Addition of a PPG necessarily increases the molecular weight of a smMTA potentially 
decreasing the penetration ability of a photoactivatable prodrug. However, pharmacokinetic properties 
such as solubility and the ability to penetrate membranes such as the blood-brain-barrier of 
photoactivatable prodrugs can be governed by specific substitution of the PPG. For instance, the water 
solubility of the DMNB protecting group can be significantly improved by the introduction of a carboxylic 
acid substituents.180,181 Importantly, the ability of a photoactivatable smMTA to cross the blood-brain-
barrier has to be assessed prior a potential medicinal application.  
Furthermore, due to the limited penetration depth of UV light, surgery is mandatory for a targeted 
irradiation of brain tumors with UV light. Even an advanced visible-light absorbing PPG such as BODIPY or 
two-photon uncaging might not overcome this restriction, since the irradiation has to penetrate the 
skull. However, utilization of Cherenkov radiation induced by high energy particle beams of linear 
particle accelerators could be highly beneficial although the question whether its intensity is enough to 
activate the prodrug in sufficient quantities remains to be answered.    
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4.2 Photoactivatable CDK inhibitor 
This project comprised the successful application of the caging technique to CDK inhibitor 16. It included 
the design, synthesis, photochemical characterization and biological evaluation of a DMNB caged CDK 
inhibitor.  
Having proven stability towards UV irradiation, molecular modelling studies were performed to reveal 
the binding mode of 16 to its target kinase, CDK2. By forming a critical H-bond towards the hinge region 
of the kinase, its free amino function was identified as crucial for ligand affinity and biological activity. 
Hence, caging aimed for that specific amino function. Again, dummy experiments were implemented 
utilizing the pharmacophoric scaffold 24 prior approaching the caging of the actual inhibitor. As an 
important insight in both projects, the implementation of dummy experiments, utilizing only the relevant 
substructures or pharmacophore respectively, turned out to be highly useful in order to save time and 
valuable drug material. Working with the pharmacophoric scaffold 24 an efficient synthetic strategy to 
attach a PPG to the amino function of the N-phenylpyrimidine-2-amine scaffold in terms of nucleophilic 
substitution reaction was identified using sodium hydride at -30°C. These optimized reaction conditions 
were not only successfully applied  for the actual CDK inhibitor 16 but for both the scaffold project as 
well as the BODIPY project. Subsequent photochemical characterization highlighted a rapid and clean 
photoactivation upon UV irradiation of the DMNB caged prodrug 23. Since the project aimed to develop 
photoactivatable prodrugs for biological applications, photoexperiments were designed as close to 
biological assay conditions as possible. This strategy turned out particularly helpful regarding the 
evaluation of the required irradiation dose for in vitro photoactivation, although true biological 
conditions could not be simulated due to limits of quantification as well as poor water solubility of the 
caged prodrug.  
Seeing the exceptional fast photoactivation of 23 under experimental conditions, the question whether 
that prompt photoactivation is generally valid for amino caged N-phenylpyrimidine-2-amine scaffolds 
arose. Hence, the hypothesis was addressed by investigating the photoactivation of differently 
substituted DMNB caged N-phenylpyrimidine-2-amine scaffolds. Specifically, the electron-donating and -
withdrawing effects of para-substituents to the caged amino function on the rate of photoactivation 
were assessed. Importantly, electron-donating substituents significantly reduced the rate of 
photoactivation. In contrast, electron-withdrawing substituents did not further increase the rate of 
photoactivation compared to the unsubstituted  DMNB caged N-phenylpyrimidine-2-amine scaffold. This 
result is of major interest since the N-phenylpyrimidine-2-amine scaffold is part of the hinge binding 
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motifs of a variety of CDK and other kinase inhibitors.78,149–151 Thus, designing further photoactivatable 
CDK or kinase inhibitors exhibiting the N-phenylpyrimidine-2-amine scaffold, strong electron-donating 
substituents should be minded in terms of a fast photoactivation.  
Having studied the rate of photoactivation under experimental conditions, the demonstration of in vitro 
photoactivation upon UV irradiation represented one central role of the biological evaluation. 
Additionally, residual biological activity of the DMNB caged prodrug 23 was to be assessed. Firstly, the 
ability of 23 to inhibit the kinase activity of CDK2 was determined. Compared to inhibitor 16, the 
inhibitory efficacy decreased by more than factor 1000 rendering the DMNB caged prodrug 23 inactive in 
CDK2 kinase assays. Secondly, cell proliferation assays using Panc89 cells were performed. The DMNB 
caged prodrug 23 exhibited a significantly higher EC50 compared to the uncaged inhibitor 16, although a 
considerably lower factor in difference of ≈ 24 was achieved. Off-target effects might contribute to 
residual cytotoxic activity in particular, since CDK2 kinase activity was not inhibited. However, the caged 
prodrug did not affect cell proliferation up to high micromolar concentrations (≈ 17.3 µM), which still 
would allow a decent therapeutic window, since potent kinase inhibitors such as 16 are applied at 
considerably lower concentrations (EC50 = 0.70 µM).  
To finalize the proof of concept, in vitro photoactivation upon irradiation with UV light worked perfectly 
in both kinase and cell proliferation assays. Upon 2 minutes of UV irradiation at a considerably low 
power of 37.5 mW  the biological activity of the caged prodrug 23 was restored completely. 
Furthermore, the used Panc89 cell tolerated the applied irradiation dose well. Hence, to the best of my 
knowledge the first photoactivatable CDK inhibitor is presented. The biological activity thus CDK 
inhibition can be activated upon irradiation with a high spatiotemporal control, making the DMNB caged 
prodrug 23 an attractive tool compound to study biological processes like CDK signal transduction within 
a cell or with regard to binding kinetics. 
Despite this notable proof of concept in vitro, the water solubility of the caged prodrug has to be 
significantly increased regarding a medicinal application. The utilization of a hydrophilic PPG represents a 
promising approach.180,181 However, the little penetration depth of UV light into biological tissues 
restricts studies utilizing the DMNB caged prodrug 23 to thin cell layers or superficial tissues. Considering 
23 as a tool compound to study biological processes in vitro, this penetration depth might be sufficient, 
whereas a medical application appears difficult. In order to overcome this limitation, two promising 
strategies were approached. Firstly, the utilization of a visible-light absorbing PPG was obvious. The 
BODIPY group was chosen due to its stability in various media, sharp absorption peaks and low in vitro 
toxicity.52 Furthermore, readily substitution of the ring systems enables custom-tailored BODIPY 
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protecting groups. 51,167,175 This is particularly interesting in terms of water solubility. Although BODIPY 
derivatives are widely used as laser dyes48,49, photosensitizers50 and fluorescent tags51, it’s utility as a PPG 
for biological applications remained unclear. Hence, caging of inhibitor 16 with a BODIPY PPG was aimed 
for with the intension of studying its photoactivation upon irradiation with visible light. As an important 
result, a universal strategy of synthesis was characterized exploiting chemical accessibility of the 8-
chloro-substituted BODIPY derivatives with a subsequent conversion to their 8-iodo-substituted 
derivatives by a Finkelstein reaction.  These 8-iodo-substituted BODIPY derivatives can serve as valuable 
precursors in order to attach the BODIPY PPG to various nucleophilic nitrogen such as amine functions of 
kinase inhibitors. Following photochemical characterization utilizing moderately tissue penetrating green 
light proved its utility for biological applications. An almost complete photoactivation upon irradiation 
was achieved within a time of irradiation which only slightly impaired cell proliferation of Panc89 cells. 
Having proven utility, the proof of concept utilizing the BODIPY PPG in vitro is part of present projects in 
our work group. The preparation of a water soluble BODIPY group, the investigation of  the mechanism 
of photorelease and assessment of a possible cellular toxicity of the cleaved protecting group will 
represent further milestones within this project.   
In a second approach to overcome the limited penetration depth of UV light, the possibility to activate a 
DMNB caged prodrug by the use of Cherenkov radiation induced by either a beta radiation emitting 
radionuclide or external particle beams from linear particle accelerators was investigated. Incubating the 
DMNB caged prodrug 23 with the positron emitting radionuclide 18F did not lead to a cleavage of the PPG 
considerably due to 18F’s decay energy which happens to be just above the threshold condition for 
induction of Cherenkov radiation. Hence, 68Ga was chosen as the positron emitting radionuclide for 
further experiments because of its significantly higher decay energy. In fact, incubation with 68Ga as the 
beta radiation emitter in 1 M HCl resulted in a 26% activation of the DMNB caged prodrug 23. This 
experiment represents an important proof of concept. However, the ability of beta radiation emitting 
radionuclides to activate a DMNB caged compound remains to be proven at a neutral pH value in order 
to validate the observed effect. Furthermore, cleavage of the PPG was assessed using external beam 
radiation from a linear particle accelerator. Therefore, compound solutions of the DMNB caged prodrug 
23 with a maximum total volume of 4 ml were placed in the particle beam of a linear particle accelerator. 
Both photon as well as electron radiation could not cleave the PPG from the DMNB caged prodrug 23. 
However, the critical total volume of the compound solutions might not have been sufficient since the 
particles from the particle beam might need to travel a certain distance within the solvent to efficiently 
induce Cherenkov radiation. The installation of a water tank surrounding the probes might be a 
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promising approach to induce Cherenkov radiation within the water tank and to subsequently activate 
the prodrug.  
In summary, the utilization of Cherenkov radiation would offer unparalleled opportunities regarding light 
delivery into difficult accessible treatment sites, since the required UV irradiation would be generated 
deep in place. An activation by a beta emitting radionuclide was firstly demonstrated by the use of 68Ga. 
To further validate and study the observed effect remains for current projects within our workgroup.   
In conclusion, both a photoactivatable small-molecule MTA as well as a photoactivatable CDK inhibitor 
with high utility in vitro were developed. Since the DMNB group was chosen as the PPG, both prodrugs 
are highly valuable as tool compounds to study biological processes in vitro due to a precise 
spatiotemporal control of their biological activity upon irradiation with UV light. Furthermore, the basis 
of two promising strategies to enhance their medicinal applicability was laid: installation of the novel 
visible-light absorbing BODIPY PPG as well as the utilization of Cherenkov radiation for photoactivation. 
Both strategies would increase the value of photoactivatable prodrugs tremendously. In particular,  
utilization of Cherenkov radiation in combination with clinically used tumor targeting vectors for delivery 
of radiation to specific tumor sites in vivo would enable a precise control of biological activity in nearly 
every spot within the human body and could lead to a novel therapeutic approach combining caged 
prodrugs with existing radiotherapeutic applications.  
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5 Experimental 
5.1 Molecular modeling 
Molecular modeling was performed on a DELL 8 core system. For visualization Maestro, version 10.4, 
Schrödinger, LLC, New York, NY, 2014 was used. Protein crystal structures were prepared prior to 
docking by the Protein Preparation Wizard135 utilizing the following programs: Epik136, version 2.7, 
2013; Impact, version 6.2, 2014; Prime137,138, version 3.4, 2014. Thus, the X-ray crystal structure 
refinement process included addition of hydrogen atoms, optimization of hydrogen bonds, and removal 
of atomic clashes. Default settings were used. Missing side chains and loops were filled in with Prime. 
Furthermore, selenomethionines were converted to methionines and water molecules were deleted.  
Additionally, ligands were prepared in order to create energetically minimized 3D geometries and assign 
proper bond orders (MacroModel, version 10.3, 2014). Accessible tautomer and ionization states were 
calculated prior to screening (LigPrep, version 2.9, 2014). To generate bioactive conformers a 
conformational search method was used (ConfGen139, version 2.7, 2014). Receptor grid generation was 
performed by Glide140,141, version 6.2, 2014. For ligand docking and screening the Glide SP workflow 
was used. Energetically minimized ligand conformations were docked into the active site of the protein; 
possible binding poses were determined and subsequently ranked based on their calculated binding 
affinities.  
Furthermore, caged ligands were investigated regarding their interactions within the ATP binding pocket. 
The structures were therefore superimposed with crystallized or modeled inhibitors by the flexible ligand 
alignment function. Afterwards, steric hindrance was determined by calculation of ligand-protein 
contacts. Ugly contacts with a contact cutoff ratio < 0.5 were indicated by red dashed lines. The cutoff 
ratio was calculated by Maestro based on the following formula: C = D1,2 / (R1+R2) where D1,2 is the 
distance between the two atomic centers and where R1 resp. R2 are the radii of the atomic centers. C 
increases monotonically for each contact type, that is C(ugly) < C(bad) < C(good). 
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5.2 Photoexperiments 
5.2.1 Inhibitor stability upon irradiation 
Compound 17 and 21 were dissolved in DMSO (1 mM). 5 mL were irradiated in a glass flask at 365 nm 
(LED source: 12x Nichia NCSU033B, Sahlmann Photochemical Solutions, 100%, 5.4 W) up to 20 min. 
Aliquots were diluted with HPLC grade methanol (1:1) and analyzed by HPLC.  
Compound 16 and 26 were dissolved in DMSO (1 mM) resp. in PBS buffer with 10% DMSO (25 µM). 
100 µL of each solution were irradiated in a well of a 96-well plate at 365 nm (LED source: 8x Nichia 
NCSU033B, Sahlmann Photochemical Solutions, 10%, 75 mW) up to 10 min. Content determination was 
performed by HPLC analysis.  
Compound 16 was dissolved in PBS buffer with 20% DMSO (25 µM). 100 µL each were irradiated in a well 
of a 96-well plate at 530 nm (LED source: 8x Nichia NCSG219-V1, Sahlmann Photochemical Solutions, 
100%, 4.6 W) up to 25 min. Content determination was performed by HPLC analysis.  
5.2.2 UV/Vis absorptions spectra 
Spectra were recorded on UV/Vis spectrophotometer Varian Cary® 50 Scan, Agilent Technologies. UV/Vis 
absorbance was measured in DMSO or PBS buffer with 10% DMSO. Concentration is either indicated or 
the compounds were dissolved and diluted until peak absorbance was in a range of 0.6 to 0.8. 
Absorbance was subsequently normalized to the uncaged compounds 16, 17 and 24.  
5.2.3 Photoactivation 
Photoactivatable small-molecule microtubule-targeting agent 
Compound 20 was dissolved in DMSO (1 mM). 5 ml were irradiated in a glass flask at 365 nm (LED 
source: 12x Nichia NCSU033B, Sahlmann Photochemical Solutions, 100%, 5.4 W). After 0, 20, 40, 60, 90, 
120, 180, 240, 300 and 600 seconds samples were taken, diluted with HPLC grade methanol (1:1) and 
analyzed by HPLC at a wavelength of 254 nm. Each sample was injected to HPLC twice. Additional to 
HPLC analysis LC-MS was used to confirm compound identity.  
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Photoactivatable CDK inhibitor 
Compounds 23 and 25 were dissolved in DMSO (1 mM) resp. in PBS buffer with 10% DMSO (25 µM). 
100 µL of each solution were irradiated in a well of a 96-well plate at 365 nm (LED source: 16x Nichia 
NCSU276A U365, Sahlmann Photochemical Solutions). The light intensity in mW is indicated for each 
experiment. After 0, 10, 20, 30, 45, 60, 90, 120 and 180 seconds samples were taken and analyzed by 
HPLC at a wavelength of 296 nm without further dilution. Each sample was injected to HPLC twice. 
Additional to HPLC analysis LC-MS was used to confirm compound identity.  
Scaffold project 
Compounds 25,35-45  were dissolved in DMSO (500 µM) resp. in PBS buffer with 20% DMSO (500 µM). 
100 µL of each solution were irradiated in a well of a 96-well plate at 365 nm (LED source: 16x Nichia 
NCSU276A U365, Sahlmann Photochemical Solutions) with 7.5 mW. After 0, 5, 10, 15, 20, 25, 30, 45, 60 
and 120 seconds samples were taken and analyzed by HPLC at a wavelength of 296 nm without further 
dilution. Each sample was injected to HPLC twice.  
Visible-light absorbing PPG 
Compounds 49,53 and 54 were dissolved in DMSO (25 µM). 100 µL of each solution were irradiated in a 
well of a 96-well plate at 530 nm (LED source: 8x Nichia NCSG219-V1, Sahlmann Photochemical 
Solutions). The light intensity in mW is indicated for each experiment. After 0, 1, 2.5, 5, 7.5, 10, 15 and 20 
minutes samples were taken and analyzed by HPLC at a wavelength of 296 nm without further dilution. 
Each sample was injected to HPLC twice. Additional to HPLC analysis LC-MS was used to confirm 
compound identity.  
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5.3 Chemical Synthesis and Characterization 
5.3.1 Reagents and solvents 
All reagents and solvents that have been applied in synthetic and analytic approaches were, if not 
specified otherwise, obtained from the commercial companies abcr GmbH (Karlsruhe, Germany), Sigma-
Aldrich Chemie GmbH, Merck Group (Munich, Germany), Merck Millipore (Darmstadt, Germany), Acros 
Organics, Thermo Fisher Scientific (Geel, Belgium), and VWR International GmbH (Hannover, Germany). 
They were used without further purification. 
5.3.2 TLC  
Monitoring of reactions progress included thin-layer chromatography (TLC) utilizing silica gel 
polyester sheets (SIL G/UV254, 0.2 mm, Polygram®, Macherey-Nagel). 
5.3.3 Flash Chromatography 
Flash chromatography was performed using a LaFlash system, VWR International GmbH (Hannover 
Germany). Pre-packed silica gel columns (PuriFlash-30SIHP, 30 μm, Interchim) and RP-18 modified silica 
gel columns (PuriFlash-15C18HP, 15 μm, Interchim) were used for separation. Composition of the mobile 
phases are indicated with the appropriate synthetic procedures. Flow rates were adjusted to column 
sizes. 
5.3.4 HPLC 
High-performance liquid chromatography (HPLC) was performed with a Hewlett Packard 1050 Series 
(Agilent Technologies, Waldbronn, Germany) and served for monitoring of reaction progress, purity 
control and peak area determination of photochemical characterizations and stability experiments.  
The column was either a Kinetex® C8, 5 μm (150 ∙ 4.6 mm, Phenomenex, Aschaffenburg, Germany) or a 
STAGROMA® C18, 5 μm (125 ∙ 4 mm, Stagroma AG, Reinach, Switzerland). The injection volume was 
20 µL. Depending of the compounds to separate, different gradients of acetonitrile and KH2PO4 buffer 
(10 mM, pH 2.3) were used as the mobile phase with a fixed flow rate (1.5 ml ∙ min-1). UV detection was 
achieved at 254 nm, 296 nm or 515 nm. 
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5.3.5 NMR 
1H and 13C NMR spectra were recorded on a Bruker Avance III 300 instrument at a temperature of 298 K 
resp. 300 K with a multinuclear probe head using the manufacture’s pulse program: 1H (300 MHz) and 13C 
(75 MHz). Spectra were referenced to the respective deuterated solvents signals of DMSO-d6 (δ 1H NMR: 
2.50 ppm, δ 13C NMR: 39.52 ppm) and CDCl3 (δ 
1H NMR: 7.26 ppm, δ 13C NMR: 77.00 ppm) as an internal 
standard. H,H-COSY, HSQC, HMBC spectra were further consulted for compound identity. The following 
abbreviations have been used to classify the appropriate signals: b (broad), s (singlet), d (doublet), t 
(triplet), q (quartet), quint (quintet), m (unresolved multiplet). 
NMR spectroscopy was performed by Dr. Ulrich Girreser and his NMR team. 
5.3.6 LC-MS 
Liquid chromatographic (LC) separation was performed with an Agilent 1100 HPLC system (Agilent 
Technologies, Waldbronn, Germany) over an Waters Xterra MS C8 (50 ∙ 4.6 mm, 3.5 μm) column 
tempered at 20°C using a 0.1 % acetic acid in double distilled water/acetonitrile gradient for mobile 
phase (flow rate = 1 ml ∙ min-1). 
Mass spectra were recorded on a Bruker Esquire ~LC ion trap mass spectrometer (Bruker Daltonics, 
Bremen, Germany) with electron spray ionization (ESI) in the positive ion mode (dry gas 6.5 l ∙ min-1, 
nebulizer 25 psi, drying temperature 250 °C). 
LC-MS analyses were performed by Dr. Ulrich Girreser and Sven Wichmann.  
5.3.7 HRMS 
High resolution mass spectra were recorded either on a Thermo Fisher Q Exative Plus mass spectrometer 
(Hybrid Quadrupol Orbitrap) with electron spray ionization (ESI) in the positive ion mode, a Joel Accu 
(TOF 4G) with electron impact ionization (EI) or a Bifex III mass spectrometer (Fa. Bruker Daltonics) with 
matrix-assisted laser desorption/ionization (MALDI, applied matrix: 4-chloro-α-cyanocinnamic acid, 
wavelength ionization laser: 337 nm, acceleration voltage: 19 kV) and time of flight detector (TOF). The 
method used is indicated for each compound respectively. 
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5.3.8 X-ray Crystallography  
X-ray ligand crystal structure analysis was performed by Dr. Dieter Schollmeyer at the Institute of 
Organic Chemistry, Johannes Gutenberg University (Mainz, Germany) on a Stoe IPDS 2T with Cu and Mo-
X ray tubes and Oxford Cryostream. 
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5.3.9 Synthetic procedures 
General procedure for caging of N-phenylpyrimidin-2-amines with benzyl bromides (23, 25, 26, 35-42) 
Sodium hydride (1.2 equiv.) was dissolved in 5 ml of dry DMF under a nitrogen atmosphere. After cooling 
to 0°C, the respective N-phenylpyrimidin-2-amine (1.0 equiv.), dissolved in 3 ml of dry DMF, was added 
dropwise to the reaction. After 1 h the reaction was cooled to -35°C and the respective benzyl bromide 
(1.1 equiv.), dissolved in 3 ml of dry DMF, was added to the reaction dropwise. After stirring at -35°C for 
1 h the reaction was quenched by slow addition of H2O. After 1 h the reaction was filtrated. The 
precipitate was purified by flash chromatography (stationary phase and eluent given for each compound, 
respectively) to afford the particular compound.  
 
General procedure for caging of N-phenylpyrimidin-2-amines with BODIPY protecting groups 
(49,53,54) 
Sodium hydride (1.2 equiv.) was dissolved in 5 ml of dry DMF under an argon atmosphere. After cooling 
to 0°C, the respective N-phenylpyrimidin-2-amine (1.0 equiv.), dissolved in 3 ml of dry DMF, was added 
dropwise to the reaction. After 1 h the reaction was cooled to -35°C and the respective BODIPY iodide or 
chloride (2.5 equiv.), dissolved in 10 ml of dry DMF, was added to the reaction dropwise. After stirring at 
-35°C for 1 h the reaction was quenched by addition of 2 drops H2O. The solvent was removed by 
reduced pressure. The raw product was purified by flash chromatography (stationary phase and eluent 
given for each compound, respectively) to afford the particular compound.  
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4-(4-(2-Fluoropyridin-3-yl)phenyl)-N-(4-hydroxyphenyl)butanamide (17)           
 
alex-raj 
C21H19FN2O2 (Mr 350.14) 
Synthesis was performed by Dr. Mohammed Abadleh. 
4-(4-(2-Fluoropyridin-3-yl)phenyl)-N-(4-hydroxyphenyl)butanamide was synthesized according to 
literature 104 (99% HPLC purity).  
 
1H NMR (300 MHz, DMSO-d6): δ = 1.92 (quint, 
3JHH = 7.5 Hz, 2H), 2.30 (t, 
3JHH = 7.4 Hz, 2H), 2.68 (t, 
3JHH = 7.5 Hz, 2H), 6.68 (d, 
3JHH = 8.9 Hz, 2H), 7.36 (m, 4H), 7.45 (m, 1H), 7.54 (dd,
 4JHH = 1.7 Hz, 
3JHH = 8.3 Hz, 2H), 8.09 (m, 1H), 8.22 (m, 1H), 9.13 (s, 1H), 9.63 (bs, 1H) ppm. 
13C NMR (75 MHz, DMSO-d6): δ = 26.6, 34.3, 35.7, 114.9, 120.9, 122.6 (d,
 4JCF = 4.3 Hz), 122.8 (d,
 
2JCF = 29.2 Hz), 128.7 (d,
 4JCF = 3.0 Hz), 128.8, 130.9 (d,
 3JCF = 5.1 Hz), 131.0, 141.2 (d,
 3JCF = 4.4 Hz), 142.2, 
146.1 (d, 3JCF = 14.9 Hz), 153.1, 159.6 (d,
 1JCF = 236.9 Hz), 170.1 ppm. 
HRMS (EI): m/z = 350.14281 M+ (calc. m/z = 350.14306) 
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N-(4-((4,5-dimethoxy-2-nitrobenzyl)oxy)phenyl)-4-(4-(2-fluoropyridin-3-yl)phenyl)butanamide (20)                       
 
alex-3.8 
C30H28FN3O6 (Mr 545.20) 
4-(4-(2-Fluoropyridin-3-yl)phenyl)-N-(4-hydroxyphenyl)butanamide 17 (100 mg, 0.29 mmol)  and 
potassium carbonate (98 mg, 0.71 mmol) were dissolved in DMF (10 ml) and stirred at room 
temperature for 30 min, followed by drop-wise addition of 4,5-dimethoxy-2-nitrobenzyl bromide (86 mg, 
0.31 mmol in DMF). The reaction mixture was stirred at RT for 12 h and demineralized water was added 
drop-wise until complete precipitation of the product. The solvent was removed by filtration and the 
product was purified by reverse phase flash silica gel chromatography with a gradient of methanol and 
water to yield N-(4-((4,5-dimethoxy-2-nitrobenzyl)oxy)phenyl)-4-(4-(2-fluoropyridin-3-yl)phenyl) 
butanamide as a yellow solid (100% HPLC purity). 
 
Yield: 93 mg (0.17 mmol, 60%) 
1H NMR (300 MHz, DMSO-d6): δ = 1.93 (quint, 
3JHH = 7.4 Hz, 2H), 2.32 (t, 
3JHH = 7.4 Hz, 2H), 2.68 (t, 
3JHH = 7.5 Hz, 2H), 3.86 (s, 3H), 3.87 (s, 3H), 5.46 (s, 2H), 6.97 (d 
3JHH = 9.0 Hz, 2H), 7.32 (s, 1H), 7.36 (d, 
3JHH = 8.1 Hz, 2H), 7.46 (m, 1H), 7.54 (m, 4H), 7.71 (s, 1H), 8.09 (m, 1H), 8.22 (m, 1H), 9.78 (bs, 1H) ppm. 
13C NMR (75 MHz, DMSO-d6): δ = 26.6, 34.3, 35.6, 56.0, 56.2, 66.8, 108.2, 111.1, 114.9, 120.6, 122.6 (d,
 
4JCF = 4.3 Hz), 122.8 (d,
 2JCF = 28.0 Hz), 127.5, 128.7 (d,
 4JCF = 3.3 Hz), 128.8, 130.9 (d,
 3JCF = 5.0 Hz), 133.1, 
139.6, 141.2 (d, 3JCF = 4.4 Hz), 142.2, 146.1 (d,
 3JCF = 15.4 Hz), 147.7, 153.1, 153.6, 159.6 (d,
 
1JCF = 237.1 Hz), 170.4 ppm. 
HRMS (EI): m/z = 545.19486 M+ (calc. m/z = 545.19621) 
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N-(4-(benzyloxy)phenyl)-4-(4-(2-fluoropyridin-3-yl)phenyl)butanamide (21)                           
 
alex-3.18 
C28H25FN2O2 (Mr 440.19) 
4-(4-(2-Fluoropyridin-3-yl)phenyl)-N-(4-hydroxyphenyl)butanamide 17 (100 mg, 0.285 mmol)  and 
sodium carbonate (38 mg, 0.570 mmol)  were dissolved in DMF (10 ml) and left stirring at room 
temperature. After 30 minutes benzyl bromide (63 mg, 0.371 mmol, 44 µl in DMF) was added to the 
reaction dropwise. The reaction mixture was left stirring at room temperature. After 12 hours the 
reaction mixture was extracted with ethyl acetate three times. The combined ethyl acetate phases were 
dried over sodium sulfate and the solvent was removed under reduced pressure. The product was 
purified by flash chromatography with a gradient of ethyl acetate and petroleum ether to yield N-(4-
(benzyloxy)phenyl)-4-(4-(2-fluoropyridin-3-yl)phenyl)butanamide as a light yellow solid (100% HPLC 
purity). 
 
Yield: 69 mg (0.16 mmol, 55%) 
1H NMR (300 MHz, DMSO-d6): δ = 1.93 (quint, 
3JHH = 7.7 Hz, 2H), 2.32 (t, 
3JHH = 7.3 Hz, 2H), 2.68 (t, 
3JHH = 7.5 Hz, 2H), 5.05 (s, 2H), 6.94 (d, 
3JHH = 9.2 Hz, 2H), 7.28-7.58 (m, 12H), 8.09 (m, 1H), 8.22 (m, 1H), 
7.32 (bs, 1H) ppm. 
13C NMR (75 MHz, DMSO-d6): δ = 26.6, 34.3, 35.6, 69.3, 114.7, 120.5, 122.6 (d,
 4JCF = 4.2 Hz), 122.8 (d,
 
2JCF = 28.2 Hz), 127.6, 127.7, 128.3, 128.7 (d,
 4JCF = 2.9 Hz), 128.8, 130.9 (d,
 3JCF = 5.1 Hz), 132.7, 137.2, 
141.2 (d, 3JCF = 4.4 Hz), 142.2, 146.1 (d,
 3JCF = 14.9 Hz), 154.0, 159.6 (d,
 1JCF = 236.6 Hz), 170.3 ppm. 
HRMS (EI): m/z = 440.18996 M+ (calc. m/z = 440.19001) 
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4-(1-Isopropyl-2-methyl-1H-imidazol-5-yl)-N-(4-(methylsulfonyl)phenyl)pyrimidin-2-amine (16) 
 
AZD5438 
C18H21N5O2S (Mr 371.46) 
AZD5438 was obtained from Taizhou Crene Biotechnology Co., Ltd (China).  
Before usage, the compound was purified and fully characterized. Purification was achieved by RP flash 
chromatography with a gradient of water and methanol to yield a white powder (100% HPLC purity).  
 
1H NMR (300 MHz, DMSO-d6): δ = 1.49 (d, 
3JHH = 7.1 Hz, 6H), 2.52 (s, 3H), 3.17 (s, 3H), 5.68 
(sept, 3JHH = 7.1 Hz, 1H), 7.19 (d,
 3JHH = 5.3 Hz, 1H), 7.48 (s, 1H), 7.83 (d, 
3JHH = 8.9 Hz, 2H), 7.98 (d, 
3JHH = 8.9 Hz, 2H), 8.49 (d,
 3JHH = 5.3 Hz, 1H), 10.0 (s, 1H) ppm. 
13C NMR (75 MHz, DMSO-d6): δ = 16.2, 21.5, 44.0, 47.1, 110.8, 118.4, 128.0, 129.2, 132.5, 132.5, 145.1, 
148.7, 158.0, 158.1, 159.0 ppm.  
HRMS (ESI): m/z = 372.14873 [M+H]+ (calc. m/z = 372.14887) 
 
 
 
 
          
 
 
 
 
Experimental         107 
 
N-(4-(methylsulfonyl)phenyl)pyrimidin-2-amine (24)         
 
Molecular structure determined by X-ray crystallography. 
 
alex-1.2 
C11H11N3O2S (Mr 249.06) 
24 was synthesized according to literature 137. 2-Chloropyrimidine (2341 mg, 20.44 mmol) and 4-
aminophenylmethylsulfonate (4200 mg, 24.53 mmol) were dissolved in 100 ml propan-2-ol. Four drops 
of conc. HCl were added and the reaction was left stirring at 85 °C for 24h. The solvent was removed 
under reduced pressure. The crude product was recrystallized from MeOH/H2O to yield N-(4-
(methylsulfonyl)phenyl)pyrimidin-2-amine as bright yellow needles (100% HPLC purity).  
 
Yield: 3100 mg (12.45 mmol, 61%). 
1H NMR (300 MHz, DMSO-d6): δ = 3.14 (s, 3H), 6.97 (t, 
3JHH = 4.8 Hz, 1H), 7.81(d, 
3JHH = 8.9 Hz, 2H), 8.02 
(d, 3JHH = 9.0 Hz, 2H), 8.57 (d, 
3JHH = 4.8 Hz, 2H), 10.2 (s, 1H) ppm. 
13C NMR (75 MHz, DMSO-d6): δ = 44.0, 113.7, 117.9, 128.0 , 132.2, 145.2, 158.2, 159.5 ppm.  
HRMS (ESI): m/z = 272.04619 [M+Na]+; 250.06434 [M+H]+ (calc. m/z = 250.06447) 
                      
108         Experimental 
 
N-(4,5-dimethoxy-2-nitrobenzyl)-N-(4-(methylsulfonyl)phenyl)pyrimidin-2-amine (25)                            
 
alex-1.3 
C20H20N4O6S (Mr 444.11) 
25 was synthesized according to the general procedure for caging of N-phenylpyrimidin-2-amines with 
benzyl bromides from 24 (122 mg, 0.44 mmol) and 4,5-dimethoxy-2-nitrobenzylbromide (137 mg, 0.484 
mmol). Purification was achieved by RP flash chromatography with a gradient of methanol and water to 
afford N-(4,5-dimethoxy-2-nitrobenzyl)-N-(4-(methylsulfonyl) phenyl)pyrimidin-2-amine as a bright 
yellow solid (98% HPLC purity).  
 
Yield: 117 mg (0.26 mmol, 60%). 
1H NMR (300 MHz, DMSO-d6): δ = 3.22 (s, 3H), 3.62 (s, 3H), 3.84 (s, 3H), 5.64 (s, 2H), 6.84 (s, 1H), 6.94 (t, 
3JHH = 4.8 Hz, 1H), 7.70 (m, 3H), 7.88 (d, 
3JHH = 8.8 Hz, 2H), 8.47 (d, 
3JHH = 4.8 Hz, 2H) ppm. 
13C NMR (75 MHz, DMSO-d6): δ = 43.6, 51.0, 56.0, 56.0, 108.5, 109.8, 133.6, 126.0, 127.8, 128.7, 136.5, 
140.0, 147.3, 148.2, 153.2, 158.2, 160.7 ppm.  
HRMS (ESI): m/z = 467.09947 [M+Na]+ (calc. m/z = 467.09958); 445.11744 [M+H]+ (calc. 
m/z = 445.11763) 
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N-(4,5-dimethoxy-2-nitrobenzyl)-4-(1-isopropyl-2-methyl-1H-imidazol-5-yl)-N-(4-(methylsulfonyl) 
phenyl)pyrimidin-2-amine (23) 
 
 
Molecular structure determined by X-ray crystallography. 
 
alex-1.4 
C27H30N6O6S (Mr 566.19) 
23 was synthesized according to the general procedure for caging of N-phenylpyrimidin-2-amines with 
benzyl bromides from 16 (100 mg, 0.27 mmol) and 4,5-dimethoxy-2-nitrobenzylbromide (82 mg, 0.30 
mmol). Purification was achieved by RP flash chromatography with a gradient of methanol and water to 
afford N-(4,5-dimethoxy-2-nitrobenzyl)-4-(1-isopropyl-2-methyl-1H-imidazol-5-yl)-N-(4-(methylsulfonyl) 
phenyl)pyrimidin-2-amine as a bright yellow solid (100% HPLC purity).   
 
Yield: 84 mg (0.15 mmol, 50%). 
1H NMR (300 MHz, DMSO-d6): δ = 1.05 (d, 
3JHH = 7.1 Hz, 6H), 2.39 (s, 3H), 3.21 (s, 3H), 3.84 (s, 3H), 3.66 (s, 
3H), 3.85 (s, 3H), 5.32 (sept, 3JHH = 7.0 Hz, 1H), 5.65 (s, 2H), 6.93 (s, 1H), 7.20 (d, 
3JHH = 5.3 Hz, 1H), 7.52 (s, 
1H), 7.73 (d, 3JHH = 8.8 Hz, 2H), 7.73 (s, 1H), 7.91 (d, 
3JHH = 8.8 Hz, 2H), 8.38 (d, 
3JHH = 5.3 Hz, 1H) ppm. 
13C NMR (75 MHz, DMSO-d6): δ = 16.1, 20.6, 43.5, 46.9, 51.4, 56.0, 56.0, 108.6, 109.8, 109.8, 126.6, 
127.9, 128.6, 128.8, 133.0, 136.9, 139.8, 148.4, 147.4, 148.8, 153.3, 157.8, 157.9, 160.7 ppm.  
HRMS (ESI): m/z = 567.20204 [M+H]+ (calc. m/z = 567.20203) 
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4,5-Dimethoxy-2-nitrobenzyl (tert-butoxycarbonyl)alaninate (22)                            
 
alex-1.6 
C17H24N2O8 (Mr 384.15) 
22 was synthesized according to literature 182. A solution of BOC protected L-alanine (22a) in toluene was 
treated with 4,5-dimethoxy-2-nitrobenzyl bromide in the presence of DBU and stirred at 80 °C for one 
hour. The crude product was filtered, washed with brine, dried over sodium carbonate and purified by 
flash silica gel chromatography to yield 4,5-dimethoxy-2-nitrobenzyl (tert-butoxycarbonyl)alaninate as a 
white solid (100% HPLC purity).  
 
Yield: 3100 mg (12.45 mmol, 61%). 
1H NMR (300 MHz, DMSO-d6): δ = 1.28 (d, 
3JHH = 7.3 Hz, 3H), 1.36 (s, 9H), 3.87 (s, 3H), 3.94 (s, 3H), 4.14 
(quint, 3JHH = 7.2 Hz, 1H), 5.43 (s, 2H), 7.20 (s, 1H), 7.41 (d, 
3JHH = 7.2 Hz, 1H), 7.70 (s, 1H) ppm. 
13C NMR (75 MHz, DMSO-d6): δ = 16.7, 28.1, 49.1, 56.1, 56.2, 62.9, 78.2, 108.2, 110.8, 126.4, 139.4, 
147.9, 153.3, 155.3, 172.8 ppm. 
HRMS (EI): m/z = 384.15347 M+ (calc. m/z = 384.15326) 
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N-benzyl-4-(1-isopropyl-2-methyl-1H-imidazol-5-yl)-N-(4-(methylsulfonyl)phenyl)pyrimidin-2-amine 
(26) 
 
alex-1.7 
C25H27N5O2S (Mr 461.19) 
26 was synthesized according to the general procedure for caging of N-phenylpyrimidin-2-amines with 
benzyl bromides from 16 (100 mg, 0.27 mmol) and benzyl bromide (51 mg, 0.30 mmol). Purification was 
achieved by RP flash chromatography with a gradient of methanol and water to afford N-benzyl-4-(1-
isopropyl-2-methyl-1H-imidazol-5-yl)-N-(4-(methylsulfonyl)phenyl)pyrimidin-2-amine as a bright yellow 
solid (100% HPLC purity).  
  
Yield: 81 mg (0.18 mmol, 65%). 
1H NMR (300 MHz, DMSO-d6): δ = 1.06 (d, 
3JHH = 7.1 Hz, 6H), 2.40 (s, 3H), 3.20 (s, 3H), 5.29-5.37 (m, 1H), 
5.37 (s, 2H), 7.15 (d, 3JHH = 5.3 Hz, 1H), 7.19-7.33 (m, 5H), 7.52 (s, 1H), 7.62 (d, 
3JHH = 8.7 Hz, 2H), 7.89 (d, 
3JHH = 8.7 Hz, 2H), 8.38 (d, 
3JHH = 5.3 Hz, 1H) ppm. 
13C NMR (75 MHz, DMSO-d6): δ = 16.1, 20.7, 43.5, 46.9, 52.7, 109.4, 126.5, 126.8, 126.8, 127.8, 128.4, 
128.7, 132.5, 136.8, 138.1, 148.7, 148.7, 157.7, 157.9, 160.8  ppm.  
HRMS (ESI): m/z = 462.19573[M+H]+ (calc. m/z = 462.19582) 
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N-phenylpyrimidin-2-amine                            
 
alex-1.1 
C10H9N3 (Mr 171.20) 
N-phenylpyrimidine-2-amine was synthesized according to literature 183. The reaction was carried out in 
a microwave for synthesis. Bis(dibenzylideneacetone)palladium(0) (30 mg, 0,03 mmol), S-BINAP (40 mg, 
0,06 mmol) and potassium tert-butoxide (505 mg, 4.5 mmol) were dissolved in 1.5 ml of anhyd. dioxane 
in a microwave vessel. The reaction was heated to 80°C and stirred for 10 min. After addition of 2-
chloropyrimidine (370 mg, 3.22 mmol), aniline (300 mg, 3.22 mmol) and 3.5 ml of anhyd. dioxane the 
reaction was heated to 100°C. After stirring for 2 hours the reaction was filtrated. The filtrate was 
concentrated under reduced pressure. The residue was dissolved in 20 ml of ethyl acetate, washed with 
brine and dried over sodium sulfate. The solvent was removed under reduced pressure. The crude 
product was purified by flash chromatography with a gradient of ethyl acetate and petroleum ether to 
afford N-phenylpyrimidine-2-amine as a white solid (100% HPLC purity). 
 
Yield: 320 mg (1.87 mmol, 58%). 
1H NMR (300 MHz, DMSO-d6): δ = 6.72 (t, 
3JHH = 4.8 Hz, 1H), 7.06 (t, 
3JHH = 7.4 Hz, 1H), 7.35 (t, 
3JHH = 7.4 Hz, 2H), 7.62 (d, 
3JHH = 7.5 Hz, 2H), 7.67 (bs, 1H), 8.43 (d, 
3JHH = 4.9 Hz, 2H) ppm. 
13C NMR (75 MHz, DMSO-d6): δ = 112.5, 119.8, 123.0, 129.1, 139.3, 158.1, 160.1 ppm. 
HRMS (ESI): m/z = 172.08699 [M+H]+ (calc. m/z = 172.08692) 
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N-(p-tolyl)pyrimidin-2-amine 
 
TD-001 
C11H11N3 (Mr 185.10) 
The synthesis of N-(p-tolyl)pyrimidin-2-amine was adapted from literature 137. 2-Chloropyrimidine 
(1602 mg, 14.0 mmol) and p-toluidine (1000 mg, 9.3 mmol) were dissolved in 20 ml dioxane. 14 ml of 
acetic acid were added and the reaction was left stirring at 85 °C for 24h. The reaction was neutralized by 
addition of an aqueous solution of NaHCO3 and extracted with ethyl acetate three times. The organic 
phase was dried over Na2SO4 and the solvent was removed under reduced pressure. The crude product 
was recrystallized from MeOH/H2O to yield N-(p-tolyl)pyrimidin-2-amine as light yellow needles (100% 
HPLC purity).  
 
Yield: 1463 mg (7.9 mmol, 85%) 
1H NMR (300 MHz, CDCl3): δ = 2.24 (s, 3H), 6.79 (t, 
3JHH = 4.8 Hz, 1H), 7.08 (d, 
3JHH = 8.6 Hz, 2H), 7.62 (d, 
3JHH = 8.6 Hz, 2H), 8.44 (d, 
3JHH = 4.8 Hz, 2H), 9.48 (s, 1H) ppm. 
13C NMR (75 MHz, CDCl3): δ = 20.3, 112.0, 118.9, 128.8, 130.1, 137.9, 157.9, 160.1 ppm. 
HRMS (ESI): m/z = 186.10260 [M+H]+ (calc. m/z = 186.10257) 
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N-(4-bromophenyl)pyrimidin-2-amine 
 
TD-002 
C10H8BrN3 (Mr 250.00) 
Synthesis of N-(4-bromophenyl)pyrimidin-2-amine was adapted from literature 183. The reaction was 
carried out in a microwave for synthesis. Bis(dibenzylideneacetone)palladium(0) (12 mg, 0.013 mmol), 
Xantphos (15 mg, 0.025 mmol) and potassium tert-butoxide (200 mg, 1.78 mmol) were dissolved in 2 ml 
of anhyd. dioxane in a microwave vessel. The reaction was heated to 110°C and stirred for 20 min. After 
addition of 2-aminopyrimidine (169 mg, 1.78 mmol), 1,4-dibromobenzene (300 mg, 1.27 mmol) and 3 ml 
of anhyd. dioxane the reaction was heated to 140°C. After stirring for 2 hours the reaction was filtrated. 
The filtrate was concentrated under reduced pressure. The residue was dissolved in 20 ml of ethyl 
acetate, washed with brine and dried over sodium sulfate. The solvent was removed under reduced 
pressure. The crude product was purified by flash chromatography with a gradient of ethyl acetate and 
petroleum ether to afford N-(4-bromophenyl)pyrimidin-2-amine as a white solid (99% HPLC purity). 
 
Yield: 119 mg (0.48 mmol, 37%) 
1H NMR (300 MHz, CDCl3): δ = 6.78 (t, 
3JHH = 4.8 Hz, 1H), 7.46 (d, 
3JHH = 9.0 Hz, 2H), 7.56 (d, 
3JHH = 9.0 Hz, 
2H), 7.68 (bs, 1H), 8.45 (d, 3JHH = 4.8 Hz, 2H) ppm. 
13C NMR (75 MHz, CDCl3): δ = 112.8, 115.2, 121.1, 131.9, 138.3, 157.9, 159.5ppm. 
HRMS (ESI): m/z = 249.99738 [M+H]+ (calc. m/z 79Br = 249.99744) 
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N-(4-nitrilephenyl)pyrimidin-2-amine  
 
TD-008 
C11H8N3 (Mr 196.08) 
Synthesis of N-(4-nitrilphenyl)pyrimidin-2-amine was adapted from literature 183.The reaction was carried 
out in a microwave for synthesis. Bis(dibenzylideneacetone)palladium(0) (15 mg, 0.017 mmol), Xantphos 
(19 mg, 0.033 mmol) and potassium tert-butoxide (259 mg, 2.31 mmol) were dissolved in 3 ml of anhyd. 
dioxane in a microwave vessel. The reaction was heated to 110°C and stirred for 20 min. After addition 
of 2-aminopyrimidine (188 mg, 1.98 mmol), 4-bromobenzonitrile (300 mg, 1.65 mmol) and 2 ml of 
anhyd. dioxane the reaction was heated to 130°C. After stirring for 2 hours the reaction was filtrated. 
The filtrate was concentrated under reduced pressure. The residue was dissolved in 20 ml of ethyl 
acetate, washed with brine and dried over sodium sulfate. The solvent was removed under reduced 
pressure. The crude product was purified by flash chromatography with a gradient of ethyl acetate and 
petroleum ether to afford N-(4-nitrilphenyl)pyrimidin-2-amine as a bright yellow solid (99% HPLC purity). 
 
Yield: 113 mg (0.58 mmol, 35%) 
1H NMR (300 MHz, DMSO-d6): δ = 6.98 (t, 
3JHH = 4.8 Hz, 1H), 7.72 (d, 
3JHH = 8.9 Hz, 2H), 7.98 (d, 
3JHH = 8.9 Hz, 2H), 8.57 (d, 
3JHH = 4.8 Hz, 2H), 10.21 (s, 1H) ppm. 
13C NMR (75 MHz, DMSO-d6): δ = 102.3, 113.8, 118.2, 119.5, 133.0, 144.9, 158.2, 159.4 ppm. 
HRMS (ESI): m/z = 197.08221 [M+H]+ (calc. m/z = 197.08217) 
 
                            
 
                   
            
Experimental         117 
 
N-(4-(trifluoromethyl)phenyl)pyrimidin-2-amine 
 
SK-006 
C11H8F3N3 (Mr 239.07) 
The synthesis of N-(4-(trifluoromethyl)phenyl)pyrimidin-2-amine was adapted from literature 137. 2-
Chloropyrimidine (1940 mg, 17.0 mmol) and 4-(trifluoromethyl)aniline (2100 mg, 13.0 mmol) were 
dissolved in 50 ml propan-2-ol. Three drops of conc. HCl were added and the reaction was left stirring at 
85 °C for 24h. The solvent was removed under reduced pressure. The crude product was recrystallized 
from MeOH/H2O to yield N-(4-(trifluoromethyl)phenyl)pyrimidin-2-amine as light yellow needles (100% 
HPLC purity).  
 
Yield: 3034 mg (12.7 mmol, 98%) 
1H NMR (300 MHz, DMSO-d6): δ = 6.95 (t, 
3JHH = 4.8 Hz, 1H), 7.63 (d, 
3JHH = 8.7 Hz, 2H), 7.99 (d, 
3JHH = 8.6 Hz, 2H), 8.55 (d, 
3JHH = 4.8 Hz, 2H), 10.07 (s, 1H) ppm. 
13C NMR (75 MHz, DMSO-d6): δ = 113.4, 118.1, 120.9, 123.1, 125.7, 144.1, 158.1, 159.6 ppm. 
HRMS (ESI): m/z = 240.07422 [M+H]+ (calc. m/z = 240.07431) 
 
 
                   
 
 
 
 
 
118         Experimental 
 
Ethyl 4-(pyrimidin-2-ylamino)benzoate 
 
SK-007 
C13H13N3O2 (Mr 243.11) 
The synthesis of Ethyl 4-(pyrimidin-2-ylamino)benzoate was adapted from literature 137. 2-
Chloropyrimidine (1000 mg, 8.73 mmol) and ethyl 4-aminobenzoate (2164 mg, 13.1 mmol) were 
dissolved in 50 ml dioxane. Subsequent, 14 ml of acetic acid were added and the reaction was left 
stirring at 110 °C for 24h. The solvent was removed under reduced pressure. The crude product was 
recrystallized from MeOH/H2O to yield ethyl 4-(pyrimidin-2-ylamino)benzoate as a bright yellow solid 
(100% HPLC purity).  
 
Yield: 1804 mg (7.42 mmol, 85%) 
1H NMR (300 MHz, DMSO-d6): δ = 1.30 (t, 
3JHH = 7.1 Hz, 3H), 4.27 (q, 
3JHH = 7.1 Hz, 2H), 6.94 (t, 
3JHH = 4.8 Hz, 1H), 7.86-7.94 (m, 4H), 8.56 (d, 
3JHH = 4.8 Hz, 2H), 10.08 (s, 1H) ppm. 
13C NMR (75 MHz, DMSO-d6): δ = 14.3, 60.2, 113.5, 117.6, 122.0, 130.1, 145.1, 158.1, 159.6, 165.5 ppm. 
HRMS (ESI): m/z = 244.10812 [M+H]+ (calc. m/z = 244.10805) 
 
                     
 
 
 
 
 
 
Experimental         119 
 
N-(4-methoxyphenyl)pyrimidin-2-amine 
 
alex-1.11 
C11H11N3O (Mr 201.09) 
Synthesis of N-(4-methoxyphenyl)pyrimidin-2-amine was adapted from literature 183. The reaction was 
carried out in a microwave for synthesis. Bis(dibenzylideneacetone)palladium(0) (16 mg, 0.018 mmol), S-
BINAP (22 mg, 0.036 mmol) and potassium tert-butoxide (274 mg, 2.45 mmol) were dissolved in 1.5 ml 
of anhyd. dioxane in a microwave vessel. The reaction was heated to 80°C and stirred for 10 min. After 
addition of 2-chloropyrimidine (200 mg, 1.75 mmol), 4-methoxyaniline (258 mg, 2.10 mmol) and 3.5 ml 
of anhyd. dioxane the reaction was heated to 130°C. After stirring for 2 hours the reaction was filtrated. 
The filtrate was concentrated under reduced pressure. The residue was dissolved in 20 ml of ethyl 
acetate, washed with brine and dried over sodium sulfate. The solvent was removed under reduced 
pressure. The crude product was purified by flash chromatography with a gradient of ethyl acetate and 
petroleum ether to afford N-(4-methoxyphenyl)pyrimidin-2-amine as a white solid (99% HPLC purity). 
 
Yield: 123 mg (0.62 mmol, 35%) 
1H NMR (300 MHz, DMSO-d6): δ = 3.72 (s, 3H), 6.75 (t, 
3JHH = 4.8 Hz, 1H), 6.86 (d, 
3JHH = 9.1 Hz, 2H), 7.61 
(d, 3JHH = 9.1 Hz, 2H), 8.41 (d, 
3JHH = 4.7 Hz, 2H), 9.38 (s, 1H) ppm. 
13C NMR (75 MHz, DMSO-d6): δ = 55.1, 111.7, 113.6, 120.7, 133.5, 154.2, 157.9, 160.2 ppm. 
HRMS (ESI): m/z = 202.09766 [M+H]+ (calc. m/z = 202.09749) 
            
         
                      
 
 
120         Experimental 
 
N1,N1-dimethyl-N4-(pyrimidin-2-yl)benzene-1,4-diamine 
 
alex-1.10 
C12H14N4 (Mr 114.12) 
The synthesis of N1,N1-dimethyl-N4-(pyrimidin-2-yl)benzene-1,4-diamine was adapted from literature 183. 
The reaction was carried out in a microwave for synthesis. Bis(dibenzylideneacetone)palladium(0) 
(24 mg, 0.026 mmol), S-BINAP (33 mg, 0.052 mmol) and potassium tert-butoxide (412 mg, 3.67 mmol) 
were dissolved in 1.5 ml of anhyd. dioxane in a microwave vessel. The reaction was heated to 80°C and 
stirred for 10 min. After addition of 2-chloropyrimidine (300 mg, 2.62 mmol), N,N-dimethylbenzene-1,4-
diamine (428 mg, 3.14 mmol) and 3.5 ml of anhyd. dioxane the reaction was heated to 130°C. After 
stirring for 2 hours the reaction was filtrated. The filtrate was concentrated under reduced pressure. The 
residue was dissolved in 20 mL of ethyl acetate, washed with brine and dried over sodium sulfate. The 
solvent was removed under reduced pressure. The crude product was purified by flash chromatography 
with a gradient of ethyl acetate and petroleum ether to afford N1,N1-dimethyl-N4-(pyrimidin-2-
yl)benzene-1,4-diamine as a yellow solid (96% HPLC purity). 
 
Yield: 72 mg (0.63 mmol, 24%) 
1H NMR (300 MHz, DMSO-d6): δ = 2.83 (s, 6H), 6.68-6.71 (m, 3H), 7.50 (d, 
3JHH = 9.1 Hz, 2H), 8.37 (d, 
3JHH = 4.8 Hz, 2H), 9.19 (s, 1H) ppm. 
13C NMR (75 MHz, DMSO-d6): δ = 40.7, 111.2, 112.9, 120.9, 130.3, 146.2, 157.8, 160.3 ppm 
HRMS (ESI): m/z = 215.12911 [M+H]+ (calc. m/z = 215.12912) 
 
            
 
 
Experimental         121 
 
N-(4,5-dimethoxy-2-nitrobenzyl)-N-phenylpyrimidin-2-amine (38)                            
 
alex-1.0 
C19H18N4O4 (Mr 366.14) 
38 was synthesized according to the general procedure for caging of N-phenylpyrimidin-2-amines with 
benzyl bromides from N-phenylpyrimidin-2-amine (200 mg, 1.16 mmol) and 4,5-dimethoxy-2-nitrobenzyl 
bromide (352 mg, 1.28 mmol). Purification was achieved by RP flash chromatography with a gradient of 
methanol and water to afford N-(4,5-dimethoxy-2-nitrobenzyl)-N-phenylpyrimidin-2-amine as a bright 
yellow solid (99% HPLC purity).  
 
Yield: 170 mg (0.46 mmol, 40%). 
1H NMR (300 MHz, DMSO-d6): δ = 3.66 (s, 3H), 3.83 (s, 3H), 5.53 (s, 2H), 6.80 (t, 
3JHH = 4.7 Hz, 1H), 6.95 (s, 
1H), 7.16-7.22 (m, 1H), 7.33-7.40 (m, 4H), 7.64 (s, 1H), 8.97 (d, 3JHH = 4.7 Hz, 2H) ppm. 
13C NMR (75 MHz, DMSO-d6): δ = 51.2, 55.9, 56.0, 108.3, 110.4, 112.2, 125.6, 126.8, 128.9, 128.9, 140.2, 
143.7, 147.2, 153.9, 157.9, 161.2 ppm. 
HRMS (ESI): m/z = 367.13991 [M+H]+ (calc. m/z = 367.1408) 
 
 
          
  
122         Experimental 
 
N-(4,5-dimethoxy-2-nitrobenzyl)-N-(p-tolyl)pyrimidin-2-amine (37) 
 
TD-S-001  
C20H20N4O4 (Mr 380.15)  
37 was synthesized according to the general procedure for caging of N-phenylpyrimidin-2-amines with 
benzyl bromides from N-(p-tolyl)pyrimidin-2-amine (300 mg, 1.61 mmol) and 4,5-dimethoxy-2-
nitrobenzyl bromide (537 mg, 1.94 mmol). Purification was achieved by flash chromatography with a 
gradient of ethyl acetate and petroleum ether to afford N-(4,5-dimethoxy-2-nitrobenzyl)-N-(p-
tolyl)pyrimidin-2-amine as a bright yellow solid (99% HPLC purity).   
 
Yield: 398 mg (1.05 mmol, 65%) 
1H NMR (300 MHz, DMSO-d6): δ = 2.28 (s, 3H), 3.67 (s, 3H), 3.83 (s, 3H), 5.50 (s, 2H), 6.78 (t, 
3JHH = 4.8 Hz, 
1H), 6.96 (s, 1H), 7.16 (d, 3JHH = 8.1 Hz, 2H), 7.26 (d, 
3JHH = 8.4 Hz, 2H), 7.63 (s, 1H), 8.35 (d, 
3JHH = 4.7 Hz, 
2H) ppm. 
13C NMR (75 MHz, DMSO-d6): δ = 20.5, 51.3, 55.9, 26.0, 108.3, 110.4, 112.0, 126.7, 128.9, 129.4, 134.9, 
140.2, 141.1, 147.2, 152.9, 157.9, 161.3 ppm.  
HRMS (ESI): m/z = 381.15560 [M+H]+ (calc. m/z = 381.15573) 
 
 
     
 
 
 
Experimental         123 
 
N-(4-bromophenyl)-N-(4,5-dimethoxy-2-nitrobenzyl)pyrimidin-2-amine (39) 
 
TD-S-002  
C19H17BrN4O4 (Mr 444.04)  
39 was synthesized according to the general procedure for caging of N-phenylpyrimidin-2-amines with 
benzyl bromides from N-(4-bromophenyl)pyrimidin-2-amine (95 mg, 0.38 mmol) and 4,5-dimethoxy-2-
nitrobenzyl bromide (105 mg, 0.38 mmol). Purification was achieved by flash chromatography with a 
gradient of ethyl acetate and petroleum ether to afford N-(4,5-dimethoxy-2-nitrobenzyl)-N-(p-
tolyl)pyrimidin-2-amine as a bright yellow solid (99% HPLC purity).   
 
Yield: 89 mg (0.20 mmol, 53%) 
1H NMR (300 MHz, DMSO-d6): δ = 3.66 (s, 3H), 3.83 (s, 3H), 5.53 (s, 2H), 6.84 (t, 
3JHH = 4.8 Hz, 1H), 6.90 (s, 
1H), 7.36 (d, 3JHH = 9.0 Hz, 2H), 7.53 (d, 
3JHH = 9.0 Hz, 2H), 7.64 (s, 1H), 8.39 (d, 
3JHH = 4.8 Hz, 2H) ppm. 
13C NMR (75 MHz, DMSO-d6): δ = 50.9, 55.9, 56.0, 108.3, 110.3, 112.6, 117.8, 128.6, 128.8, 131.7, 140.2, 
142.9, 147.3, 153.0, 158.0, 160.9 ppm. 
HRMS (ESI): m/z = 445.05035 [M+H]+ (calc. m/z 79Br = 445.05059) 
 
 
 
                
 
 
 
124         Experimental 
 
N-(4,5-dimethoxy-2-nitrobenzyl)-N-(4-nitrilephenyl)pyrimidin-2-amine (42) 
 
TD-S-008  
C20H17N5O4 (Mr 391.14)  
42 was synthesized according to the general procedure for caging of N-phenylpyrimidin-2-amines with 
benzyl bromides from N-(4-nitrilephenyl)pyrimidin-2-amine (105 mg, 0.54 mmol) and 4,5-dimethoxy-2-
nitrobenzyl bromide (148 mg, 0.54 mmol). Purification was achieved by flash chromatography with a 
gradient of ethyl acetate and petroleum ether to afford N-(4,5-dimethoxy-2-nitrobenzyl)-N-(4-
nitrilephenyl)pyrimidin-2-amine as a bright yellow solid (95% HPLC purity). 
   
Yield: 120 mg (0.33 mmol, 57%) 
1H NMR (300 MHz, DMSO-d6): δ = 3.61 (s, 3H), 3.83 (s, 3H), 5.64 (s, 2H), 6.81 (s, 1H), 6.95 (t, 
3JHH = 4.8 Hz, 
1H), 7.63 (d, 3JHH = 8.7 Hz, 2H), 7.68 (s, 1H), 7.78 (d, 
3JHH = 8.7 Hz, 2H), 8.47 (d, 
3JHH = 4.8 Hz, 2H) ppm. 
13C NMR (75 MHz, DMSO-d6): δ = 50.7, 55.9, 56.0, 106.7, 108.5, 109.9, 113.8, 118.8, 125.9, 128.5, 132.8, 
140.1, 147.3, 147.8, 153.1, 158.2, 160.6 ppm. 
HRMS (ESI): m/z = 392.13510 [M+H]+ (calc. m/z = 392.13533) 
 
        
 
 
 
 
 
Experimental         125 
 
N-(4,5-dimethoxy-2-nitrobenzyl)-N-(4-(trifluoromethyl)phenyl)pyrimidin-2-amine (41) 
 
SK-C-006 
C20H17F3N4O4 (Mr 434.12) 
41 was synthesized according to the general procedure for caging of N-phenylpyrimidin-2-amines with 
benzyl bromides from N-(4-(trifluoromethyl)phenyl)pyrimidin-2-amine (300 mg, 1.25 mmol) and 4,5-
dimethoxy-2-nitrobenzyl bromide (416 mg, 1.51 mmol). Purification was achieved by flash 
chromatography with a gradient of ethyl acetate and petroleum ether to afford N-(4,5-dimethoxy-2-
nitrobenzyl)-N-(4-(trifluoromethyl)phenyl)pyrimidin-2-amine as a bright yellow solid (97% HPLC purity).   
 
Yield: 293 mg (0.68 mmol, 54%) 
1H NMR (300 MHz, DMSO-d6): δ = 3.93 (s, 3H), 3.83 (s, 3H), 5.62 (s, 2H), 6.87 (s, 1H), 6.91 (t, 
3JHH = 4.8 Hz, 
1H), 7.66-7.72 (m, 5H), 8.45 (d, 3JHH = 4.8 Hz, 2H) ppm.  
13C NMR (75 MHz, DMSO-d6): δ = 50.9, 55.9, 56.0, 108.5, 110.0, 113.3, 122.4, 125.2, 125.9, 126.4, 128.6, 
140.1,147.2, 147.3, 153.1, 158.1, 160.8 ppm. 
HRMS (ESI): m/z = 435.12750 [M+H]+ (calc. m/z = 435.12747) 
 
       
  
126         Experimental 
 
Ethyl 4-((4,5-dimethoxy-2-nitrobenzyl)(pyrimidin-2-yl)amino)benzoate (40) 
 
SK-C-007 
C22H22N4O6 (Mr 438.15) 
40 was synthesized according to the general procedure for caging of N-phenylpyrimidin-2-amines with 
benzyl bromides from ethyl 4-(pyrimidin-2-ylamino)benzoate (100 mg, 0.41 mmol) and 4,5-dimethoxy-2-
nitrobenzyl bromide (136 mg, 0.49 mmol). Purification was achieved by flash chromatography with a 
gradient of ethyl acetate and petroleum ether to afford ethyl 4-((4,5-dimethoxy-2-nitrobenzyl) 
(pyrimidin-2-yl)amino)benzoate as a brown yellow solid (94% HPLC purity). 
  
Yield: 131 mg (0.30 mmol, 73%) 
1H NMR (300 MHz, DMSO-d6): δ = 1.30 (t, 
3JHH = 7.1 Hz, 3H), 3.62 (s, 3H), 3.83 (s, 3H), 4.29 (q, 
3JHH = 7.1 Hz, 2H), 5.62 (s, 2H), 6.86 (s, 1H), 6.91 (t, 
3JHH = 4.8 Hz, 1H), 7.56 (d, 
3JHH = 8.7 Hz, 1H), 7.66 (s, 
1H), 7.92 (d, 3JHH = 8.7 Hz, 1H), 8.45 (d, 
3JHH = 4.8 Hz, 2H) ppm. 
13C NMR (75 MHz, DMSO-d6): δ = 14.1, 50.8, 55.9, 56.0, 60.5, 108.4, 110.0, 113.3, 125.5, 126.0, 128.7, 
129.8, 140.1, 147.2, 147.9, 153.1, 158.1, 160.8, 165.2 ppm. 
HRMS (EI): m/z = 438.15296 M+ (calc. m/z = 438.15393) 
 
 
             
 
 
 
Experimental         127 
 
N-(4,5-dimethoxy-2-nitrobenzyl)-N-(4-methoxyphenyl)pyrimidin-2-amine (36) 
 
alex-1.12 
C2H20N4O5 (Mr 396.14) 
36 was synthesized according to the general procedure for caging of N-phenylpyrimidin-2-amines with 
benzyl bromides from N-(4-methoxyphenyl)pyrimidin-2-amine (90 mg, 0.44 mmol) and 4,5-dimethoxy-2-
nitrobenzyl bromide (134 mg, 0.48 mmol). Purification was achieved by flash chromatography with a 
gradient of ethyl acetate and petroleum ether to afford N-(4,5-dimethoxy-2-nitrobenzyl)-N-(4-
methoxyphenyl)pyrimidin-2-amine as a bright yellow solid (100% HPLC purity).   
 
Yield: 107 mg (0.27 mmol, 62%) 
1H NMR (300 MHz, DMSO- d6): δ = 3.69 (s, 3H), 3.74 (s, 3H), 3.83 (s, 3H), 5.46 (s, 2H), 6.76 (t, 
3JHH = 4.7 Hz, 
1H), 6.91 (d, 3JHH = 8.8 Hz, 1H), 6.98 (s, 1H), 7.27 (d, 
3JHH = 8.8 Hz, 1H), 7.62 (s, 1H), 8.34 (d, 
3JHH = 4.7 Hz, 
2H) ppm.  
13C NMR (75 MHz, DMSO-d6): δ = 51.4, 55.2, 55.9, 56.0, 108.2, 110.6, 111.7, 114.2, 128.4, 128.8, 136.5, 
140.3, 147.2, 152.9, 157.1, 157.9,  161.5 ppm. 
HRMS (ESI): m/z = 397.15062 [M+H]+ (calc. m/z = 397.15065) 
 
 
          
 
 
 
128         Experimental 
 
N1-(4,5-dimethoxy-2-nitrobenzyl)-N4,N4-dimethyl-N1-(pyrimidin-2-yl)benzene-1,4-diamine (35) 
 
alex-1.13 
C21H23N5O4 (Mr 409.18) 
35 was synthesized according to the general procedure for caging of N-phenylpyrimidin-2-amines with 
benzyl bromides from N1,N1-dimethyl-N4-(pyrimidin-2-yl)benzene-1,4-diamine (80 mg, 0.38 mmol) and 
4,5-dimethoxy-2-nitrobenzyl bromide (115 mg, 0.42 mmol). Purification was achieved by flash 
chromatography with a gradient of ethyl acetate and petroleum ether to afford N1-(4,5-dimethoxy-2-
nitrobenzyl)-N4,N4-dimethyl-N1-(pyrimidin-2-yl)benzene-1,4-diamine as a yellow solid (95% HPLC purity).   
 
Yield: 109 mg (0.27 mmol, 70%) 
1H NMR (300 MHz, DMSO-d6): δ = 2.87 (s, 6H), 3.69 (s, 3H), 3.83 (s, 3H), 5.43 (s, 2H), 6.68-6.74 (m, 3H), 
6.99 (s, 1H), 7.15 (d, 3JHH = 8.8 Hz, 2H) 7.62 (s, 1H), 8.32 (d, 
3JHH = 4.7 Hz, 2H) ppm. 
13C NMR (75 MHz, DMSO-d6): δ = 40.3, 51.5, 55.9, 56.0, 108.2, 110.5, 111.4, 112.7, 127.8, 129.1, 132.7, 
140.3, 147.2, 148.5, 152.9, 157.8, 161.7 ppm 
HRMS (ESI): m/z = 410.18214 [M+H]+ (calc. m/z = 410.18228) 
 
 
               
 
  
Experimental         129 
 
8-Chloromethyl-4,4-difluoro-1,3,5,7-tetramethyl-4-bora-3a,4a-diaza-s-indacene (47) 
 
alex-1.29 
C14H16BClF2N2 (Mr 296.55) 
8-Chloromethyl-4,4-difluoro-1,3,5,7-tetramethyl-4-bora-3a,4a-diaza-s-indacene was synthesized 
according to literature 171. Under an argon atmosphere chloroacetyl chloride (1098 mg, 9.7 mmol) was 
added dropwise to a solution of 2,4-dimethylpyrrole (1850 mg, 19.4 mmol) in 100 ml of anhyd. 
dichloromethane at room temperature with intense stirring. The reaction was heated to 50°C and left 
stirring for two hours. Subsequently, the mixture was cooled to 0°C and neutralized by addition of 
triethylamine (4922 mg, 48.6 mmol). After 15 min boron trifluoride etherate (9661 mg, 68.1 mmol) was 
added dropwise to the reaction. The reaction was heated to 50°C and left stirring for another hour. After 
full conversion the organic layer was washed with both a solution of hydrogen carbonate and water 
twice, dried over anhyd. sodium sulfate and concentrated under reduced pressure. The crude product 
was purified by flash chromatography with a gradient of dichloromethane and petroleum ether to afford 
8-chloromethyl-4,4-difluoro-1,3,5,7-tetramethyl-4-bora-3a,4a-diaza-s-indacene as a dark orange solid 
with a green gloss (93% HPLC purity). 
 
Yield: 450 mg (1.52 mmol, 16%). 
1H NMR (300 MHz, CDCl3): δ = 2.53 (s, 12H), 4.77 (s, 2H), 6.09 (s, 2H) ppm. 
13C NMR (75 MHz, CDCl3): δ = 14.8, 15.7, 37.3, 122.4, 131.5, 136.1, 141.3, 156.8  ppm.  
HRMS (EI): m/z = 296.10607 M+ (calc. m/z = 296.10631) 
 
                 
 
130         Experimental 
 
8-Chloromethyl-4,4-difluoro-1,3,5,7-tetramethyl-2,6-diethyl-4-bora-3a,4a-diaza-s-indacene (51) 
 
alex-1.21 
C18H24BClF2N2 (Mr 352.17) 
Synthesis was performed according to literature 173. Under an argon atmosphere chloroacetyl chloride 
(834 mg, 7.4 mmol) was added dropwise to a solution of 3-ethyl-2,4-dimethylpyrrole (1820 mg, 14.8 
mmol) in 100 ml of anhyd. dichloromethane at room temperature with intense stirring. The reaction was 
heated to 50°C and left stirring for two hours. Subsequently, the mixture was cooled to 0°C and 
neutralized by addition of triethylamine (3738 mg, 36.9 mmol). After 15 min boron trifluoride etherate 
(7337 mg, 51.7 mmol) was added dropwise to the reaction. The reaction was heated to 50°C and left 
stirring for another hour. After full conversion the organic layer was washed with both a solution of 
hydrogen carbonate and water twice, dried over anhyd. sodium sulfate and concentrated under reduced 
pressure. The crude product was purified by flash chromatography with a gradient of dichloromethane 
and petroleum ether to afford 8-chloromethyl-4,4-difluoro-1,3,5,7-tetramethyl-2,6-diethyl-4-bora-3a,4a-
diaza-s-indacene as a dark orange solid with a green gloss (90% HPLC purity). 
 
Yield: 1300 mg (3.7 mmol, 52%). 
1H NMR (300 MHz, CDCl3): δ = 1.06 (t, 
3JHH = 7.6 Hz, 6H), 2.41 (q, 
3JHH = 7.6 Hz, 4H), 2.46 (s, 6H), 2.51 (s, 
6H), 4.83 (s, 2H) ppm. 
13C NMR (75 MHz, CDCl3): δ = 12.7, 12.8, 14.9, 17.3, 38.1, 130.8, 133.4, 134.1, 136.2, 154.9 ppm.  
HRMS (EI): m/z = 352.16990 M+ (calc. m/z = 352.16891) 
 
        
 
Experimental         131 
 
8-Iodomethyl-4,4-difluoro-1,3,5,7-tetramethyl-2,6-diethyl-4-bora-3a,4a-diaza-s-indacene (52) 
 
alex-1.34 
C18H24BF2IN2 (Mr 444.10) 
Synthesis was performed according to literature 174. Under an argon atmosphere 8-chloromethyl-4,4-
difluoro-1,3,5,7-tetramethyl-2,6-diethyl-4-bora-3a,4a-diaza-s-indacene (500 mg, 1.4 mmol) and sodium 
iodide (425 mg, 2.8 mmol) were dissolved in 10 mL of anhyd. THF. The reaction was refluxed for one 
hour. After cooling, the solution was diluted with Et2O (20 ml), washed with water (20 ml) and the 
organic phase was dried (MgSO4), filtered and evaporated. The residue was purified by flash column 
chromatography (hexane/Et2O) to give the title compound as a dark purple solid (90% HPLC purity).  
 
Yield: 498 mg (1.1 mmol, 80%). 
1H NMR (300 MHz, CDCl3): δ = 1.06 (t, 
3JHH = 7.6 Hz, 6H), 2.38-2.45 (m, 10H), 2.52 (s, 6H), 4.72 (s, 2H) 
ppm.  
13C NMR (75 MHz, CDCl3): δ = -0.3, 12.7, 13.8, 14.9, 17.3, 129.9, 133.5, 135.7, 139.1, 154.4 ppm. 
HRMS (EI): m/z = 444.10421 M+ (calc. m/z = 444.10453) 
 
 
            
 
 
 
 
132         Experimental 
 
N-((4,4-difluoro-1,3,5,7-tetramethyl-4-bora-3a,4a-diaza-s-indacen-8-yl)methyl)-N-(4-(methylsulfonyl) 
phenyl)pyrimidin-2-amine (49) 
 
alex-1.26 
C25H36BF2N5O2S (Mr 509.19) 
49 was synthesized according to the general procedure for caging of N-phenylpyrimidin-2-amines with 
BODIPY protecting groups from 24 (50 mg, 0.20 mmol) and 8-chloromethyl-4,4-difluoro-1,3,5,7-
tetramethyl-4-bora-3a,4a-diaza-s-indacene (150 mg, 0.50 mmol). Purification was achieved by flash 
chromatography on aluminum oxide with a gradient of ethyl acetate and petroleum ether, followed by 
RP flash chromatography with a gradient of acetonitrile and water to afford the title compound as a 
bright red solid (100% HPLC purity).   
 
Yield: 5 mg (0.01 mmol, 3%). 
1H NMR (300 MHz, DMSO-d6): δ = 2.37 (s, 6H), 2.42 (s, 6H), 2.92 (s, 3H), 5.36 (s, 2H), 6.00 (s, 2H), 6.79 (t, 
3JHH = 4.8 Hz, 1H), 7.08 (d, 
3JHH = 8.6 Hz, 2H), 7.72 (d, 
3JHH = 8.6 Hz, 2H), 8.44 (d, 
3JHH = 4.8 Hz, 2H) ppm. 
13C NMR (75 MHz, DMSO- d6): δ = 14.7, 16.5, 44.7, 44.9, 112.6, 122.5, 128.1, 130.4, 133.5, 135.8, 139.1, 
141.2, 145.1, 156.0, 158.1, 161.3 ppm.  
HRMS (MALDI): m/z = 531.17999 [M+Na]+ (calc. m/z = 531.17969) 
 
            
Experimental         133 
 
N-((4,4-difluoro-1,3,5,7-tetramethyl-2,6-diethyl-4-bora-3a,4a-diaza-s-indacen-8-yl)methyl)-N-(4-
(methylsulfonyl)phenyl)pyrimidin-2-amine (53) 
 
alex-1.30 
C29H34BF2N5O2S (Mr 565.26) 
53 was synthesized according to the general procedure for caging of N-phenylpyrimidin-2-amines with 
BODIPY protecting groups from 24 (80 mg, 0.32 mmol) and 8-iodomethyl-4,4-difluoro-1,3,5,7-
tetramethyl-2,6-diethyl-4-bora-3a,4a-diaza-s-indacene (357 mg, 0.80 mmol). Purification was achieved 
by flash chromatography on aluminum oxide with a gradient of ethyl acetate and petroleum ether, 
followed by RP flash chromatography with a gradient of acetonitrile and water to afford the title 
compound as a bright red solid (100% HPLC purity).   
 
Yield: 22 mg (0.04 mmol, 12%). 
1H NMR (300 MHz, DMSO-d6): δ =  1.00 (t,
 3JHH = 7.5 Hz, 6H), 2.29 (s, 6H), 2.35 (q,
 3JHH = 7.5 Hz, 4H), 2.40 
(s, 6H), 2.91 (s, 3H), 5.42 (s, 2H), 6.81 (t, 3JHH = 4.9 Hz, 1H), 7.06 (d,
 3JHH = 8.6 Hz, 2H), 7.70 (d,
 3JHH = 8.6 Hz, 
2H), 8.47 (d, 3JHH = 4.9 Hz, 2H) ppm. 
13C NMR (75 MHz, DMSO- d6): δ = 12.7, 13.6, 15.1, 17.3, 44.8, 45.5, 112.4, 128.1, 130.3, 133.4, 134.0, 
136.2, 139.0, 144.7, 154.6, 158.0, 160.7 ppm. 
HRMS (ESI): m/z = 566.26370 [M+H]+ (calc. m/z = 566.26034) 
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N-((4,4-difluoro-1,3,5,7-tetramethyl-2,6-diethyl-4-bora-3a,4a-diaza-s-indacen-8-yl)methyl)-4-(1-
isopropyl-2-methyl-1H-imidazol-5-yl)-N-(4-(methylsulfonyl)phenyl)pyrimidin-2-amine (54) 
 
alex-1.42 
C36H44BF2N7O2S (Mr 687.33) 
54 was synthesized according to the general procedure for caging of N-phenylpyrimidin-2-amines with 
BODIPY protecting groups from 16 (150 mg, 0.40 mmol) and 8-iodomethyl-4,4-difluoro-1,3,5,7-
tetramethyl-2,6-diethyl-4-bora-3a,4a-diaza-s-indacene (450 mg, 1.0 mmol). Purification was achieved by 
flash chromatography on silica with a gradient of methanol and dichloromethane, followed by RP flash 
chromatography with a gradient of acetonitrile and water to afford the title compound as a red solid 
(100% HPLC purity).   
 
Yield: 41 mg (0.06 mmol, 15%). 
1H NMR (300 MHz, DMSO-d6): δ = 1.02 (t, 
3JHH = 7.5 Hz, 6H), 1.09 (d,  
3JHH = 7.1 Hz, 6H), 2.33-2.41 (m, 
16H), 2.83 (s, 3H), 2.91 (s, 3H), 5.27 (sept, 3JHH = 7.1 Hz, 1H), 5.44 (s, 2H), 6.96 (d, 
3JHH = 5.2 Hz, 1 H), 7.00 
(d, 3JHH = 8.5 Hz, 2H), 7.63 (s, 1H), 7.69 (d, 
3JHH = 8.5 Hz, 2H), 8.61 (d, 
3JHH = 5.2 Hz, 1 H) ppm. 
13C NMR (75 MHz, DMSO- d6): δ = 12.6, 13.6, 13.6, 15.1, 17.3, 20.7, 44.5, 45.2, 51.0, 109.9, 120.7, 127.8, 
130.1, 130.7, 133.2, 133.9, 134.0, 136.1, 139.7, 145.1, 146.3, 154.4, 154.9, 159.9 ppm.  
HRMS (EI): m/z = 687.33350 M+ (calc. m/z = 687.33383) 
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5.4 Biological evaluation 
5.4.1 Kinase assay 
CDK2 Cyclin E1 assays were performed with the ADP-GloTM Assay (Promega) according to the 
manufacturer’s manual. Compounds 16 and 23 were dissolved in 100% DMSO and tested in a range of 
1 · 10-5 to 2 ∙10-10 M, in duplicate. Kinase, the respective compound, ATP and substrate were incubated 
for 1 h at 30°C under ambient light exclusion. For the photoactivation experiments the test plates were 
irradiated at 365 nm for 3 min (LED source:  16x Nichia NCSU276A U365, 5%, 37.5 mW, Sahlmann 
Photochemical Solutions). Final concentrations of reagents were 10 µM ATP, 0,1 µg/µl Histone H1 
(substrate), 1% DMSO. Plate read out was performed with the FLUOstar Omega (BMG Labtech). Dose 
response curves and IC50-values were calculated with GraphPad Prism 7.03 using the Sigmoidal fitting 
(log(inhibitor) vs. response – variable slope). 
Analysis was performed by Theo Rhodat.184 
5.4.1  Tubulin polymerization assay 
Compound 20 (0.5 mM in H2O) was UV irradiated for 5 min (365 nm, 1800 mW). Fluorescence-based 
tubulin polymerization assay was conducted in a final volume of 55 μL using the Tubulin Polymerization 
Assay kit (Cytoskeleton, CO, USA) as per manufacturer’s instructions. Porcine brain tubulin was 
incubated with test compounds at 37°C and fluorescence was measured using Tecan M200 PRO+ 
microplate reader (excitation at 350 nm and emission at 420 nm). 
5.4.2 Immunofluorescence imaging 
Compound 20 (0.5 mM in DMEM) was irradiated with UV light (365 nm, 1800 mW, 5 min). U251 cells 
(3x103) were treated with vehicle or compounds for 24 h. Cells were fixed with ice-cold 100% methanol 
for 20 min at RT and blocked in 1% bovine serum albumin/PBS for 20 min. Cells were incubated with β-
tubulin antibody (Abcam, #11308) and Alexa488-conjugated anti-mouse IgG (Life Technologies, #A-
11029). Cell nuclei were counterstained using Prolong Gold mounting media with DAPI (4’,6’-diamidino-
2-phenylindole) and images were captured under an Olympus IX81 inverted fluorescence microscope 
and analyzed using AutoDEblur v 9.3 (AutoQuant Imaging). 
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5.4.3 Apoptosis assay 
RN1 cells (2x105 cells/well) were treated with vehicle or test compounds and exposed to UV irradiation 
for 30s (365 nm, 1800 mW). The quantitative analysis of apoptotic cells after 48 h incubation was 
performed using the Muse™ Annexin V and Dead Cell Kit (MerckMillipore), as per manufacturer’s 
instructions and analyzed using the Muse™ Cell Analyzer (MerckMillipore). 
 
5.4.4 Cell culture 
Photoactivatable small-molecule microtubule-targeting agent 
U251 cell lines were obtained from the European Collection of Cell Cultures (ECACC, Salisbury, UK) 
through CellBank Australia and were cultured in DMEM medium supplemented with 10% FBS and 
Antibiotic-Antimycotic solution (both Life Technologies) at 37°C and 5% CO2. RN1 glioblastoma cell line 
was derived from glioblastoma specimen and maintained in KnockOut DMEM/F-12 basal medium 
supplemented with StemPro NSC SFM supplement, 2 mM GlutaMAX-ICTS, 20 ng/mL EGF, 10 ng/mL FGFβ 
and Antibiotic-Antimycotic solution (all Life Technologies). RN1 cells were grown as adherent cells on 
Matrigel-coated flasks. The protocols have been approved by the Human Ethics Committee of The 
University of Sydney (HREC 2013/131) and the Human Ethics Committee of the Royal Brisbane & 
Women’s Hospital (RBWH 2004/161). 
 
Photoactivatable CDK inhibitor 
Panc89 (also known as T3M4) cell lines were kindly provided by Dr. Anna Trauzold from the Institute for 
Experimental Tumor Research, Faculty of Medicine, University of Kiel, Germany and were cultured in 
RPMI 1640 medium supplemented with 10% FBS and 1 mM pyruvate at 37°C and 5% CO2. 
Cell culture was performed by Theo Rhodat.184 
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5.4.5 Cell viability assay 
U251 (2x103 cells/well) and RN1 (4x103 cells/well) were seeded in 96-well plate in triplicate. On the 
following day, cells were treated with vehicle or test compounds (0.001 - 50 μM) and exposed to UV 
irradiation (365 nm, 1800 mW, LED source:  8x Nichia NCSU033B, Sahlmann Photochemical Solutions) for 
30 s (RN1 cells) or 60 s (U251 cells). After 72 h incubation, 10 μL of the Cell-Titer Blue reagent (Promega) 
was added to the cell culture and incubated at 37°C for 4 h. Fluorescence was measured with Tecan 
M200 PRO+ microplate reader (excitation at 560 nm and emission at 590 nm). 
 
5.4.6 Cell proliferation assay 
The cells were grown in cell flasks until approximately 90% confluence and then seeded to give 1000 - 
1500 cells in 100 μL per well into 96-well CulturePlatesTM (PerkinElmer, US). In addition to the test 
plates, one plate was prepared for reference measurement at day zero. All plates were incubated for 
24 h at 37 °C in a humidified atmosphere with 5% CO2. Compounds 16, 22, 22a, 23 and 26 were dissolved 
in 100% DMSO (v/v) and added to the test plates. The final DMSO concentration in the assay was 1% 
(v/v). Viability of the cells in the day zero control plates were determined on the same day without 
adding any compounds. For viability measurement the resazurin assay was used. The shift in the 
fluorescence signal was measured at the FLUOstar Omega (BMG Labtech). For the photoactivation 
experiments the test plates were irradiated at 365 nm for 3 min (LED source:  16x Nichia NCSU276A 
U365, 5%, 37.5 mW, Sahlmann Photochemical Solutions). Test plates were incubated for further 48 h 
and cell viability was defined as described above. Measured raw data was converted into percent of cell 
growth by using the high control (1% DMSO (v/v) without compound) and the day zero control. For dose-
response studies, 11 different concentrations of compounds were tested in triplicates. EC50 values were 
calculated using the log(inhibitor) - variable slope fit option of GraphPad Prism 5. 
Analysis was performed by Theo Rhodat.184 
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5.4.7 Compound stability for biological evaluation 
Compound 23 and 26 were dissolved in DMSO or PBS buffer with 20% DMSO (100 µM resp. 50 µM) and 
incubated in a clear glass HPLC vial either at a shelf in the lab (room temperature and ambient light) or 
inside the incubator of the cell culture (37°C, 5% CO2 humidified atmosphere and dark) for 48 h. The 
samples were analyzed by HPLC after 0, 12, 24, 36 and 48 hours.  
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5.5 Cherenkov radiation experiments 
All experiments were carried out in the clinic for nuclear medicine and radiopharmacy at the UKSH in 
Kiel. 
18F experiments 
A stock solution (500 µM) of compound 23 was prepared in DMSO. 100 µL of the stock solution were 
transferred into a common amber glass HPLC vial (1.5 ml maximum volume). 900 µL of 18F in water 
respectively 900 µL water for the negative control were added to the HPLC vial. Both samples were 
incubated in the autosampler of the HPLC at room temperature behind shielding. Samples were injected 
to HPLC alternating and analyzed. Time points and peak areas are indicated for each experiment.   
18Fluorodeoxyglucose experiments 
A stock solution (250 µM) of compound 23 was prepared in HPLC methanol. 200 µL of the stock solution 
were transferred into a common amber glass HPLC vial (1.5 ml maximum volume). 200 µL of 18FDG in 
water respectively 200 µL water for the negative control were added to the HPLC vial. Both samples 
were incubated in the autosampler of the HPLC at room temperature behind shielding. Samples were 
injected to HPLC alternating and analyzed. Time points and peak areas are indicated for each 
experiment.   
68Gallium experiments 
A stock solution (250 µM) of compound 23 was prepared in DMSO. 250 µL of the stock solution were 
transferred into a common amber glass HPLC vial (1.5 ml maximum volume). 1000 µL of 68Ga in 1 M HCl, 
prepared with a Gallium-68 generator, respectively 1000 µL of 100 µM non-radioactive 69Ga in 1 M HCl 
for the negative control were added to the HPLC vial behind shielding. The used radioactivity is indicated 
at each experiment. Both samples were incubated in the autosampler of the HPLC at room temperature 
behind shielding. Samples were injected to HPLC alternating and analyzed. Time points and peak areas 
are indicated for each experiment.   
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Activation experiments using the linear particle accelerator 
Compound solutions of 23 (50 µM) were prepared according to Table 6 in either a clear glass HPLC vial 
(Experiments 1 and 2) or in a 10 ml clear glass vessel (Experiment 3). The vessels or HPLC vials resp. were 
placed without a cap in the particle beam of the linear particle accelerator and irradiated with the resp. 
radiation, energy and maximum dose. Peak areas of both the caged and uncaged species were 
determined by HPLC analysis before and after irradiation. Additionally, both a negative and positive 
sample were measured. The positive samples were irradiated with UV light by a LED (5.4 W, 365 nm, 
2 min) after irradiation using the linear particle accelerator.     
5.5.1 Reagents 
Both 18F and 18Fluorodeoxyglucose were obtained from the commercial company: f-con Eckert & Ziegler 
(Strahlen- und Medizintechnik AG, Berlin). They were used without further purification. 68Gallium was 
generated in place at the UKSH Kiel in the department of nuclear medicine and radiopharmacy using a 
Gallium-68 generator.  
5.5.2 Linear Particle Accelerator 
Activation experiments using a linear particle accelerator were performed using an electron linear 
accelerator type Artiste (Siemens Medical Systems).  
5.5.3 HPLC  
Content determination of radioactive samples were performed using a Agilent 1100 HPLC with DAD 
detector and column heating placed behind shielding (Agilent Technologies, Waldbronn, Germany). The 
column was a Chromolit® SemiPrep RP18 (100 ∙ 4.6 mm, Merck Millipore, Darmstadt, Germany). The 
injection volume was 20 µL. A gradient of acetonitrile and water both with 0.1% (v/v) formic acid were 
used as the mobile phase with a fixed flow rate (1.5 ml ∙ min-1). UV detection at 296 nm was used for 
content determination. 
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7 Appendix 
 
Supplementary Figure 1: Stability of analogue 21 upon irradiation with UV light. The compound solution was irradiated at 365 
nm (5.4 W) and subsequently analyzed by HPLC. Each value is a mean ± SD of two independent experiments.  
 
 
 
Supplementary Figure 2: Cell viability of (A) U251 and (B) RN1 glioblastoma cells upon irradiation with UV light. U251 cells 
were irradiated with 60 s of UV light (365 nm, 1.8 W). RN1 cells were irradiated for 30 s (365 nm, 1.8 W). Cell viability was 
assessed after 48 h of incubation respectively 72 h for RN1 cells. 
 
 
Appendix         155 
 
 
Supplementary Figure 3: Stability of benzyl caged analogue 26 upon irradiation with UV light. The compound solutions  A) 
1 mM in DMSO and B) 25 µM in PBS buffer with 10% DMSO were irradiated in a well of a 96-well plate at 365 nm (75 mW) and 
subsequently analyzed by HPLC. Each value is a mean ± SD of two independent experiments.  
 
 
 
 
 
 
Supplementary Figure 4: Light absorbance of scaffolds 25,35-42 at a wavelength of 365 nm. A light absorbance spectra of each 
compound solution (DMSO, 25 µM) was measured. The absorbance of 365 nm of each scaffold was plotted. Each value is a 
mean ± SD of two independent experiments.  
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List of Abbreviations 
°C   degrees Celsius 
µ   micro 
2D / 3D   two-dimensional / three-dimensional 
AlCl3   aluminium chloride 
ATP   adenosine triphosphate 
β   beta 
b (NMR)  broad 
BF3-OEt2  boron trifluoride etherate 
boc   tert-butyloxycarbonyl 
BODIPY   meso-methyl boron-dipyrromethene analogues 
Br   bromo 
C2   carbon number 2 
C8   carbon number 8 
CDK   cyclin-dependent kinase 
CF3   trifluoromethyl 
CH3   methyl 
C-lobe   C-terminal lobe 
cm   centimeter 
CN   nitrile 
CO2   carbon dioxide 
COOEt   carboxyethyl ester 
COSY (NMR)  correlation spectroscopy 
CR   Cherenkov radiation 
d (NMR)  doublet 
DCM   dichloromethane 
DEAC   diethylaminocoumarin analogues 
DIPEA   diisopropylethylamine 
DMEM   Dulbecco’s modified Eagle’s medium 
DMF   dimethylformamide 
DMNB   4,5-dimethoxy-2-nitrobenzyl 
DMSO   dimethyl sulfoxide 
EC50   half maximal effective concentration 
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e.g.   exemplī grātiā (lat. for example) 
EI   electron impact 
EMA   European Medicine Agency 
equiv.   equivalents 
ESI   electrospray ionization 
EtOH   ethanol 
18F   18-Fluorine 
FBS   fetal bovine serum 
FDA   Food and Drug Administration 
FDG   fluordesoxyglucose 
g   gram 
68Ga   Gallium-68 
Gy   gray 
h   hour(s) 
H   hydrogen 
HCl   hydrochloric acid 
Hg   Mercury 
HMBC (NMR)  heteronuclear multiple-bond correlation spectroscopy 
H2O   water 
HPLC   high-performance liquid chromatography 
HRMS   high-resolution mass spectrometry 
HSQC (NMR)  heteronuclear single-quantum correlation spectroscopy 
Hz   hertz 
IC50   half maximal inhibitory concentration 
INN   international nonproprietary name 
i-PrOH   isopropyl alcohol 
J (NMR)   coupling constant 
K   Kelvin 
K2CO3   potassium carbonate 
KH2PO4   potassium dihydrogen phosphate 
KO-t-butyl  potassium-tert-butoxide 
L   liter 
LC-MS   liquid chromatography–mass spectrometry 
LED   light-emitting diode 
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LEU   leucine 
LG   leaving group 
m   meter 
m   milli 
M   molar 
m (NMR)  unresolved multiplet 
MALDI   matrix-assisted  laser desorption/ionization 
MBq   mega becquerel  
MeV   mega electronvolt 
m/z   mass-to-charge ratio 
MeOH   methanol 
MHz   megahertz 
min   minute(s) 
mol   mole 
Mr   relative molecular mass 
MS   mass spectrometry 
MTA   microtubule-targeting agent 
n   nano 
N2   nitrogen 
n/a   not applicable 
Na2CO3   sodium carbonate 
NaH   sodium hydride 
NaI   sodium iodide 
N(CH3)2   dimethylamine 
NB   o-nitrobenzyl 
N-lobe   N-terminal lobe 
nm   nanometer 
NMR   nuclear magnetic resonance spectroscopy 
OCH3   methoxy 
PBS   phosphate-buffered saline 
pdb   protein data bank (RCSB) 
Pd2(dba)3  Tris(dibenzylideneacetone)dipalladium(0) 
Pd(PPh3)4  Tetrakis(triphenylphosphine)palladium(0) 
PDT   photodynamic therapy 
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PET   positron emission tomography 
PPG   photoremovable protection group 
ppm   parts per million 
PS   phosphatidylserine 
psi   pounds per square inch 
PyBOP   (Benzotriazol-1-yloxy)tripyrrolidinophosphonium hexafluorophosphate 
R   residue 
resp.   respectively 
ROS   reactive oxygen species 
RP   reversed phase 
rt   room temperature 
s   second(s) 
s (NMR)  singlet 
S-BINAP  (S)-(−)-(1,1′-Binaphthalene-2,2′-diyl)bis(diphenylphosphine) 
SD   standard deviation 
SEM   standard error of the mean 
smKI   small-molecule kinase inhibitor 
smMTA   small-molecule microtubule-targeting agent 
SN   nucleophilic substitution 
SO2CH3   sulfonylmethyl 
t (NMR)  triplet 
TEA   triethylamine 
TLC   thin-layer chromatography 
TOF   time of flight 
UKSH   university hospital Schleswig-Holstein 
UV   ultraviolet 
V   volt 
v/v   volume fraction 
vis   visible 
vs.   versus 
W   watt 
Xantphos  4,5-bis(diphenylphosphino)-9,9-dimethylxanthene 
Zn   Zinc 
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Table of Compounds 
# 
lab 
code 
formula nomenclature 
Page 
(prep.) 
16 alex-raj 
 
4-(4-(2-Fluoropyridin-3-yl)phenyl)-N-
(4-hydroxyphenyl)butanamide 
101 
17 AZD5438 
 
4-(1-Isopropyl-2-methyl-1H-imidazol-5-
yl)-N-(4-
(methylsulfonyl)phenyl)pyrimidin-2-
amine 
106 
20 alex-3.8 
 
N-(4-((4,5-dimethoxy-2-
nitrobenzyl)oxy)phenyl)-4-(4-(2-
fluoropyridin-3-yl)phenyl)butanamide 
102 
21 alex-3.18 
 
N-(4-(benzyloxy)phenyl)-4-(4-(2-
fluoropyridin-3-yl)phenyl)butanamide 
104 
22 alex-1.6 
 
4,5-Dimethoxy-2-nitrobenzyl(tert-
butoxycarbonyl)alaninate 
111 
23 alex-1.4 
 
N-(4,5-dimethoxy-2-nitrobenzyl)-4-(1-
isopropyl-2-methyl-1H-imidazol-5-yl)-
N-(4-(methylsulfonyl)phenyl)pyrimidin-
2-amine 
109 
24 alex-1.2 
 
N-(4-(methylsulfonyl)phenyl)pyrimidin-
2-amine 
107 
25 alex-1.3 
 
N-(4,5-dimethoxy-2-nitrobenzyl)-N-(4-
(methylsulfonyl)phenyl)pyrimidin-2-
amine 
108 
26 alex-1.7 
 
N-benzyl-4-(1-isopropyl-2-methyl-1H-
imidazol-5-yl)-N-(4-
(methylsulfonyl)phenyl)pyrimidin-2-
amine 
112 
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without alex-1.1 
 
N-phenylpyrimidine-2-amine 113 
without TD-001 
 
N-(p-tolyl)pyrimidin-2-amine 114 
without TD-002 
 
N-(4-bromophenyl)pyrimidin-2-amine 115 
without TD-008 
 
N-(4-nitrilphenyl)pyrimidin-2-amine 116 
without SK-006 
 
N-(4-
(trifluoromethyl)phenyl)pyrimidin-2-
amine 
117 
without SK-007 
 
Ethyl 4-(pyrimidin-2-ylamino)benzoate 118 
without  alex-1.11 
 
N-(4-methoxyphenyl)pyrimidin-2-
amine 
119 
without alex-1.10 
 
N1,N1-dimethyl-N4-(pyrimidin-2-
yl)benzene-1,4-diamine 
120 
35 alex-1.13 
 
N1-(4,5-dimethoxy-2-nitrobenzyl)-
N4,N4-dimethyl-N1-(pyrimidin-2-
yl)benzene-1,4-diamine 
128 
36 alex-1.12 
 
N-(4,5-dimethoxy-2-nitrobenzyl)-N-(4-
methoxyphenyl)pyrimidin-2-amine 
127 
37 TD-S-001 
 
N-(4,5-dimethoxy-2-nitrobenzyl)-N-(p-
tolyl)pyrimidin-2-amine 
122 
162         Table of Compounds 
 
38 alex-1.0 
 
N-(4,5-dimethoxy-2-nitrobenzyl)-N-
phenylpyrimidin-2-amine 
121 
39 TD-S-002 
 
N-(4-bromophenyl)-N-(4,5-dimethoxy-
2-nitrobenzyl)pyrimidin-2-amine 
123 
40 SK-C-007 
 
Ethyl 4-((4,5-dimethoxy-2-
nitrobenzyl)(pyrimidin-2-
yl)amino)benzoate 
126 
41 SK-C-006 
 
N-(4,5-dimethoxy-2-nitrobenzyl)-N-(4-
(trifluoromethyl)phenyl)pyrimidin-2-
amine 
125 
42 TD-S-008 
 
N-(4,5-dimethoxy-2-nitrobenzyl)-N-(4-
nitrilephenyl)pyrimidin-2-amine 
124 
47 alex-1.29 
 
8-Chloromethyl-4,4-difluoro-1,3,5,7-
tetramethyl-4-bora-3a,4a-diaza-s-
indacene 
129 
49 alex-1.26 
 
N-((4,4-difluoro-1,3,5,7-tetramethyl-4-
bora-3a,4a-diaza-s-indacen-8-
yl)methyl)-N-(4-(methylsulfonyl) 
phenyl)pyrimidin-2-amine 
132 
51 alex-1.21 
 
8-Chloromethyl-4,4-difluoro-1,3,5,7-
tetramethyl-2,6-diethyl-4-bora-3a,4a-
diaza-s-indacene 
130 
Table of Compounds          163 
 
52 alex-1.34 
 
8-Iodomethyl-4,4-difluoro-1,3,5,7-
tetramethyl-2,6-diethyl-4-bora-3a,4a-
diaza-s-indacene 
131 
53 alex-1.30 
 
N-((4,4-difluoro-1,3,5,7-tetramethyl-
2,6-diethyl-4-bora-3a,4a-diaza-s-
indacen-8-yl)methyl)-N-(4-
(methylsulfonyl)phenyl)pyrimidin-2-
amine 
133 
54 alex-1.42 
 
N-((4,4-difluoro-1,3,5,7-tetramethyl-
2,6-diethyl-4-bora-3a,4a-diaza-s-
indacen-8-yl)methyl)-4-(1-isopropyl-2-
methyl-1H-imidazol-5-yl)-N-(4-
(methylsulfonyl)phenyl)pyrimidin-2-
amine 
134 
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